Methods for the Analysis of Matched Molecular Pairs and Chemical Space Representations by de la Vega de León, Antonio
Methods for the Analysis of
Matched Molecular Pairs and
Chemical Space Representations
Kumulative Dissertation
zur Erlangung des Doktorgrades (Dr. rer. nat.)
der Mathematisch-Naturwissenschaftlichen Fakultät
der Rheinischen Friedrich-Wilhelms-Universität Bonn
vorgelegt von
ANTONIO DE LA VEGA DE LEÓN
aus Madrid, Spanien
Bonn, 2016

Angefertigt mit Genehmigung
der Mathematisch-Naturwissenschaftlichen Fakultät
der Rheinischen Friedrich-Wilhelms-Universität Bonn
1. Gutachter: Univ.-Prof. Dr. rer. nat. Jürgen Bajorath
2. Gutachter: Jun.-Prof. Dr. rer. nat. Thomas Schultz
Tag der Promotion: 27. September 2016
Erscheinungsjahr: 2016

Para mis padres,
por todo el amor y el apoyo que siempre me han dado

Abstract
Compound optimization is a complex process where different properties are
optimized to increase the biological activity and therapeutic effects of a molecule.
Frequently, the structure of molecules is modified in order to improve their prop-
erty values. Therefore, computational analysis of the effects of structure modifica-
tions on property values is of great importance for the drug discovery process. It
is also essential to analyze chemical space, i.e., the set of all chemically feasible
molecules, in order to find subsets of molecules that display favorable property
values. This thesis aims to expand the computational repertoire to analyze the
effect of structure alterations and visualize chemical space.
Matched molecular pairs are defined as pairs of compounds that share a large
common substructure and only differ by a small chemical transformation. They
have been frequently used to study property changes caused by structure modifica-
tions. These analyses are expanded in this thesis by studying the effect of chemical
transformations on the ionization state and ligand efficiency, both measures of
great importance in drug design. Additionally, novel matched molecular pairs
based on retrosynthetic rules are developed to increase their utility for prospective
use of chemical transformations in compound optimization. Further, new meth-
ods based on matched molecular pairs are described to obtain preliminary SAR
information of screening hit compounds and predict the potency change caused
by a chemical transformation.
Visualizations of chemical space are introduced to aid compound optimiza-
tion efforts. First, principal component plots are used to rationalize a matched
molecular pair based multi-objective compound optimization procedure. Then,
star coordinate and parallel coordinate plots are introduced to analyze drug-like
subspaces, where compounds with favorable property values can be found. Fi-
nally, a novel network-based visualization of high-dimensional property space
is developed. Concluding, the applications developed in this thesis expand the
methodological spectrum of computer-aided compound optimization.
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1 Introduction
1.1 Drug discovery
Drug discovery is the process of identifying small molecules that treat a specific
disease and developing them to market approval. The entire process generally
takes 10 to 15 years1 and costs billions of dollars2. It can be separated into several
stages that will be described below and are shown schematically in Figure 1.3
The first stage involves finding a target, usually a protein, whose inhibition (or
activation) treats the symptoms or cures the disease.4 An assay is developed in
order to easily test the activity of compounds in a high-throughput fashion. Al-
though target-based drug discovery has been very popular in the era of molecular
sciences, alternative approaches like phenotypic assays are used when the target
is unknown.5 In this case, an assay is prepared whose readout is the alteration of
molecular markers related to the disease. The molecular basis of the effect of the
compound may not be known but can be neglected as long as the assay is a good
representation of the biology associated with the disease condition.
Once a reliable assay has been developed, a large screen of small molecules
is carried out.6 Active compounds found in the assays are called “hits”. These
hits are small molecules for which activity against the desired target has been con-
firmed.7 The structure of these compounds is optimized in design-make-test cycles
where new alterations are tested to determine their effect on molecular properties.
These modifications normally introduce chemical groups that create energetically
favorable contacts with the target, while reducing the possibility of binding to
undesired targets. At the same time, the absorption, distribution, metabolism,
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Figure 1: Drug discovery process. A schematic representation of the drug discovery
process is shown. The figure has been adapted from [3].
excretion, and toxicity (ADMET) of the molecules in vivo is modeled through
biochemical assays or computational prediction algorithms.8 If the ADMET prop-
erties are not managed correctly, the molecules will not be able to reach the target
(i.e., they will not be bioavailable) and will not show pharmacological effect.9
They could also develop toxic properties causing severe side effects. Therefore,
compound optimization is a multi-objective process where activity, bioavailability,
toxicity, and chemical synthesizability are improved together through structure
modifications.7 This process generates “lead” compounds that can be optimized
further to obtain drug candidates.
Preclinical studies begin once a candidate molecule is found that is safe, active,
and bioavailable. The compound is tested in vivo or in vitro to obtain an approxima-
tion of dosage for “first-in-man” studies.10 The information obtained in this step
will serve to design clinical trials, the final step in the drug discovery process. In
clinical trials the compound will be tested in humans against a control treatment
or a placebo.11 The results from these trials should provide evidence of the safety
and effectiveness of the candidate molecule. They will be submitted to regulatory
agencies as a prerequisite to bring the drug to the market.
The drug discovery process is a long and costly procedure. The cost of de-
veloping new drugs has increased exponentially for the past decades and the
number of new drugs introduced each year has remained constant.1 In order to
increase the efficiency of drug discovery, chemoinformatic approaches are used
to assist at different stages.12 Chemoinformatics has been defined as “the mixing
of those information resources to transform data into information and information into
knowledge for the intended purpose of making better decisions faster in the arena of drug
lead identification and optimization”.13 A central theme of this discipline is under-
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standing how structure modifications affect the properties of molecules. With this
information, compound optimization can be more focused, resulting in a faster
and more efficient process. In the next chapter, the analysis of the relation between
structure and property is introduced.
1.2 Structure-property relationship
There are many properties that need to be considered during compound opti-
mization. Activity is the most important one to take into account because without
it the disease condition is not treated. However, activity alone is not sufficient
to develop a drug and many other properties need to be examined. A common
example is lipophilicity, i.e., the tendency of a compound to dissolve in a nonpolar
medium like octanol.14 If a compound is too lipophilic, it will become trapped
in the cellular bilayer. If it is not lipophilic enough, it will not cross the mem-
brane of cells and not be absorbed from the gastrointestinal tract. Therefore, for
lipophilicity and many other properties some value ranges are considered favor-
able and others unfavorable. Another important property is the ionization state of
a molecule, i.e., the presence or absence of ionized chemical groups.15 The presence
of charged groups affects many other ADMET properties such as bioavailability
or lipophilicity.
Activity has been the main focus of chemoinformatics analyses because of its
importance in drug discovery. Structure-activity relationship (SAR) analysis aims
to determine how alterations in the structure of molecules affect their binding prop-
erties to a specific target.16 SAR analysis is frequently carried out on structurally
related compounds such as those forming analog series. If small modifications in
the molecular structure result in small differences in activity, the set of compounds
has continuous SAR character (Figure 2 top). By contrast, when small structural
changes lead to large potency differences, the SAR character is discontinuous
(Figure 2 bottom).
Discontinuous SAR often result in the presence of activity cliffs. Activity cliffs
are pairs of compounds that are structurally similar but have a large potency
difference.17 They have been extensively studied and characterized in various
ways.18 Alternative molecular representations and similarity measures (vide infra)
may create large variability in the distribution of activity cliffs for the same set
of compounds.19 The large potency difference between activity cliff partners has
also been rationalized on the basis of protein-ligand three-dimensional crystal
3
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Figure 2: SAR character. Two analog series are shown that display continuous (top) or
discontinuous (bottom) SAR character. Below each molecule its inhibition constant value
against carbonic anhydrase II is given.
structures.20 Therefore, activity cliffs highlight chemical groups critical for activity
against a specific target.
Although the previous paragraphs have focused on activity, the relation of
different properties to structure changes is analyzed in a similar manner. In this
way, SAR analysis is expanded to structure-property relationship (SPR) analysis.
In order to analyze SPRs of large molecule data sets, computational methods are
applied. These methods require molecules to be in a computer-accessible format.
Relations between compounds can only be studied with formally defined similar-
ity measures. In the next section, different molecular representations and similarity
measures are described. Afterwards, computational methods that analyze SPRs in
order to aid compound optimization efforts are reported.
1.3 Molecular representations and similarity measures
Appropriate representations are required to handle molecules in computer
code. Molecular structures are commonly modeled as annotated graphs where
vertices are the atoms and edges are the bonds of the molecule.21 For each atom,
4
characteristics such as charge, hybridization state, or stereochemistry are saved.
Additionally, two- or three-dimensional atom coordinates are stored if only the
topology of the molecule or a specific conformation is modeled, respectively.
Likewise, bond information such as order or stereochemistry is saved. This data
can be encoded into connectivity table file types, such as the MOL file type.22
In addition, linear notations such as SMILES23 and InChI24 can encode the two-
dimensional structure as a string.
Linear notations are very useful for fast identity comparisons of molecules.
Still, if the molecules are not identical, similarity measures need to compare the
two molecular graphs. This task is often performed through maximum common
substructure (MCS) computation, whose time complexity is known to be NP-
complete. Therefore, it is a computationally demanding calculation.25 Similarity
measures are important because many chemoinformatics algorithms rely on the
“similarity property principle”.26 This principle states that two molecules that are
similar should have similar properties. Accordingly, the systematic extraction of
pairwise similarity relationships is crucial for many chemoinformatics analyses.
1.3.1 Molecular descriptors
Molecular descriptors are mathematical models that describe the structure or
the properties of molecules. They represent various characteristics of the molecule
such as its topology, lipophilicity, size, or charge.27 Some simple descriptors, such
as atom counts and molecular weight, can be directly calculated from the molecular
formula or from linear notations. These simple descriptors are frequently called
1D descriptors, because they do not require atom connectivity information. Those
descriptors that require the molecular structure, such as topological indices, are
considered 2D descriptors. Finally, some descriptors, such as the dipole moment,
require a pre-specified three-dimensional conformation of the molecule to be
computed and are called 3D descriptors. A molecule can be represented by a set
of different descriptors encoded as a vector of numeric values (Figure 3).
Descriptor value vectors can be interpreted as positions in high-dimensional
space. In this property space each dimension corresponds to one descriptor and
molecules distribute based on their descriptor values. These high-dimensional
spaces are used to represent and study chemical space. Therefore, distance in
property space accounts for similarity between molecules. Any Lp-norm distance
(also called Minkowski distance) can be used, but the most common distances
employed are the Euclidean (p=2) and Manhattan (also called Hamming) distance
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Figure 3: Molecular descriptors and fingerprints. Penicillin G and the computation of
fingerprints and descriptors are depicted schematically. For substructure and pharma-
cophore fingerprints (FPs) the bit string is represented as a set of cells. Filled cells denote
chemical patterns present in the molecule. Unfilled cells represent absent patterns. For the
combinatorial FP one atom is taken as an example and all substructures rooted on this
atom with maximum radius of 2 are depicted with concentric layers. For each layer, the
substructure is given as a SMILES string and the hash value is reported. Finally, different
molecular descriptors are given.
(p=1).28 For two molecules, x and y, represented by n descriptor values, the
Minkowski distance follows the equation:
distance(x, y, p) =
(
n
∑
i=1
|xi − yi|p
)1/p
where xi and yi are the values of molecules x and y for descriptor i.
1.3.2 Fingerprints
Fingerprints represent a molecule with a set of Boolean values encoded as
a bit string. Each position in the bit string represents one chemical pattern and
if this pattern is present in the molecule the corresponding position will be set
on. There are different kinds of fingerprints depending on the types of chemical
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patterns they use. Substructure fingerprints use pre-specified molecular fragments
as patterns (Figure 3). One example is the Molecular ACCess System (MACCS)
keys consisting of a set of 166 substructures.29 Pharmacophore fingerprints de-
fine combinations of two, three, or four pharmacophore centers with different
distances between their members (Figure 3).30 These pharmacophore centers are
abstractions of the molecular structure where different chemical groups that share
common characteristics are considered together as the same pharmacophore type.
Common pharmacophore types include hydrogen bond donors, hydrogen bond
acceptors, and hydrophobic centers. Combinatorial fingerprints, in contrast to the
previous two, do not have a fixed size as they do not use pre-specified patterns
(Figure 3). For each molecule, all possible subgraphs up to a specific size are
enumerated and hashed into numbers. The set of numbers represent all possible
substructures present in the molecule. A commonly used combinatorial fingerprint
is the Extended Connectivity FingerPrint (ECFP).31
Similarity indices permit the calculation of chemical similarity based on bit
strings. They compare the overlap in chemical patterns present in each molecule
to obtain a similarity value. As with distances, there are many similarity indices
that can be employed. However, the Tanimoto coefficient (also called Jaccard
coefficient) is the most commonly used similarity index in chemoinformatics.32
It is a measure of the intersection divided by the union of the two pattern sets.28
Therefore, it can be understood as the percentage of shared chemical patterns
between two molecules. For a molecule x with a chemical patterns and a molecule
y with b chemical patterns, c of which are also present on molecule x, the Tanimoto
coefficient (Tc) is described as:
Tc(x, y) =
c
a + b− c
1.3.3 Scaffolds
Molecular similarity can be quickly computed as distances on property space
or as similarity indices based on binary bit strings. In comparison to graph-based
similarity measures, these methods trade a one-time penalty (calculation of the
fingerprint/descriptor vector) for a much faster similarity assessment. However,
it is sometimes not intuitive why two molecules have high similarity with these
methods when comparing their chemical structures.33 There have been many
attempts to provide similarity relationships based on chemical structures that are
not too computationally demanding. One approach is based on scaffolds.
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Figure 4: Scaffolds. The hierarchical organization of chemical structures is schematically
represented. The six molecules shown yield two different Bemis-Murcko scaffolds (BMSs).
These two BMSs both share the same cyclic skeleton (CSK).
Scaffolds represent chemical abstractions that describe the core structure of
a molecule.34 Two molecules that generate the same scaffold share a common
substructure. Although the term “scaffold” has been used frequently in medicinal
chemistry, authors apply it with different meanings and implementations.35 How-
ever, many applications have chosen a consistent definition proposed by Bemis
and Murcko.36
Bemis and Murcko divided compounds into rings, linkers, and sidechains.
Linkers are atom chains that do not belong to any ring, but connect two or more
rings. Sidechains, by process of elimination, are terminal atom chains connected
to a ring or a linker. According to the original definition, the combination of rings
and linkers creates a “framework”. These frameworks have emerged as the basis
for standard representations of scaffolds.
Two different scaffold representations can be derived from a framework. The
first one maintains the chemical information of the atoms and bonds that form
the framework. These are often called Bemis-Murcko scaffolds (BMSs). For the
second, all atoms in the framework are transformed to carbons and all bonds are
considered as single bonds.37 In this manner, chemical information is abstracted
but the connectivity information is preserved. These scaffolds are called cyclic
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skeletons (CSKs). There is an increasing abstraction of chemical information going
from molecules to BMSs to CSKs (Figure 4).
Although BMSs and CSKs are widely applied, they have some limitations. In
drug discovery, small rings are typically among the different chemical groups used
to optimize compounds. However, the addition of a ring modifies the framework
and, therefore, these molecules produce different BMSs and CSKs.38 This can make
a data set appear more diverse. There have been several attempts to organize
scaffold information on the basis of substructure relationships to identify sets of
structurally similar scaffolds.39,40
Two compounds that generate the same scaffold can be considered similar
because they have a common substructure. However, the size of the shared sub-
structure varies widely between different molecules. Additionally, molecules that
only differ by a small ring would be considered different. Therefore, scaffolds have
not frequently been used for pairwise similarity assessment but rather to cluster
heterogeneous compound data sets according to their chemical structure.
1.3.4 Matched molecular pairs
Matched molecular pairs (MMPs) are pairs of compounds that have a large
common substructure and differ only at one site.41 Similar to scaffolds, the two
molecules that form an MMP share a common substructure. Nonetheless, MMPs
can only have one site of variation while scaffolds can have many. The substructure
that is shared between MMP partners is called the key fragment. The substructures
that are different are called value fragments and together they define a chemical
transformation.42
After they were introduced, the calculation of MMPs was mainly done by
MCS computation between all pairs of compounds in a data set.43,44 This made
MMP generation very time consuming. An alternative method consisted of for-
mally defining a set of chemical transformations that were matched against all
compound pairs.45,46 MMPs were extracted from compounds matching any pre-
defined substitution. Still, this method restricted the chemical variety of MMPs to
study.
These methods were followed by a fragmentation-based algorithm published
in 2010.42 This algorithm consists of two steps: molecule fragmentation and MMP
generation. In the fragmentation, each molecule is split along single bonds that are
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Figure 5: Fragmentation. The four types of cuts performed during fragmentation are
schematically represented. The fragmented molecule is shown in the center. For each cut,
the key fragment is colored red and the value fragment is colored blue.
not part of a ring. When a bond is broken, an attachment point is added to each
fragment to keep connectivity information. Fragmentation can occur at one, two, or
three bonds at the same time generating single, double, or triple cuts, respectively.
In single cuts, the molecule is split into two fragments where the bigger one is
considered the key fragment (Figure 5 top left). In double cuts, three fragments are
generated. The two fragments with a single attachment point together constitute
the key fragment (Figure 5 bottom left). In triple cuts, four fragments are created
but only those cuts that generate three fragments with one attachment point and
one with three attachment points are considered valid. Similar to double cuts,
all fragments with a single attachment point are pooled together to generate
the key fragment (Figure 5 bottom right). Hydrogens are not usually present
as atoms in the molecule but as properties of other atoms. Therefore, the cuts
described so far cannot identify chemical transformations involving hydrogen
atoms, and hydrogen cuts are required to find those transformations. Hydrogen
cuts are obtained by taking every key fragment from single cuts, substituting the
attachment point for a hydrogen atom, and comparing the resulting structure to
all data set molecules. If any molecule matches, a new fragmentation is generated
where the key fragment is the same as in the single cut and the value fragment is a
hydrogen atom (Figure 5 top right).
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MMP generation begins after all molecules have been systematically frag-
mented. The resulting cuts are organized in an index table (Figure 6B). Key frag-
ments are used as indices while the value fragments are grouped according to
their key fragments. Once the fragmentation of all molecules is complete, the
index table is used to obtain the MMPs. For each entry, all pairs of value fragments
form MMPs. If for two molecules more than one MMP can be formed, the MMP
that maximizes the size of the shared substructure is chosen (Figure 6C). Size
restrictions should be applied to constrain the generation of MMPs to chemically
relevant analogs. A set of previously described size restrictions47 based on the
heavy atom (HA) number of the fragments is adopted throughout this thesis:
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(i) the number of HAs in key fragments should be at least twice the number of
HAs in their corresponding value fragments; (ii) value fragments should not ex-
ceed 13 HAs; and (iii) the size difference between the two value fragments of an
MMP should not be larger than 8 HAs.
MMPs represent an intuitive measure of chemical similarity. In contrast to sim-
ilarity indices and descriptor distances, there is always a structural justification for
each similarity relationship. However, it is a Boolean measure as two compounds
either form an MMP or they do not. Similarity indices and descriptor distances, by
contrast, can distinguish between closely related and distinct structures.
1.3.5 Extensions and applications of matched molecular pairs
The concept of MMPs has been heavily studied in recent years and several
extensions have been developed. One extension is fuzzy MMPs, i.e., pairs defined
not on molecules but on fuzzy representations thereof.48 Fuzzy molecular graphs
are typically pharmacophore-based simplifications that group different atoms
into a single element. For example, a benzene ring would be simplified to a
hydrophobic element.
MMPs have also been studied on the basis of protein-ligand crystal structures.49
The conformation of a ligand present in the crystal was used as a template to
superpose MMP partners. The effect of the chemical transformation on the affinity
was related to the binding pocket environment. These MMPs were published
on a public database called VAMMPIRE (Virtually Aligned Matched Molecular
Pairs Including Receptor Environment). This database was later used to derive
a predictive tool for lead optimization named VAMMPIRE-LORD.50 A similar
methodology has been reported to describe three-dimensional matched pairs
(3DMPs).51 In this case, ligand conformations were generated using templates
from analogous molecules in prealigned protein-ligand crystal structures. These
conformations were fragmented and those pairs of molecules that shared a large
common substructure that was near in three-dimensional space were considered
3DMPs. The analysis of 3DMPs and their activity change was applied to compound
design.
Matching molecular series (MMS) are sets of three or more molecules that
share a common substructure.52 This straightforward extension allows the study
of several closely related structures at the same time. They can represent analog
series for SPR analysis. MMS are obtained from the index table generated to
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create MMPs. Each entry in the table that contains at least three different value
fragments generates one series. MMS have been used to study SAR transfer.53
In SAR transfer, the potency progression of two chemically related MMS that
share several substitutions is analyzed. It not only allows the transfer of insights
obtained for one chemical series to another, but can also provide novel compound
suggestions. The SAR transfer methodology was extended to create a predictive
algorithm that suggested possible chemical modifications to improve activity
based on statistical analysis of large numbers of potency-ordered MMS.54
Additionally, the concept of chemically related MMS was used to develop a
novel visualization called the SAR Matrix (Figure 7).55 The set of SAR Matrices of a
data set organizes all structural relationships between compounds and enumerates
virtual molecules that represent analogous compounds not present in the data set.
Each compound is annotated with its activity. The SAR Matrix concept has been
extended to create Free-Wilson-type models that can predict the activity of virtual
compounds.56 It has also been adapted to analyze screening data and predict novel
hit compounds.57
Activity cliffs (vide supra) have been analyzed on the basis of MMP relation-
ships.47 These are called MMP-cliffs and they have become the preferred activity
cliff representation because of their intuitive nature. MMPs represent a conser-
vative measure of similarity compared to fingerprint-based similarity indices.19
They have not only been studied as isolated compound pairs. If any compound
forms more than one MMP-cliff to different partner molecules, networks of coordi-
nated MMP-cliffs emerge and their topology has been analyzed.58 A method was
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later developed to prioritize clusters of coordinated MMP-cliffs and extract SAR
information.59
MMPs are frequently used to obtain chemical transformations from sets of
compounds. In MMP analysis (MMPA), transformations are collected by grouping
MMPs with identical structure modifications and their effect on different molecular
properties is analyzed.60 In some cases, these transformations conserve the values
of different chemical properties such as activity and are considered bioisosteric. In
others, small modifications consistently cause large changes in property values.
Bioisosteric replacements have been intensively studied on the basis of MMPs61,
as well as chemical transformations that are frequently found between activity
cliff partners62. Recently, a study expanded on this idea analyzing the effect of
transformations on both potency and ADMET descriptors.63
Fuzzy MMPs are useful for MMPA on small compound data sets. By abstracting
chemical information, each different transformation will be more frequent. It
has been shown that a large number of MMPs per transformation is needed
to statistically characterize a large change in activity from heterogeneous data
sources (such as publicly available databases).64 Therefore, the effect of chemical
transformations can be determined with greater statistical rigor.
1.4 Compound optimization
Compound optimization is a multi-objective procedure that takes many prop-
erties such as potency, selectivity, bioavailability, and toxicity into account. These
properties generate a high-dimensional space where compounds distribute based
on their property values. The high-dimensional property space is used to represent
and study the chemical space, the set of all chemically feasible molecules. Because
of the large number of possible molecules (estimated to be 1033)65, the chemical
space is very large and a systematic exploration is complicated. However, drug
compounds are thought to be present in specific drug-like subspaces rather than
distributed over the whole space. Therefore, the search of characteristic property
value combinations that better determine drug-like character is a central part of
compound optimization. Additionally, the structure of the molecule determines
its property values and modifications of the structure affect several properties
at the same time. Hence, SPR analysis is crucial to understand which chemical
modifications lead to favorable value changes in order for compound optimization
to be a targeted process.
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Compound optimization can be approached with different methodologies.
Prediction methods and visualizations give insights into how chemical modifi-
cations affect property values. Composite measures are frequently used to drive
compound optimization or to filter out compounds thought to have unfavorable
properties. Moreover, multi-objective optimization algorithms are used to find the
most suitable compounds that best balance different properties.
1.4.1 Quantitative structure-property relationship
Quantitative structure-property relationship (QSPR) produces mathematical
models that attempt to predict property values of a compound based on its struc-
ture.66 Hansch and coworkers pioneered QSPR studies, focusing on activity pre-
diction or quantitative structure-activity relationship (QSAR).67 They analyzed
how different substitutions of a benzene ring altered properties such as lipophilic-
ity. Then, they correlated these changes to activity using linear functions. Along
with activity, toxicity prediction has also been heavily studied and is often used
by environmental government agencies and pharmaceutical companies to detect
hazardous substances or identify potentially toxic drug candidates.66
The first QSPR models aimed to provide a mechanistic interpretation of re-
lations between chemical structure and biological properties. Recent studies in-
creasingly focus on accurate predictions or classifications using nonlinear methods
taken from the machine learning field. These models are called “black boxes” be-
cause the results they provide are difficult to rationalize chemically.68 However,
recent studies have developed visualization strategies to better understand the
prediction results of these models.69
Support vector machine (SVM)70 is a popular machine learning method that
has been used in SPR analysis. SVM searches for a hyperplane that best separates
positive and negative instances in the data set. It has been used to predict activity
cliffs71 and find highly potent compounds72. The adaptation of SVM to regression
is called support vector regression (SVR).73 They are methodologically very similar.
SVR searches for a function that can predict values with a maximal error of
ε. The regression function is based on the hyperplane formulation from SVM
methodology and is defined as:
f (x) = 〈w, x〉+ b
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Similar to SVM, slack variables (ξi and ξ∗i ) are used to model penalties when
the predictive function cannot fit the data with a maximal error of ε. The parameter
C determines the cost of these slack variables for the optimization algorithm. SVR
attempts to minimize w based on a set of constraints.
minimize
1
2
‖w‖2 + C
l
∑
i=1
(ξi + ξ
∗
i )
subject to

yi − 〈w, xi〉 − b ≤ ε+ ξi
〈w, xi〉+ b− yi ≤ ε+ ξ∗i
ξi, ξ∗i ≥ 0
This optimization problem can be solved using the Lagrange formulation.
Thereby, αi, α∗i , ηi, and η
∗
i denote the Lagrange multipliers for each of the four
conditions specified above. All four multipliers have to be non-negative. The value
of the partial derivatives of the Lagrange function for w, b, ξi, and ξ∗i is zero at an
optimal point, allowing to reformulate the optimization problem as:
maximize
{
−12 ∑li,j=1(αi − α∗i )(αj − α∗j )
〈
xi, xj
〉
−ε∑li=1(αi + α∗i ) +∑li=1 yi(αi − α∗i )
subject to
l
∑
i=1
(αi + α
∗
i ) = 0 and αi, α
∗
i ∈ [0, C]
From this system, w can now be expressed as:
w =
l
∑
i=1
(αi − α∗i )xi
and the function can be then reformulated as:
f (x) =
l
∑
i=1
(αi − α∗i ) 〈xi, x〉+ b
Therefore, w is a linear combination of the training points xi and the prediction
formula only needs to calculate dot products between data points. Only those
data points for which (αi − α∗i ) is non-zero are taken into account for the model
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and are called the support vectors. Although the regression formula described
above can only model linear relations between structure and property, it can be
adapted for nonlinear regression with the “kernel trick”.74 Kernel functions replace
the dot product 〈xi, x〉 to obtain nonlinear models. The kernels are defined as:
k(xi, x) = 〈Φ(xi),Φ(x)〉, whereΦ is a mapping function into a higher dimensional
space. By finding a suitable kernel function, an explicit mapping of the data points
does not need to be calculated. However, unless the kernel function applied
is symmetric and positive semi-definite there are no guarantees that the SVR
optimization will find solutions.
1.4.2 Visualization
Visualizations allow the study of chemical space. They can offer insight into
SPRs present among compounds of a data set. Therefore, they can be used to
highlight subsets of compounds that present interesting properties and search for
regions of space with drug-like compounds. Most implementations have focused
first on activity analysis. Consequently, SAR visualization has received a lot of
attention in the last years.33 Several applications have been developed based on
different molecular representations or for specific types of data sets.
Visualizations can be categorized as coordinate-free or coordinate-based. In
coordinate-free representations, the distance between molecules in the plot is
meaningless. A common example is a graph. In coordinate-based visualizations,
the distance between molecules in the display correlates with their similarity. A
prototypical example is a scatter plot. The first implementations did not represent
molecules directly but rather molecule pairs.
Coordinate-based plots were introduced for SAR analysis with the Structure-
Activity Similarity (SAS) maps.75 SAS maps are two-dimensional scatter plots
where every data point represents a compound pair. One axis measures the sim-
ilarity between the two compounds of the pair. The other axis represents the
potency difference. This visualization can quickly highlight activity cliffs, as they
concentrate on a specific quadrant of the plot. Several other scatter plot designs
have been derived from the SAS maps. They all use compound pairs as data points
but differ in the information that is displayed on the axes. Dual and triple activity
difference maps are two- and three-dimensional scatter plots where each axis
displays potency difference for a defined target.76 In comparison to SAS maps,
compound similarity is not modeled explicitly in the represented space but can
be added through data point annotation. Additionally, molecule pairs with low
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similarity can be omitted to focus the visualization on selectivity switches and
multi-target activity cliffs.
In the previous paragraph, only similarity values between molecules were
needed because compound pairs, rather than single molecules, were studied.
However, the distribution of individual compounds in high-dimensional property
space cannot be visualized directly. Therefore, dimensionality reduction techniques
are used to obtain representations of chemical space suitable for visualization.
The more frequently used methods in chemoinformatics are principal component
analysis (PCA) and multi-dimensional scaling (MDS).
PCA performs an orthogonal transformation of the original high-dimensional
space.77 It generates a set of uncorrelated principal components created as linear
combinations of original descriptors and ranked based on the fraction of original
variance that they conserve. Principal components can be obtained from the
eigenvectors of the covariance matrix of the descriptor values and can therefore
vary when the descriptor values are scaled.78
MDS is not a transformation like PCA but a mapping. Its modern implemen-
tation was defined by Kruskal.79 Each data point in high-dimensional space is
mapped to a point in a space with reduced dimensionality (for display purposes it
will be two- or three-dimensional). The mapping function minimizes the difference
between the distances in high-dimensional space and the distances in the reduced
space.
Three-dimensional activity landscapes use dimensionality reduction to dis-
play chemical space.80 In contrast to SAS maps, each data point is a molecule
rather than a molecule pair. Principal components of a descriptor set or MDS of a
fingerprint-based similarity matrix are used to obtain a two-dimensional repre-
sentation of chemical space. Activity is displayed on the third axis. A surface is
interpolated between data points, colored based on the activity values, to create a
plot reminiscent of geographical landscapes (Figure 8A). This activity landscape
gives a quick overview of the SAR character of the data set. Continuous sets do
not have large differences in their potency values and therefore resemble plains.
Discontinuous sets, however, have a much more mountain-like character with
highly potent molecules generating peaks and weakly potent molecules produc-
ing valleys. An extension to multi-target analysis has been published where the
chemical and biological space are visualized together using radial coordinates.81
Coordinate-free visualizations were popularized by the Network-like Similar-
ity Graph (NSG).82 The underlying data structure is a fingerprint-based similarity
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Figure 8: SAR visualization. A three-dimensional activity landscape (A) and a network-
like similarity graph (B) are shown. In both visualizations, potency is represented by the
same color scheme, going from red (high potency) through yellow to green (weak potency).
In (B), the size of the nodes correlates with their compound-based SAR discontinuity
measure.
matrix that is transformed into an adjacency matrix using a pre-specified threshold
value. All pairwise relations between compounds are contained in the similarity
matrix but only those that are of interest will be displayed. The nodes in the graph
are colored according to activity values. Their size correlates with their SAR dis-
continuity, i.e., if many neighboring molecules have large differences in activity the
node will be large. The layout of the graph is generated algorithmically (usually
with force-directed layouts such as the Fruchterman-Reingold algorithm83) to
maximize clarity. Therefore, pairwise distances between molecules are meaning-
less in the visualization (Figure 8B). The NSG has been adapted for selectivity84,
mechanism of action85, or multi-target analysis86.
MMP relationships have also been used to generate network representations
such as the bipartite matching molecular series graph.52 Each key in the index
table that has at least two values creates an uncolored node connected to nodes
representing the molecules that generated the value fragments. Molecule nodes are
colored based on activity. If molecules participate in MMP relationships based on
different key fragments, they will be connected to several key nodes. Additionally,
scaffold relations have been used as the basis of a visualization. In the layered
skeleton-scaffold organization graph, BMSs and CSKs are systematically generated
for all compounds.87 Each CSK is displayed as a black square containing one pie
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chart per BMS they represent. Each pie chart is divided into equal sections for
each compound the BMS represents and each section is colored based on potency.
CSKs are laid out in concentric circles based on their ring number and connected
to other CSKs with which they have substructure relationships.
1.4.3 Composite measures in compound optimization
Measures that combine several properties have been described to filter com-
pounds with unfavorable properties. One well known example is Lipinski’s rule
of five that classifies compounds as orally available or not.88 A research group
at Pfizer analyzed the values of four molecular descriptors for compounds that
reached phase II clinical trials. These molecules were considered to have good oral
bioavailability. They found a set of threshold values that contained around 90% of
the compounds under study. According to these rules, a molecule is expected to
have good oral bioavailability for values of:
• molecular weight lower than 500 Da
• lipophilicity (as cLogP) lower than 5
• number of hydrogen bond donors (OH and NH groups) less than or equal 5
• number of hydrogen bond acceptors (O and N atoms) less than or equal 10
It must be emphasized that although the simplicity of these rules have made
them ubiquitous they are not infallible. There are successful oral drugs, such as
atorvastatin, that fail one or more of these rules.89 Natural products, source of
several drugs, are also frequent violators of these rules.90
Another popular measure applied in compound optimization is ligand effi-
ciency.91 The concept originated from an analysis comparing binding affinities
to molecular size.92 According to this study, for small molecules the addition of
one atom can lead to an improvement of up to 1.5 kcal/mol in binding affinity.
However, as molecules become larger, this gain per atom is reduced. The energy
contributed by each atom becomes lower and the efficiency of the ligand decreases.
Ligand efficiency has been measured in many ways.93 At its core, it is a ratio
of affinity against size. Affinity can be measured as change in free energy or
through dissociation constants. Similarly, size can be measured as number of HAs
or with molecular weight. Ligand efficiency has been used to drive compound
optimization successfully.94 There are alternative measures that compare activity
not against size but against lipophilicity95 or polar surface area96.
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Figure 9: Pareto optimization. A schematic representation of a multi-objective optimiza-
tion is shown. Two different objectives are minimized. Each data point corresponds to
a molecule. If any other compound has lower values for both objective functions, it is
considered dominated and colored red. If no other molecule has lower values for both
objective functions, it is considered non-dominated and colored blue.
1.4.4 Multi-objective optimization
Compound optimization is straightforward when a single objective is applied
to rank compounds. However, if two or more conflicting objectives are evaluated,
ranking compounds becomes challenging. Rather than focusing on each objective
sequentially, multi-objective optimization searches for solutions that represent the
best compromise between the different objectives.97 Consider a set of compounds
ranked based on different objectives. For each objective, an individual ranking is
obtained. Those molecules for which no other compound is better in all rankings
are considered non-dominated and represent unique optimal trade-offs between
the different objectives (Figure 9). The concept originated in economics and was
developed by Vilfedo Pareto.98 Consequently, these solutions are often called
Pareto solutions and their combination the Pareto front. However, the modern
mathematical formulation of multi-objective optimization was pioneered by Kuhn
and Tucker.99
Multi-objective optimization has been applied to docking, de novo compound
design, and library generation.100 Heuristic methods are often needed to drive
the optimization because of the large size of chemical space. Some of the more
common ones are evolutionary algorithms that simulate natural selection.101 Other
algorithms that use biological concepts are swarm intelligence algorithms like
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particle swarm optimization, which mimics the behavior of birds in a flock.102
Particle swarm optimization has been applied to obtain subsets of compounds
from a data set with desired properties.103
1.5 Outline of the thesis
This thesis focuses first on the development of novel applications of MMPA. In
chapter 2, the ionization state of publicly available bioactive molecules is explored.
The frequency of ionization state changes among MMP partners is analyzed.
Additionally, the relation between ionization state and activity is rationalized.
In chapter 3, ligand efficiency is examined. The difference in ligand efficiency
is compared on the basis of different molecular representations of activity cliffs,
including MMP-cliffs.
The following chapters focus on extensions of MMPs. In chapter 4, second
generation MMPs created on the basis of retrosynthetic rules are described. These
new MMPs, named RECAP-MMPs, have transformations that are easier to apply
to chemical synthesis than standard MMPs. In chapter 5, MMS are used to obtain
SAR information for confirmed hit compounds. SAR information is gained from
potency-ordered MMS to which these hits are mapped through MMP fragmenta-
tion. In chapter 6, MMPs are used to develop kernel functions for SVR. These SVR
models are applied to predict the potency change between MMP partners.
In the final chapters, the focus changes to representations of chemical space
and their utility to multi-objective compound optimization. In chapter 7, MMPA
is combined with visualization of high-dimensional space. Principal component
plots are used to rationalize property changes from an MMP-driven compound
optimization procedure. In chapter 8, star coordinate and parallel coordinate plots
are introduced to the medicinal chemistry community. They are applied to dif-
ferentiate between distinct drug-like subspaces obtained from an optimization
task. In chapter 9, a novel visualization to explore high-dimensional spaces us-
ing coordinate-free representations is presented. It extends the chemical space
network concept and offers an overview of important similarities in property
space to quickly focus on specific compound subsets of interest. The final chapter
summarizes the main points of this work and serves as a conclusion of the thesis.
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2 Target-based analysis of
ionization states of bioactive
compounds
Introduction
The ionization state of a compound is important for its activity and in vivo
properties. Many drugs, nearly four out of five, contain chemical groups that are
partly ionized under physiological pH, i.e., the pH commonly encountered in
humans.15 Because of its importance, there have been several studies of ionization
state of drugs and bioactive compounds.104–106 However, the effect of structure
modifications on the ionization state has not been previously evaluated. In this
study, the ionization state of bioactive compounds is analyzed in detail. The
relationship of activity and ionization state is evaluated for individual targets
and superfamilies. Finally, the effect of small structure modifications is studied
through MMP relationships.
My main contribution to this work was the analysis of the ionization state
distribution among ligands active against specific targets and superfamilies. This
study was published as:
S. Kayastha, A. de la Vega de León, D. Dimova, J. Bajorath. Target-based analysis
of ionization states of bioactive compounds. MedChemComm 2015, 6, 1030–1035.
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Materials and methods
Bioactive compounds were obtained from the ChEMBL database107 (version
19). Compounds were extracted only if equilibrium constant (Ki) values were
available with the highest confidence level for human proteins. In case several
activity measures were present for a single compound and they differed by more
than one order of magnitude, this compound was excluded from the analysis. If
all values were within one order of magnitude, the geometric mean was taken
as the final activity measure. Compounds were considered highly potent if their
potency value was at least 100 nM and weakly potent if it was at most 1 µM. A
total of 80 776 compounds were obtained and they were organized in 719 different
target sets. Each target was assigned to a superfamily based on the ChEMBL target
classification.
The dissociation constant (Ka) is the equilibrium constant between the ionized
and neutral form of a chemical group. The dissociation constant for the most acidic
chemical group (A_pKa) and the most basic chemical group (B_pKa) were obtained
from ChEMBL as pKa values, i.e., the negative decadic logarithm of Ka. Com-
pounds were classified on the basis of A_pKa and B_pKa values as four ionization
state classes (IS-classes): neutral, acidic, basic, and zwitterionic. The classification
was based on a previously published methodology.106 The Henderson-Hasselbalch
equation108 was employed, along with a physiological pH of 7.4, to calculate how
ionized the most acidic and basic chemical groups were. If both an acidic and a
basic group in the same molecule were more than 50% ionized, the compound
was classified as zwitterionic. If only an acidic group or a basic group, but not
both, were more than 50% ionized, the compound was classified as acidic or basic,
respectively. If no chemical group was more than 50% ionized, the compound was
classified as neutral. Finally, if no A_pKa and B_pKa values were present in the
database, the molecule was not classified (NA). Target sets were excluded from the
target distribution analysis if they contained less than 10 compounds or if more
than 20% of their compounds were not classified, leaving 351 target sets.
MMPs were obtained for each target set (see section 1.3.4) using an in-house
Java program based on the OpenEye toolkit110. MMPs were not calculated for
compounds that could not be classified. Those target sets that generated less than
50 MMPs were excluded from the MMP analysis. Finally, 290 different target sets
were left, representing 66 871 compounds and 338 419 MMPs. Compounds were
assigned to three different categories based on the ionization state of MMP partners
(Figure 10). If all partners had the same IS-class as the molecule, it belonged to
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Figure 10: Chemical neighborhoods. The figure shows the IS-class composition of chem-
ical neighborhoods formed by compounds assigned to category (CAT) I–III and their
MMP partners. Color denotes IS-class (red, acidic; blue, basic; white, neutral; dual colored,
zwitterionic). The figure has been adapted from [109].
category I. If some but not all partners belonged to different IS-classes, the molecule
was added to category II. Finally, if all partners belonged to different IS-classes
than the compound, it was considered category III.
Results and discussion
We first analyzed the frequency of different IS-classes among bioactive com-
pounds (Figure 11A). Similar frequency of basic (39.2%) and neutral compounds
(38.6%) were present in the target sets. The frequency of acidic (10.3%) and zwitte-
rionic (3.5%) compounds was much lower. Comparable proportions were found
when focusing only on highly potent compounds. Over all target sets, IS-class
distribution of highly potent compounds did not differ from weakly potent com-
pounds.
Next, we focused on the distribution of IS-classes in different target sets. For
individual target sets, one IS-class was usually prevalent. In 90% of the target sets,
at least 50% of the compounds belonged to the same IS-class. Moreover, for 40%
of the target sets, at least 80% were assigned to the same class. Table 1 lists target
sets with over 200 compounds where the largest prevalence of IS-classes was
observed. For many targets, basic compounds represented the dominant IS-class.
Nevertheless, large prevalence of acidic compounds (among prostaglandin D2
receptor 2 ligands) and neutral compounds (among vanilloid receptor ligands)
was also observed. These values indicate that many targets may preferentially
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Figure 11: IS-class distribution. (A) Distribution of IS-classes among bioactive com-
pounds (solid bars) and a subset of highly potent (HP) compounds (striped bars). Numbers
over the bars represent the number of compounds for each IS-class. (B) IS-class distribution
over superfamilies. The percentage of compounds belonging to each IS-class is displayed
over each bar. Compounds that could not be classified are not shown. The figure has been
adapted from [109].
bind compounds from a specific IS-class. Furthermore, for 57 target sets a notable
difference in the distribution of IS-classes between weakly and highly potent
compounds was found. For example, for the neurokinin 2 receptor target set, more
than 70% of highly potent compounds were basic while only 12% of weakly potent
molecules were. On the other hand, almost 80% of weakly potent neurokinin
2 ligands were neutral but only 24% of highly potent compounds were. Taken
together, these results provide further evidence of the importance of ionization
state for compound activity values.
Target sets were further grouped into four different superfamilies: enzymes,
membrane receptors, transporters, and ion channels. Targets that did not belong
to any of the previous four superfamilies were grouped together as other. Large
differences in IS-class distribution were present between the superfamilies (Figure
11B). For enzymes, neutral compounds represented the majority IS-class (50%)
while basic and acidic compounds had similar frequency, 20% and 15% respec-
tively. Basic compounds were the most frequent IS-class in all other superfamilies.
However, the difference in frequency to neutral compounds was small in mem-
brane receptor (46% to 36%) and other (44% to 31%) but large in transporter (67%
to 14%) and ion channel (50% to 26%) superfamilies. Acidic and zwitterionic com-
pounds were not frequent in the superfamilies, rarely exceeding a frequency of
10%. Similar to individual target sets, superfamilies displayed marked preferences
for specific IS-classes.
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Table 1: Target sets that display large ionization state class prevalencea
TID Target name # Cpds IS-class
5071 Prostaglandin D2 receptor 2 468 99% acidic
4794 Vanilloid receptor 253 97% neutral
259 Melanocortin receptor 4 1217 92% basic
264 Histamine H3 receptor 2023 92% basic
1898 Serotonin 1b (5-HT1b) receptor 364 92% basic
335 Protein-tyrosine phosphatase 1B 243 91% acid
344 Melanin-concentrating hormone receptor 1 846 90% basic
4644 Melanocortin receptor 3 350 90% basic
4608 Melanocortin receptor 5 268 88% basic
1983 Serotonin 1d (5-HT1d) receptor 359 87% basic
1800 Corticotropin releasing factor receptor 1 473 84% neutral
222 Norepinephrine transporter 1010 84% basic
232 Alpha-1b adrenergic receptor 290 84% basic
228 Serotonin transporter 1337 83% basic
2492 Neuronal acetylcholine receptor protein 253 83% basic
alpha-7 subunit
238 Dopamine transporter 867 81% basic
3798 Calcitonin gene-related peptide 349 81% neutral
type 1 receptor
1916 Alpha-2c adrenergic receptor 295 80% basic
2954 Cathepsin S 375 80% neutral
210 Beta-2 adrenergic receptor 241 80% basic
aThe top 20 target sets with largest prevalence of a single ionization state class
(IS-class) are reported. The table lists the ChEMBL target identifier (TID), name,
number of compounds (# Cpds), and IS-class.
The second part of the analysis focused on the effect of small structure changes
on the ionization state and the description of chemical neighborhoods on the
basis of IS-classes. Most MMPs were ionization state conservative because only in
13.6% the two compounds of the pair had different IS-classes. Even though most
chemical transformations did not alter the ionization state of a molecule, almost
a third of the compounds had heterogeneous chemical neighborhoods. 28.7% of
the compounds were assigned to category II and 2.5% to category III. 68.8% of
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all molecules explored had neighborhoods with conserved ionization states. The
conservation of IS-classes for MMP partners is a favorable characteristic, because
binding to a particular target often requires a specific IS-class.
Conclusions
We have systematically analyzed the ionization state of publicly available
bioactive compounds on the basis of high-confidence activity data. The focus of
this study was not on drug compounds and this set it apart from many previous
analyses of ionization state. Bioactive compounds were predominantly neutral
or basic under physiological pH. The overall distribution of IS-classes in highly
potent and weakly potent compounds was very similar. However, for many target
sets a strong preference for a specific IS-class was detected. There were also many
target sets where different IS-class distributions were found for highly and weakly
potent compounds. Small structural changes encoded in MMP transformations
only rarely altered the ionization state of a molecule.
Ionization state has been further established as an important property for drug
development efforts. A specific IS-class is often found in most compounds that
bind to a particular target and structural changes do not often change the IS-class.
Another important property used in compound optimization is ligand efficiency, a
measure that relates potency and size. In the next chapter, a ligand efficiency anal-
ysis is carried out on the basis of different activity cliff representations including
MMP-cliffs.
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3 Formation of activity cliffs is
accompanied by systematic increases
in ligand efficiency from lowly to
highly potent compounds
Introduction
Ligand efficiency has proven to be an effective measure to drive compound
optimization. Additionally, activity cliffs represent important sources of SAR
information for compound optimization. Despite the fact that both topics have
seen large interest in the chemoinformatics and medicinal chemistry community,
their connection has never been explored before. It is unknown if the large potency
increase found in activity cliffs is correlated with a proportional increase in the size
of the molecule that would leave ligand efficiency unchanged. In this study, we
present an analysis of the ligand efficiency change between compounds forming
activity cliffs. Ligand efficiency change is compared for activity cliffs based on
fingerprint-based similarity indices and MMPs.
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Abstract. Activity cliffs (ACs) are defined as pairs of structurally similar compounds sharing the same
biological activity but having a large difference in potency. Therefore, ACs are often studied to
rationalize structure-activity relationships (SARs) and aid in lead optimization. Hence, the AC concept
plays an important role in compound development. For compound optimization, ligand efficiency (LE)
represents another key concept. LE accounts for the relation between compound potency and mass. A
major goal of lead optimization is to increase potency and also LE. Despite their high relevance for drug
development, the AC and LE concepts have thus far not been considered in combination. It is currently
unknown how compounds forming ACs might be related in terms of LE. To explore this question, ACs
were systematically identified on the basis of high-confidence activity data and LE values for cliff partners
were determined. Surprisingly, a significant increase in LE was generally detected for highly potent cliff
partners compared to their lowly potent counterparts, regardless of the compound classes and their
targets. Hence, ACs reveal chemical modifications that determine SARs and improve LE. These findings
further increase the attractiveness of AC information for compound optimization and development.
KEY WORDS: activity cliffs; drug development; ligand efficiency; matched molecular pairs; structure-
activity relationships.
INTRODUCTION
The activity cliff (AC) concept plays a key role in structure-
activity relationship (SAR) analysis (1–3). ACs are generally
defined as pairs or groups of structurally similar or analogous
active compounds having a large difference in potency (1–3). As
such, ACs are prime indicators of SAR discontinuity (1,2)
because small chemical changes lead to large biological effects.
Therefore, SAR determinants can often be deduced from ACs
(2,3). Although ACs have traditionally been considered on a
case-by-case basis by focusing on one compound series at a time,
they have recently been systematically investigated across
compounds active against current pharmaceutical targets (2,3),
thereby considerably increasing the knowledge base for SAR
exploration and compound development (3).
Lead optimization generally aims to improve target-specific
potency and other compound properties relevant for drug
development (4). In order to increase potency, various R-groups
are typically added to candidate compounds and their hydro-
phobic character is frequently increased (4). Thus, potency
improvements often come at a price of increasing molecular
mass and hydrophobicity, which in turn result in less favorable
absorption, distribution, metabolism, and excretion
characteristics. Therefore, potency is often not considered as
an individual property but related to molecular mass, thus
leading to the ligand efficiency (LE) assessment (5,6). The LE
concept has its origins in attempts to account for compound
potency on a per-atom basis (7). Accordingly, LE is usually
calculated by dividing compound potency (e.g., pKi values) by
the number of non-hydrogen atoms in a compound (5) or by its
molecular weight (6). As such, LE is a simple and intuitive
measure of compound optimization progress, despite some
intrinsic limitations (8). Ideally, LE values should increase
during compound optimization but not significantly decrease.
In practice, LE values often remain more or less constant during
successful optimization efforts (9–11).
Despite their intuitive nature and high relevance for
compound optimization, the AC and LE concepts have thus
far not been considered in combination. Rather, AC analysis
has generally been potency-centric (2). Therefore, we have
systematically analyzed ACs from an LE perspective and
compared LE values for highly and lowly potent cliff partners
across many different compound activity classes. The results
of our analysis are presented herein.
MATERIALS AND METHODS
Datasets
Compounds against human targets were extracted from
ChEMBL version 15 (12) by applying the following criteria.
Only compounds with numerically exact Ki values reported
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for direct target interactions at the highest level of confidence
(ChEMBL confidence score 9) were considered. If more than
one Ki value for the same target was reported for a
compound, it was discarded if these values differed by more
than one order of magnitude. If the values fell within the
same order of magnitude, their average was calculated as the
final potency annotation. We obtained 610 different target
sets comprising a total of 41,127 compounds. Individual target
sets contained up to 2,307 compounds.
Molecular Representations
Molecular fingerprint- and graph-based compound
representations (e.g., matched molecular pairs; see below)
were calculated to identify ACs (2,3). As fingerprints,
MACCS structural keys (13), a dictionary containing 166
different molecular fragments, and the extended connec-
tivity fingerprint with bond diameter 4 (ECFP4) (14), a
topological fingerprint capturing layered atom environ-
ments, were calculated using the molecular operating
environment (MOE) (15). These two fingerprints of
different design are currently most frequently used in AC
analysis (2). The molecular weight (MW) and logP value, a
measure of lipophilicity, of each compound was also calculated
with MOE.
Matched Molecular Pairs
Matched molecular pairs (MMPs) are defined as pairs of
compounds that differ only by a structural change at a single
site (16), i.e., the exchange of a substructure, termed a
chemical transformation (17). MMPs were systematically
calculated for compounds in all target sets using an in-house
implementation of the algorithm by Hussain and Rea (17)
based on the OEChem toolkit (18). For AC assessment,
transformation size-restricted MMPs were selected (19). The
difference in size between the exchanged substructures was
limited to at most 8 non-hydrogen atoms and the maximal
size of an exchanged fragment was limited to 13 non-
hydrogen atoms. In addition, the number of non-hydrogen
atoms comprising the common parts (core structure) of two
compounds had to be at least twice the size of each of two
distinguishing substructures. These size restrictions generally
limit transformations to chemically meaningful replacements
(19). If several transformations met the size restrictions for a
given compound pair, the smallest transformation was
selected.
Activity Cliffs
For AC assessment, similarity and potency difference
criteria must be specified. In order to limit the analysis to ACs
of significant magnitude, a difference in potency (equilibrium
constants) of at least two orders of magnitude was consis-
tently applied (2,3). Alternative similarity criteria were
considered. For MACCS and ECFP4 fingerprint representa-
tions, Tanimoto coefficient (20) values of at least 0.85 and
0.56, respectively, were required to qualify two compounds as
cliff partners (3). ACs formed on the basis of MACCS and
ECFP4 representations were designated fingerprint-cliffs. In
addition, the formation of transformation size-restricted
MMPs was applied as a substructure-based similarity criterion
for AC formation (3). If compounds in a transformation size-
restricted MMP displayed a potency difference of at least two
orders of magnitude, they formed a so-called MMP-cliff (19).
For each AC, the compound with high potency and com-
pound with low potency forming the cliff were designated the
“highly potent cliff partner” and the “lowly potent cliff
partner,” respectively.
Ligand Efficiency
LE was calculated using the Binding Efficiency Index
(BEI) (6) defined as follows:
BEI ¼ pKi=MW log unit=kDa½ :
Because BEI values were only calculated and compared
for structurally similar/analogous compounds, corrections for
potential size dependence were not required (8).
Statistical Analysis
Statistical analysis of data distributions was carried out
using the R package stats (21).
Table I. Target Sets with Largest Numbers of ACs
Target name No. ACs
Coagulation factor X 3,972
Melanocortin receptor 4 2,890
Mu opioid receptor 2,645
Cannabinoid CB2 receptor 2,380
Adenosine A2a receptor 2,290
Adenosine A3 receptor 2,096
Thrombin 1,810
Kappa opioid receptor 1,704
Histamine H3 receptor 1,643
Purinergic receptor P2Y12 1,601
Dopamine D2 receptor 1,524
Melanin-concentrating hormone receptor 1 1,500
Bradykinin B1 receptor 1,210
Histamine H4 receptor 1,126
Serotonin 6 (5-HT6) receptor 949
Calcitonin gene-related peptide type 1 receptor 918
Corticotropin releasing factor receptor 1 888
G protein-coupled receptor 44 853
Muscarinic acetylcholine receptor M3 832
Gonadotropin-releasing hormone receptor 755
Serotonin 1a (5-HT1a) receptor 720
Adenosine A2b receptor 695
Cannabinoid CB1 receptor 666
Vasopressin V1a receptor 590
Furin 519
Carbonic anhydrase I 518
Neuropeptide Y receptor type 5 513
Dopamine transporter 495
Dopamine D3 receptor 494
Delta opioid receptor 478
Targets yielding the largest number of ACs (fingerprint plus MMP-
cliffs) are reported
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RESULTS AND DISCUSSION
AC Statistics
For each of our 610 target sets, ACs were systemat-
ically calculated using alternative molecular representa-
tions. From all 41,127 compounds, 22,109 and 17,312
MACCS- and ECFP4-based fingerprint-cliffs were obtain-
ed, respectively. In addition, 18,208 MMP-cliffs were
identified. Thus, a very large pool of ACs was available
for our analysis, originating from compounds active against
the spectrum of current pharmaceutical targets. Table I
lists the 30 targets yielding most ACs. The frequency of
occurrence and potency range distribution of ACs has
previously been determined (22). ACs spanning a potency
difference of at least two orders of magnitude on the basis
of equilibrium constants over all available potency ranges
provide a statistically preferred and chemically reliable
pool of ACs for further exploration (22). We adhere to this
AC assessment herein.
LE Analysis
For each AC-forming compound, its LE value was
calculated, and for each AC, the LE values of highly and
lowly potent cliff partners were compared. Figure 1 reports
the distribution of LE values for highly and lowly potent cliff
partners identified on the basis of different molecular
representations. In each case, LE values of highly potent cliff
compounds were on average significantly larger than the
values of lowly potent cliff partners. For different molecular
representations, the profiles of the LE distributions were
rather similar. Importantly, for 99.1, 96.9, and 97.4% of the
MMP-, MACCS-, and ECFP4-based ACs, respectively, an
Fig. 1. Distribution of LE values. For all ACs obtained on the basis of MMPs (blue),
MACCS (red), and ECFP4 (green), the distribution of LE values for lowly potent (dashed
lines) and highly potent cliff partners (solid lines) is reported
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increase in LE was detected for the highly potent
compared to the lowly potent cliff compound; a surprising
finding.
LE Differences
Figure 2 compares the distributions of LE differences
between cliff-forming compounds. For fingerprint-based
ACs, the distributions were extremely similar, with
average LE difference values of 5.38 for both MACCS
and ECFP4. However, for MMP-cliffs, the distribution was
shifted towards larger LE differences, yielding an average
value of 6.25. On the basis of a two sample unpaired t test
(Table II), the difference between fingerprint- and MMP-
based ACs was statistically highly significant. Thus, for the
structurally more conservative MMP-based AC represen-
tations, larger differences in LE values between lowly and
highly potent cliff partners were detected than for
fingerprint-based AC representations that relied on the
calculation of (whole-molecule) Tanimoto similarity. Hence,
from an LE perspective, MMP-cliffs were preferred for AC
representations.
LE vs. MW, Potency, and logP Differences
We also analyzed the relationship between LE and
MW differences of AC partners. For 54.9, 58.2, and 57.3%
of all MMP-, MACCS-, and ECFP4-based ACs, respec-
tively, the highly potent cliff partners had larger MW than
the lowly potent compounds. However, for 98.4, 95.4, and
95.5% of these ACs, the highly potent cliff partners also
had larger LE values than their lowly potent counterparts.
Figure 3 shows the comparison of LE and MW differences
for MMP-cliffs and Fig. 4 the comparison of LE and
potency differences. No statistically significant correlation
between LE and MW or potency differences was detected.
Furthermore, the relationship between LE and logP
differences was also explored. LogP values of highly and
lowly potent cliff partners were calculated as a measure of
lipophilicity. For MMP-, MACCS-, and ECFP4-based
ACs, the average change in logP values between com-
pounds forming an AC was 0.16, 0.19, and 0.20, respec-
tively. Figure 5 shows a comparison of LE and logP
differences for MMP-cliffs. No significant correlation
between LE and logP differences was observed. Taken
together, these findings indicated that the observed LE
increases for ACs were largely independent of MW or
lipophilicity variations between cliff partners. Hence, large
potency differences between cliff partners mostly deter-
mined LE increases.
Exemplary ACs
In Fig. 6, four MMP-cliffs are shown in which the highly
potent cliff partner had larger MW and LE values than the
lowly potent compound. These MMP-cliffs involve com-
pounds of different size and chemical complexity (as well as
different activity). In the first two examples (from the top),
the MW increase was small and the LE increase was large, as
often observed for different ACs. In the two remaining
examples, MW increases are nearly maximal for MMP-cliffs
(given the transformation size restrictions). In these extreme
cases, MW increases are large and LE increases are small. In
Fig. 2. LE difference distribution. The difference in LE between highly and lowly potent
partners are compared for ACs obtained on the basis of MMPs (blue), MACCS (red), and
ECFP4 (green). Negative values represent a decrease in LE as potency increases and
positive values a corresponding increase in LE
Table II. T-test for LE Difference Distributions
LE diff. distribution T statistic p value
MMP vs. MACCS 20.58 1.54E-93
MMP vs. ECFP4 19.59 5.93E-85
MACCS vs. ECFP4 −0.012 0.99
In order to compare LE difference distributions forAC sets according to
Fig. 2, a two-sample unpaired t test was performed. Values of the T
statistic and p values are reported
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the majority of cases, larger LE increases were observed, as
reflected by the LE value and difference distributions
reported herein.
CONCLUSIONS
The AC and LE concepts are focal points of SAR
analysis and compound development. ACs are explored to
identify SAR determinants and design analogs of active
compounds, and increasing LE is utilized as a guiding
principle during lead optimization. However, despite these
conceptual relationships, ACs have, thus far, not been
analyzed from an LE perspective. To these ends, we have
carried out a large-scale analysis of ACs and calculated LE
values for cliff-forming compounds. From a total of more than
41,000 unique compounds belonging to 610 different target
sets, ACs were systematically extracted on the basis of high-
confidence activity data and alternative molecular represen-
tations. The resulting AC populations were subjected to LE
analysis. For each AC, LE values of the highly and lowly
potent cliff partners were compared. On the basis of this
analysis, very strong trends were observed. Regardless of
chosen molecular representations and target activities, in
more than 96% of all ACs, highly potent cliff partners had
consistently higher LE values than their lowly potent
counterparts. Thus, the formation of ACs was accompanied
by a systematic increase in LE in the direction of increasing
compound potency. Increases in LE were not accompanied by
Fig. 3. LE vs. molecular weight difference. Each data point represents an MMP-cliff. Its
position in the graph is determined by the LE and MW difference between highly and
lowly potent cliff partners
Fig. 4. LE vs. potency difference. Each data point represents an MMP-cliff. Its position in
the graph is determined by the LE and potency difference between highly and lowly potent
cliff partners
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general increases in logP as a measure of lipophilicity. LE
differences were larger for MMP- than for fingerprint-based
ACs, and LE increases in ACs were independent of MW
variations between cliff-forming compounds. The systematic
differences between LE values of highly and lowly potent AC
compounds revealed by our analysis further increase the value
Fig. 5. LE vs. logP difference. Each data point represents an MMP-cliff. Its position in the
graph is determined by the LE and logP difference between highly potent and lowly potent
cliff partners
Fig. 6. Exemplary ACs. Four MMP-cliffs are shown. In each pair, the left compound
represents the lowly potent and the right compound the highly potent cliff partner, (arrows
point from the lowly to the highly potent compound). Substructures constituting the MMP
transformation are highlighted in red. For compound pairs, ChEMBL IDs (below the
compounds) and targets (above the arrows) are provided. In addition, potency (pKi), MW,
lipophilicity (logP), and LE differences are reported
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of AC information for compound development. ACs not only
uncover SAR determinants but critical chemical changes
encoded by ACs also lead to LE improvements. Especially for
MMP-cliffs, this dual role renders the underlying chemical
transformations highly attractive for compound design.
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Conclusions
We have analyzed activity cliffs for more than 600 target sets extracted from
ChEMBL. Regardless of their molecular representation, more than 95% of activity
cliffs showed an increase in ligand efficiency from the weakly to the highly potent
cliff partner. However, when the ligand efficiency distribution was compared,
MMP-cliffs had a larger average ligand efficiency increase than fingerprint-based
activity cliffs. The increase in ligand efficiency could not be fully explained by
changes in molecular weight or lipophilicity. This result provided further evidence
for the preference of substructure-based representations of activity cliffs over
fingerprint-based representations.
In the previous studies, we have analyzed the effect of MMPs on properties
important for drug design. However, for MMPs to become more relevant in drug
discovery, the chemical change they encode should be applicable to the synthetic
modification of compounds. Still, this is not always the case. In order to increase
the utility of MMPs for medicinal chemists, a novel fragmentation algorithm on
the basis of retrosynthetic rules was designed and is presented in the next chapter.
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4 Matched molecular pairs
derived by retrosynthetic
fragmentation
Introduction
MMPs can be used to analyze structural relations in a systematic manner.
Nonetheless, the chemical transformation encoded in an MMP is in many cases
not synthetically feasible. A very frequent transformation is the exchange of a
hydrogen atom for a methyl group. However, the exchange of a methyl group
with one specific hydrogen atom of the molecule, e.g. at an unreactive C-H bond,
can be very challenging.111 This limits the applicability of MMP-derived chem-
ical transformations in compound optimization procedures. Here, we present
a modification of the MMP fragmentation algorithm. Reactions encoded in the
REtrosynthetic Combinatorial Analysis Procedure (RECAP) are used to guide the
fragmentation step in the MMP generation, creating RECAP-MMPs. The distribu-
tion of RECAP-MMPs in public data is explored.
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Matched molecular pairs derived by retrosynthetic
fragmentation
Antonio de la Vega de Leo´n and Ju¨rgen Bajorath*
Matchedmolecular pairs (MMPs) are defined as pairs of compounds that only differ by a chemical change at
a single site. MMPs have become popular in medicinal chemistry to support lead optimization, absorption,
distribution, metabolism, excretion, and toxicity (ADMET) analysis, and other applications. Thus far, MMPs
have been algorithmically defined and not on the basis of reaction information. This often limits the
chemical interpretability and practical utility of MMPs. Therefore, we introduce synthetically accessible
MMPs that are automatically generated by applying reaction rules following the retrosynthetic
combinatorial analysis procedure (RECAP). A library of more than 92 000 RECAP-MMPs was generated
from public domain compounds active against 435 different targets exclusively utilizing high-confidence
activity data. This library is made freely available for use in medicinal chemistry.
Introduction
MMPs have been introduced as pairs of compounds that only
differ by a chemical change at a single site,1,2 a so-called
chemical transformation.3 They are mostly generated by frag-
mentation-3 or maximum common substructure-based1,4 algo-
rithms. In recent years, MMPs have become popular tools in
medicinal chemistry for a variety of applications5,6 including
structure–activity relationship (SAR)7,8 and activity prole9
analysis, lead optimization,10,11 ADMET analysis,11–13 or the
exploration of bioisosterism.14 A major reason for the attrac-
tiveness of the MMP concept in medicinal chemistry is that
chemical transformations such as R-group replacements or core
structure modications can directly be associated with dened
property changes (e.g., activity, solubility, or stability) within the
context of actual compounds,5,6 hence providing a basis for
chemically intuitive analysis. By contrast, a shortcoming of
current MMPs is that participating compounds are usually not
related by chemical reactions. Hence, chemical transformations
constituting MMPs are oen not chemically interpretable and
accessible, which limits their practical utility in medicinal
chemistry, for example, when attempting to convert compounds
into MMP partners with more favorable properties. Therefore,
we introduce herein a new category of MMPs that are generated
on the basis of retrosynthetic fragmentation employing the well-
known RECAP reaction rules.15 Accordingly, these second-
generation MMPs are termed RECAP-MMPs. The chemical
transformation relating compounds forming RECAP-MMPs to
each other results from a specic reaction. We show that
RECAP-MMPs are a subset of original MMPs, with very few
exceptions, and generate a large library of RECAP-MMPs for 435
different compound classes exclusively utilizing high-con-
dence activity data. This library is made available to the scien-
tic community without restrictions.
Methods
All activity classes from ChEMBL16 (release 15) were collected
that contained at least 5 compounds with available (assay-
independent) Ki values. Equilibrium constants were exclusively
used to ensure high condence of activity data.17 A total of 435
target-specic datasets comprising 40 650 unique active
compounds were obtained. Compounds with multiple Ki values
for the same target were only considered if all values fell within
one order of magnitude. If this condence criterion was met,
the average value of independent measurements was used as
the nal potency annotation.
From each activity class, MMPs were systematically gener-
ated using an in-house implementation of the Hussain and Rea
algorithm.3 Each compound was subjected to systematic single-,
double-, and triple-cut fragmentation of all exocyclic single
bonds between non-hydrogen atoms. During fragmentation,
connectivity information was retained. Core structures and
variable substituents resulting from fragmentation were stored
in an index table as key and value fragments, respectively. Each
pair of compounds having the same key and different value
fragments formed an MMP. The size of a transformation was
limited to a maximum of 13 non-hydrogen atoms and the size
difference between exchanged fragments to 8 non-hydrogen
atoms. In addition, keys were required to have at least twice the
size of value fragments for each transformation. Application of
these criteria yielded transformation size-restricted MMPs18 in
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which value fragments (substituents) were generally limited to
relatively small substructures.18 Fig. 1 shows exemplary MMPs.
In the following, MMPs generated by systematic fragmentation
are referred to as “standard MMPs”.
For the generation of RECAP-MMPs, a RECAP rule-based
fragmentation scheme was applied.15,19 Accordingly, bonds were
only cut on the basis of retrosynthetic rules. In addition, a
transformation was only accepted if the two exchanged fragments
were generated by the same reaction. Transformation size
restrictions were applied as specied above. Original RECAP rules
were slightly modied for single bond fragmentation. The urea
and thiourea rules were not utilized because they affect multiple
bonds. In addition, quaternary amines were not distinguished
from non-charged amines. All applied retrosynthetic rules are
reported in Fig. 2. RECAP-MMPs were systematically generated
using in-house Java code and the Open Eye Toolkit.20 For non-
commercial applications source code is available upon request.
Statistical analyses were carried out using R.21
Results and discussion
Standard versus RECAP-MMPs
As reported in Table 1, we obtained 435 Ki-based datasets from
ChEMBL with 40 650 compounds. From these compounds, we
systematically generated standard MMPs and RECAP-MMPs. A
total of 223 671 unique standard and 92 743 unique RECAP-
MMPs were obtained. Many MMPs originated from multiple
datasets. For 86 datasets, no RECAP-MMP was obtained, due to
small compound numbers (on average, these 86 datasets
contained only 10.6 compounds). The application of a conned
set of retrosynthetic rules yielded fewer MMPs than systematic
fragmentation, as expected. Surprisingly, however, nearly half as
many RECAP-MMPs were obtained. Moreover, we found that
essentially all RECAP-MMPs were reproduced by systematic
fragmentation. Only 11 instances of RECAP-MMPs were detected
that were not obtained by systematic fragmentation. An example
is shown in Fig. 3. In this pair of compounds, qualifying exocy-
clic single bonds were absent. Hence, systematic fragmentation
did not yield an MMP. Because RECAP-MMPs were a subset of
standard MMPs, with only very few exceptions, 42% of all stan-
dard MMPs were conserved when reaction-based fragmentation
was applied, a larger proportion than anticipated.
Chemical transformations
However, despite the high degree of MMP conservation, we
generally observed that standard and RECAP-based trans-
formations differed for a qualifying compound pair. Thus,
although the same MMP was obtained on the basis of system-
atic or retrosynthetic fragmentation, the corresponding trans-
formations were distinct. Examples are provided in Fig. 4. In
general, RECAP-based transformations tended to be larger than
Fig. 1 MMPs. Two exemplary MMPs are shown. Exchanged fragments
are highlighted in red.
Fig. 2 RECAP rules. Thirteen retrosynthetic fragmentation rules are
illustrated that were applied to generate RECAP-MMPs. The red line
indicates the bond that is cut according to each reaction. In the case of
amines, ethers, and thioethers the heteroatom should not be a part of
any other functional group and not form exclusive bonds to multiple
aromatic carbons.
Table 1 Datasets and MMP statisticsa
Datasets 435
Compounds 40 650
Standard MMPs 223 671
RECAP-MMPs 92 734
Standard MMP cliffs 13 261
RECAP-MMP cliffs 4406
Standard MMP cliff frequency 5.9%
RECAP-MMP cliff frequency 4.8%
a Statistics are reported for compound datasets, standard and RECAP-
MMPs, and MMP cliffs.
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standard transformations, on average by 3–5 non-hydrogen
atoms per MMP depending on the dataset. From RECAP
transformations, reagents could oen be deduced for the given
reaction. By contrast, exchanges of small fragments in standard
MMPs were typically not interpretable in reaction terms. Thus,
transformation information clearly distinguished RECAP-
MMPs from standard MMPs.
Reaction distribution
Fig. 5 reports the fractions of RECAP-MMPs that were dened by
specic retrosynthetic rules according to Fig. 2. Interestingly, no
instances of RECAP-MMPs were detected that resulted from
fragmentation of thioester and disulde bonds, and thioamide
bond cleavage accounted for less than 1% of all RECAP-MMPs.
By contrast, amine and amide chemistry dominated the distri-
bution of RECAP-MMPs, with 33% and 27%, respectively, fol-
lowed by ethers (13%) and aromatic carbon–aromatic carbon
bonds (10%), hence reecting the current compound portfolio
in medicinal chemistry.22 In addition, between 6% and 1% of
RECAP-MMPs resulted from fragmentation of aromatic
nitrogen–aliphatic carbon bonds, esters, lactams and olens.
MMP cliffs
As an indicator of the SAR information content, we also deter-
mined the fraction of activity cliffs that were captured by stan-
dard and RECAP-MMPs, so-called MMP cliffs.18 Activity cliffs are
generally dened as pairs of structurally similar or analogous
compounds with a large difference in potency.23 Therefore, all
MMPs were determined in which the two compounds displayed
a potency difference (Ki values) of at least two orders of
magnitude.18,23 As reported in Table 1, the frequency of occur-
rence of standard MMP and RECAP-MMP cliffs was 5.9% and
4.8%, respectively. Thus, systematic and retrosynthetic frag-
mentation captured activity cliffs with similar frequency.
RECAP-MMP library
The 92 734 unique RECAP-MMPs identied in our study aremade
freely available as a machine-readable library organized on the
basis of target sets (available at http://www.limes.uni-bonn.de/
forschung/abteilungen/Bajorath/labwebsite/downloads). Given
Fig. 3 Unique RECAP-MMP. Two compounds forming a RECAP-MMP
are shown that was not generated by systematic fragmentation.
RECAP-MMP value fragments are highlighted in blue. Compound
ChEMBL IDs are given.
Fig. 4 Comparison of standard and RECAP-MMPs. Two pairs of
compounds forming standard and RECAP-MMPs are shown. ChEMBL
IDs are provided. Transformations in standard MMPs are highlighted in
red and transformations in RECAP-MMPs in red and blue. The
comparison illustrates that RECAP-based substructures representing a
transformation were typically larger than substructures produced by
systematic fragmentation. The RECAP-MMPs at the top and bottom
were obtained through cuts of two amide bonds and an aromatic
carbon–aromatic carbon bond, respectively.
Fig. 5 Reaction frequency. The graph reports the proportions of
RECAP-MMPs that were obtained on the basis of different retro-
synthetic rules.
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the target set organization, individual RECAP-MMPs might
occur multiple times in different sets. This ensures that a
complete set of RECAP-MMPs is available for each compound
class. Furthermore, in the library, standard and retrosynthetic
transformations are provided for each RECAP-MMP that was
reproduced by systematic fragmentation to enable direct
comparison of these transformations. Moreover, all RECAP-
MMP cliffs are specied.
A randomly chosen sample of 50 RECAP-MMPs was traced
back to compounds in original publications (via ChEMBL
compound IDs) and it was examined whether the synthesis of
these compounds was reported in the original publications. For
more than 75% of these RECAP-MMPs, compounds were found
to be synthesized by corresponding routes (in a number of
original references, no compound synthesis was reported).
Hence, in many cases, there was a direct link between RECAP-
MMPs and synthetic routes of compounds from which these
RECAP-MMPs originated.
Conclusions
Herein we have introduced second-generation MMPs dened
on the basis of retrosynthetic rules and compared these RECAP-
MMPs with standard MMPs. In RECAP-MMPs, chemical trans-
formations are reaction-based and interpretable. Given the
current popularity of the MMP concept, it is hoped that the
library of RECAP-MMPs we provide will serve as a knowledge
base to further improve the utility of matched molecular pairs
in medicinal chemistry.
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Conclusions
Novel MMPs have been developed on the basis of retrosynthetic fragmenta-
tion. In total, 13 different rules were implemented to recognize specific bonds in
molecules. These rules were generated based on simple chemical reactions, such
as an ester bond created from the condensation of an alcohol and a carboxylic
acid. The distribution of RECAP-MMPs among compounds active against human
targets was analyzed. Because of the more restrictive fragmentation, the number of
RECAP-MMPs was less than half of the number of standard MMPs. Nonetheless,
their SAR content, measured as activity cliff frequency, was very similar. More than
half of the RECAP-MMPs found were generated because of nitrogen containing
bonds such as amide bonds. The set of more than 92 000 unique RECAP-MMPs
obtained was made publicly available.
Following development of RECAP-MMPs, novel applications of standard
MMP relationships for drug discovery are explored. In the next chapter, a new
methodology is introduced based on MMS to obtain preliminary SAR information
for confirmed hit molecules. This information can be used to drive the optimization
of a hit molecule.
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5 Systematic identification of
matching molecular series and
mapping of screening hits
Introduction
MMS organize substructure relations on the basis of MMP sets. They can be
rationalized as analog series and have been used to study SAR information in
network representations.52 They have also been used to analyze SAR transfer.53
In this study, MMS are systematically generated for bioactive compounds and
their properties are explored. Confirmed hit compounds are mapped to MMS
through MMP fragmentation in order to obtain initial SAR information. My main
contribution to this study was the analysis of confirmed hit compounds and their
mapping to MMS.
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Systematic Identification of Matching Molecular Series and
Mapping of Screening Hits
Antonio de la Vega de Len,[a] Ye Hu,[a] and Jrgen Bajorath*[a]
Matched molecular pairs (MMPs) are defined as pairs of
compounds that only differ by the exchange of a substruc-
ture at a single site.[1] The MMP concept is widely applied
in medicinal chemistry[2] to associate molecular property
changes with defined structural modifications,[2,3] study ab-
sorption, distribution, metabolism, and excretion (ADME)
properties,[3] or systematically analyze structure-activity rela-
tionship (SAR) information.[4,5] MMPs can be algorithmically
generated in an efficient manner,[6,7] which enables large-
scale analysis of compound structures and associated data.
The MMP concept has been extended by introducing
matching molecular series (MMS).[8] An MMS is defined as
a series of compounds forming pairwise MMP relationships.
Hence, an MMS consists of compounds sharing the same
structural core, a “key fragment” following MMP terminolo-
gy,[7] and varying substitutions (“values”) at a single site
(i.e. , exchanges of substructures). The MMS concept was
originally introduced to facilitate the design of structure-ac-
tivity relationship (SAR) network/graph representations in
which similarity relationships between compounds were ac-
counted for by MMS memberships.[8] However, algorithmic
generation of MMS can also be applied to generalize the
search for series of structurally related compounds or ana-
logs, as reported herein. In addition, ordering MMS com-
pounds according to increasing potency often reveals SAR
information.[9] We have systematically searched public
domain bioactive compounds with well-defined activity
measurements for MMS, analyzed the identified MMS, and
generated a comprehensive MMS database. As an exempla-
ry application, we introduce MMP-based mapping of
screening hits to MMS to search for initial SAR information.
Compound data sets were assembled from ChEMBL[10] re-
lease 17. Compound data available in ChEMBL are mostly
extracted from medicinal chemistry literature. In this study,
two types of potency measurements were separately con-
sidered, including assay-dependent IC50 values and assay-in-
dependent equilibrium constants (Ki values). From ChEMBL
records, it can usually not be determined if Ki values were
measured or calculated from IC50 values (which is frequently
done using the ChengPrusoff estimation). Nonetheless,
since IC50 and Ki values should not be directly compared,
they are separately analyzed. In addition, only explicitly de-
fined activity values for direct interactions with a specific
human target at the highest level of confidence (with
a ChEMBL confidence score of 9)[10] were considered. All ap-
proximate potency annotations such as “> ”, “< ” or “~ ”
were discarded. If one compound had more than one activ-
ity value for a given target, these values were required to
fall within the same order of magnitude. Then, the geomet-
ric mean was calculated as the final potency annotation.
On the basis of these selection criteria, a total of 661 Ki-
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been introduced as an extension of the matched molecular
pair (MMP) concept to facilitate the design of substructure-
based structure-activity relationship (SAR) networks. An
MMP is defined as a pair of compounds that only differ by
a structural change at a single site. In addition, an MMS is
defined as an MMP-based series of compounds that have
a conserved structural core and are distinguished by modi-
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from specifically active compounds generalizes the search
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vide series associated with SAR information. We have sys-
tematically extracted MMS from publicly available com-
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based compound data sets were obtained that contained
more than 45000 compounds with more than 77000 po-
tency annotations. In addition, 1203 IC50-based data sets
were assembled that contained more than 95000 com-
pounds with more than 135000 potency annotations. The
compound data sets are summarized in Table 1. These data
sets were systematically searched for MMS.
From the PubChem BioAssay database (accessed August
20th, 2012),[11] all confirmatory assays that corresponded to
targets of our ChEMBL data sets were identified. In total,
241 confirmatory assays were obtained for 88 different tar-
gets. From these 241 assays, all confirmed active com-
pounds with explicitly defined IC50 measurements were
taken and searched against the ChEMBL database. A total
of 3123 screening hits from the PubChem assays were not
detected in ChEMBL. For these hits, a total of 5182 IC50
measurements were available (Table 2). The screening hits
were then mapped to MMS, as described below.
The selected ChEMBL compounds were systematically
fragmented using an in-house implementation of the algo-
rithm by Hussain and Rea[7] utilizing the OEChem toolkit.[12]
All exocyclic single bonds and all possible combinations
of two or three bonds in a compound were cleaved in sub-
sequent fragmentation trials. Accordingly, the MMP frag-
mentation scheme differed from the generation of Bemis-
Murcko scaffolds[13] that are extracted from molecules by
removing all R-groups at once and retaining ring systems
and linkers between rings. An index table was created
using the key fragments to organize all associated value
fragments. Indexing was limited to keys that consisted of
at least twice the size of corresponding values and to
values with no more than 13 non-hydrogen atoms. In addi-
tion, the difference in the size between the exchanged
value fragments was limited to at most eight non-hydrogen
atoms.[14] These restrictions ensured that values represented
structural changes of relatively small size compared to keys
(core structures).[14] The index table contained all MMPs
formed by pairs of ChEMBL compounds yielding the same
key and different values.
In the index table, MMS were identified that consisted of
a common key and at least three different values (i.e. , three
structurally related compounds). Compounds forming an
MMS were ordered by increasing potency.
PubChem screening hits were also subjected to system-
atic fragmentation, as described above, and the resulting
key fragments were searched against the MMS keys. If
a match was detected, the PubChem hit was assigned to
the MMS as an extension.
MMS are formed on the basis of systematically detected
MMP relationships between specifically active compounds,
as illustrated in Figure 1. By design, MMS comprehensively
account for all possible structural relationships and include
classical analog series, as shown in Figure 1, and also series
with site-specific modifications in core structures (depend-
ing on the fragmentation scheme). Hence, the MMS con-
cept represents a generalized compound series format that
retrospectively accounts for all detectable pairwise structur-
al relationships in data sets and organizes compounds ac-
cording to these structural relations in a consistent manner.
This is different from combinatorially decorated scaffolds
where a series of previously chosen scaffolds are prospec-
tively explored with defined structural permutations or
chemical modifications.[15] If complemented with activity in-
formation, MMS can be utilized for SAR data mining and
analysis, which is facilitated by potency-based ordering of
compounds within series, as also illustrated in Figure 1.
Given the general applicability of the MMS concept, we
have set out to determine all MMS comprising at least
three currently available bioactive compounds with defined
activity measurements and target annotations.
From ChEMBL, 661 Ki and 1203 IC50 value based data sets
were assembled that contained a total of more than 133
000 compounds (Table 1). Each data set consisted of com-
pounds active against a specific target. The Ki- and IC50-
based sets were separately searched for MMS to avoid the
identification of series comprising compounds with differ-
ent types of potency measurements that cannot be directly
compared.
As reported in Table 1, 30452 and 45607 MMS were
identified in 406 Ki- and 790 IC50-based data sets, respec-
Table 1. Compound data sets and MMS. For the Ki- and IC50-based
data sets from ChEMBL (release 17), the numbers of targets, com-
pounds, and corresponding potency measurements are reported.
In addition, the total number of target-based MMS, unique MMS,
and targets for which MMS were obtained are provided. Further-
more, the number (and ratio) of MMS that were associated with
single- or multi-target activities are given.
Number of ChEMBL
Ki IC50
Targets 661 1203
Compounds 45353 95685
Potency measurements 77421 135291
Target-based MMS 30452 45607
Unique MMS 19427 35627
Targets with MMS 406 790
Single-target MMS 12755 (65.7%) 28080 (79.6%)
Multi-target MMS 6672 (34.3%) 7187 (20.4%)
Table 2. PubChem assay data and hits. The number of confirmato-
ry assays taken from the PubChem BioAssay database (accessed
August 20th, 2012) and the number of different targets these
assays covered are reported. In addition, the number of confirmed
hits reported to be active in at least one assay that were not found
in ChEMBL (release 17) and the total number of activity measure-
ments associated with these hits are reported.
Number of PubChem
Assays 241
Targets 88
Confirmed hits 3123
Activity measurements 5182
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tively. Thus, MMS were found in ~64% of all data sets, pro-
viding broad target coverage. Because a given MMS might
be present in different data sets, we determined the total
number of unique series. As reported in Table 1, 19427 and
35627 unique MMS were detected in the Ki- and IC50-based
sets, respectively, thus providing a large database of series
for SAR exploration. The majority of these MMS was associ-
ated with single-target activities, but a significant propor-
tion of series consisted of multi-target MMS. In the Ki-based
sets, 6672 multi-target MMS were present (~34% of all
MMS) and in the IC50-based sets, 7187 (~20%) multi-target
MMS (Table 1). Interestingly, Ki-based sets contained
a higher proportion of multi-target MMS than IC50-based
sets.
We then determined the composition and size distribu-
tion of MMS. Figure 2a reveals that MMS from both Ki- and
IC50-based sets yielded a similar distribution of core struc-
ture sizes (with the majority of key fragments consisting of
21 to 30 non-hydrogen atoms). In addition, MMS from both
sets also consisted of very similar numbers of compounds
Figure 1. Exemplary MMS and its extension. Four inhibitors of protein-tyrosine phosphatase LC-PTP are shown that form pairwise MMP re-
lationships and thus an MMS. Their common structural core (key fragment, black) is displayed and distinguishing substituents (values, red)
are ordered according to increasing compound potency. The MMS is extended by mapping a screening hit (blue) that also forms MMP rela-
tionships with all compounds of this series.
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(Figure 2b). Approx. 40% of MMS from both sets consisted
of three compounds and ~50% of four to 10 compounds.
Moreover, ~8% of all MMS contained 11 to 20 compounds
and individual series with 40 or more compounds were
also detected. Nearly 10% of all MMS comprised 10 or
more compounds.
The target distribution of MMS is reported in Figure 2c.
The majority of MMS was associated with single-target ac-
tivities (see also Table 1). Most multi-target MMS were
active against two to four targets. In Figure 2d, the distribu-
tion of median potency values of MMS is reported, reveal-
ing that most series contained compounds active in the
nanomolar range, regardless of the type of potency meas-
urements, which further emphasized the relevance of MMS
for SAR analysis.
MMS can also be utilized for compound mapping, as il-
lustrated in Figure 1 (bottom). On the basis of MMP calcula-
tions, test compounds can be searched against MMS to
identify series that test compounds further extend
(Figure 1). Compound mapping can be carried out for dif-
ferent purposes. For example, hits from screening cam-
paigns might be searched against MMS to determine if hits
further extend MMS sharing the same activity. In this case,
at least preliminary SAR information has been obtained for
a given hit. Moreover, if hits are found to further extend
MMS with a different activity, an additional activity hypoth-
esis can be explored.
To illustrate the underlying idea we have systematically
searched 3123 confirmed screening hits from PubChem
against our MMS database that had reported activity
against targets also contained in ChEMBL. A total of 40 hits
were found to map to existing MMS sharing the same ac-
tivity. As reported in Table 3, these 40 hits further extended
28 MMS from IC50-based compound sets that were active
Figure 2. Characterization of MMS. Reported are the distributions of the number of (a) non-hydrogen atoms of key fragments, (b) com-
pounds, and (c) targets over MMS as well as (d) the median potency values for MMS from the Ki- (red) and IC50- based (blue) subsets.
Table 3. Mapping of screening hits to MMS. The number of screen-
ing hits from PubChem (accessed August 20th, 2012) that extended
existing MMS, their number, and targets are reported. All screening
hits were found to map to IC50-based MMS.
Number of IC50
Hits 40
MMS 28
Targets 15
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Mol. Inf. 2014, 33, 257 – 263 260
Communication www.molinf.com
Figure 3. Extended MMS. Two exemplary MMS are shown together with mapped screening hits including inhibitors of (a) alkaline phos-
phatase and (b) ubiquitin-conjugating enzyme. Hits extending each MMS are displayed on a gray background. Structural differences be-
tween compounds (value fragments) are highlighted in red. From the top (left) to the bottom (right) compounds are arranged in the order
of increasing potency.
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against 15 different targets. We found that 30 of these hits
mapped to a single MMS, whereas the remaining 10 hits
mapped to two or more target-based MMS. In addition,
five of these hits further extended multi-target MMS, hence
providing attractive activity hypotheses for further investi-
gation.
In Figure 3, exemplary MMS are shown that were further
extended by multiple screening hits sharing the same activ-
ity. In Figure 3a, an MMS comprising six alkaline phospha-
tase inhibitors is shown that was extended by three con-
firmed hits from a screen against this enzyme. In Figure 3b,
an MMS consisting of six inhibitors of ubiquitin-conjugating
enzyme is shown to which three confirmed hits mapped.
Both MMS represent classical analog series and illustrate
how mapping of screening hits complements available SAR
information.
In conclusion, we have reported a systematic search for
matching molecular series in target-based sets of bioactive
compounds with well-defined activity data. Different types
of potency measurements were separately considered. In
total, approx. 53000 MMS with activity against 877 different
targets were identified and characterized. Potency-based
ordering of compounds forming MMS renders theses series
attractive for SAR analysis. The series we identified included
a significant proportion of multi-target MMS. We have also
introduced an MMP-based strategy for compound mapping
to MMS that can be utilized in different ways. As an exem-
plary application, it has been shown how screening hits
can be mapped to MMS to search for initial SAR informa-
tion and further extend existing series. Our large database
of potency-ordered MMS has been made freely available[16]
as a resource for exploring single- and multi-target SARs,
compound mapping, and other medicinal chemistry appli-
cations.
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Conclusions
We have systematically generated potency-ordered MMS from bioactive com-
pounds. 53 000 unique MMS were generated from 133 000 compounds on the basis
of Ki and IC50 activity data. The properties of MMS for Ki and IC50 data were very
similar. MMS were found that contained large numbers of compounds or that were
annotated with activity against more than one target. Confirmed hits from 241
confirmatory assays were fragmented and mapped to previously generated MMS.
Several hit compounds with different activities were mapped. Preliminary SAR
information was obtained for mapped screening hits that could inform compound
optimization efforts. The set of potency-ordered MMS was made available to the
medicinal chemistry community for compound mapping applications.
We have presented a method to obtain SAR information from potency-ordered
MMS to aid compound optimization efforts. Activity comparisons between chemi-
cally related compounds provide initial SAR information. However, several hit
compounds could not be mapped to any MMS and no SAR information was
present for these molecules. In the next study, we developed a predictive method-
ology based on MMP representations and SVR that can predict the difference in
activity between MMP partners. With this methodology, potency difference caused
by chemical transformations not found in the data can be estimated.
59
60
6 Prediction of compound potency
changes in matched molecular pairs
using support vector regression
Introduction
Activity prediction is the goal of QSAR. Traditionally, activity prediction was
confined to structurally related compounds sets. However, in order to predict
activity from heterogeneous sets of compounds, methods from machine learning
have been applied in chemoinformatics. These methods, such as SVR, are thought
to be able to model complex nonlinear relationships between structure and activity.
Thus far, MMPs have rarely been used in machine learning. A previous application
accurately predicted the presence of MMP-cliffs.71 In this study, we expand on this
effort by using SVR and MMP-based kernel functions to predict the activity change
between compounds forming an MMP. Different kernel functions that represent
only the chemical transformation (transformation kernels) or that combine the key
fragment with the transformation (MMP kernels) are compared.
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ABSTRACT: Matched molecular pairs (MMPs) consist of pairs of compounds that are
transformed into each other by a substructure exchange. If MMPs are formed by
compounds sharing the same biological activity, they encode a potency change. If the
potency difference between MMP compounds is very small, the substructure exchange
(chemical transformation) encodes a bioisosteric replacement; if the difference is very
large, the transformation encodes an activity cliff. For a given compound activity class,
MMPs comprehensively capture existing structural relationships and represent a spectrum
of potency changes for structurally analogous compounds. We have aimed to predict
potency changes encoded by MMPs. This prediction task principally differs from
conventional quantitative structure−activity relationship (QSAR) analysis. For the
prediction of MMP-associated potency changes, we introduce direction-dependent
MMPs and combine MMP analysis with support vector regression (SVR) modeling.
Combinations of newly designed kernel functions and fingerprint descriptors are explored.
The resulting SVR models yield accurate predictions of MMP-encoded potency changes for many different data sets. Shared key
structure context is found to contribute critically to prediction accuracy. SVR models reach higher performance than random
forest (RF) and MMP-based averaging calculations carried out as controls. A comparison of SVR with kernel ridge regression
indicates that prediction accuracy has largely been a consequence of kernel characteristics rather than SVR optimization details.
■ INTRODUCTION
The prediction of changes in compound potency as a
consequence of chemical modifications typically falls into the
domain of classical quantitative structure−activity relationship
(QSAR) analysis.1 However, QSAR modeling is usually limited
to congeneric compound series1 and cannot be systematically
applied to large and structurally diverse compound data sets. In
addition, conventional QSAR predictions are based upon linear
regression models. To account for the nonlinearity of many
SARs, machine learning approaches such as random forest2
(RF) and support vector regression3 (SVR) analysis have
gained popularity in recent years. In addition to potency
prediction,4−6 these methods have also been applied, for
example, to predict ADME properties7,8 or toxicology end
points.9−11
The congeneric compound series constraint of standard
QSAR can be addressed by considering alternative structural
representations, which can also be combined with nonlinear
prediction methods. For example, an attractive opportunity to
further extend potency predictions to large and heterogeneous
compound data sets is provided by the matched molecular pair
(MMP) formalism.12 An MMP is defined as a pair of
compounds that only differ by a structural change at a single
site.12 This modification is accounted for by the exchange of a
pair of substructures termed a chemical transformation. MMPs
can be systematically generated for a given compound data set,
which reveals all possible pairs of structural analogs and
comprehensively captures structural relationships present
within the set. Then, it can be attempted to predict changes
in potency or other chemical properties associated with
chemical transformations at the level of compound pairs, rather
than series. For example, property value changes in multiple
MMPs have been used to predict value changes associated with
equivalent transformations.13,14 However, such MMP-based
extrapolations cannot be generalized and have often limited
statistical significance.14
Accordingly, first attempts have been made to combine
MMP analysis with machine learning, for example, by
predicting changes in potency and ADME properties using
RF calculations15 or by predicting activity cliffs (i.e., pairs of
structurally analogous compounds having a large difference in
potency)16 using support vector machines (SVMs).17,18 SVM-
based activity cliff prediction has distinguished pairs of
compounds forming activity cliffs from others,18 without
predicting numerical potency differences. In addition to using
SVM models for classification and ranking, prediction of
numerical potency (difference) values encoded by MMPs can
be attempted via SVR.
Herein, we combine MMP analysis with SVR and system-
atically predict potency difference values for MMPs using
kernel functions of different design. Combinations of different
kernel functions and fingerprint descriptors used as molecular
fragment representations are explored, and preferred combina-
tions are identified. In calculations on a variety of compound
data sets, preferred kernel-fingerprint combinations yield high
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SVR accuracy in predicting numerical potency differences (and
reach higher accuracy than RF calculations). The MMP-based
SVR methodology introduced herein is generally applicable for
numerical property predictions.
■ MATERIALS AND METHODS
Compound Data Sets. From ChEMBL (version 17),19 17
compound activity classes including a variety of targets were
selected. For each class, all compounds having defined Ki values
(with activity relation “=”, assay confidence score 9, the highest
possible score, and target relationship “D” indicating “direct”
relationships) were collected. Compounds having multiple
potency values that differed by more than 1 order of magnitude
(considering the highest and lowest values) were discarded. For
compounds with multiple activity values falling within 1 order
of magnitude range, the arithmetic mean was calculated as the
final potency annotation. The compound data sets contained
between 1200 and 2500 compounds, as reported in Table 1.
From these compound data sets, between 5700 and 32 000
direction-dependent MMPs were obtained, as also reported in
Table 1.
Direction-Dependent Matched Molecular Pairs.
Matched molecular pairs were systematically calculated for
data set compounds using an in-house Java implementation of
the algorithm developed by Hussain and Rea20 based upon the
OEChem Toolkit21 from OpenEye. Single-, dual-, and triple-cut
fragmentation of exocyclic bonds was carried out generating
conserved key and variable value fragments stored in an index
table.20 In addition, transformation size restrictions22 were
applied to ensure a meaningful distinction between core
structures (key) and substituents (values). Accordingly, a key
fragment was required to consist of at least twice the number of
non-hydrogen atoms as a value fragment; a value fragment was
permitted to contain a maximum of at most 13 non-hydrogen
atoms, and the size difference between values of a given key was
limited to at most eight non-hydrogen atoms.22 If two
compounds formed several MMPs, the one having the largest
key fragment was selected.
For each MMP, the potency difference between the
participating compounds was recorded in a direction-depend-
ent manner, as illustrated in Figure 1A. Thus, for each original
MMP, two direction-dependent MMPs were generated
encoding a potency-decreasing and a potency-increasing
transformation (i.e., value fragment 1 → 2 vs 2 → 1).
Molecular Representation. For each direction-dependent
MMP, five fingerprint representations were calculated, as also
illustrated in Figure 1A, including a fingerprint of the key
fragment (KeyFP), fingerprint of the value fragments (V1FP
and V2FP, respectively), a fingerprint containing bits shared by
V1FP and V2FP (CommV1V2FP), and two value fragment
difference fingerprints (V1FP-V2FP and V2FP-V1FP, respec-
tively). For keyed fingerprint descriptors such as MACCS23 (in
which each bit position is assigned to a specific structural
fragment or pattern), a difference fingerprint of size 2n was
calculated from value fingerprints of size n by merging the value
fingerprints with uniquely set bit positions. For hashed
fingerprints such as extended connectivity fingerprints
(ECFPs),24 which represent feature sets, a difference fingerprint
was generated by combining unique features of the first value
and unique features of the second value with inverted sign.
These types of difference fingerprints accounted for direction-
dependent transformations. To implement these five fingerprint
designs, different fingerprint descriptors were used including
ECFPs of bond diameter 2, 4, and 6 as well as MACCS
structural keys (166 bit version). Fingerprint calculations were
carried out using in-house Python scripts based upon the
OEChem Toolkit.21
Support Vector Regression. SVR is a nonlinear prediction
method and variant of SVM classification that maps data points
into higher-dimensional chemical (descriptor) reference spaces
with the aid of kernel functions. A linear regression is
performed in the high dimensional space. More formally, the
predicted value y of the input vector x is calculated as
= +y K w x b( , )
K(w,x) is the kernel function that maps x into the high-
dimensional space; w (the normal weight vector) and b (the
bias) determine a hyperplane in this space to separate positive
and negative training instances and are estimated by minimizing
the so-called structural risk:
∑= + || ||ε
=
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1
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RSVR represents the risk function and depends on a loss
function Lε and a regularization parameter depending on w. Lε
measures the difference between the predicted value y and
observed value d and is only applied when the difference is
larger than ε. C is a factor determining the trade-off between
the loss function and the regularization term.
Kernel Functions. For SVR, six alternative kernels were
designed and investigated. All kernels were based on the
Tanimoto similarity function25 but utilized different types of
fingerprint representations. The design of these kernels was
Table 1. Compound Data Setsa
ID name abbreviation Cpds MMPs
A 205 carbonic anhydrase II CA2 1566 8248
B 214 serotonin 1a receptor 5-HT1A 1276 9352
C 217 dopamine D2 receptor DRD2 1916 17 630
D 218 cannabinoid CB1
receptor
CB1 1673 16 004
E 226 adenosine A1 receptor ADORA1 2107 24 534
F 228 serotonin transporter 5HTT 1317 9352
G 233 mu opioid receptor MOR1 1447 15 712
H 234 dopamine D3 receptor DRD3 1332 9532
I 237 kappa opioid receptor KOR-1 1302 17 654
J 251 adenosine A2a receptor ADORA2A 2538 32 086
K 253 cannabinoid CB2
receptor
CB2 1903 18 548
L 256 adenosine A3 receptor ADORA3 2037 22 316
M 259 melanocortin receptor 4 MC4R 1209 28 274
N 261 carbonic anhydrase I CA1 1528 7,804
O 264 histamine H3 receptor H3R 1,849 19 256
P 3371 serotonin 6 receptor 5-HT6 1291 9648
Q 3594 carbonic anhydrase IX CA9 1220 5756
aFor each data set, the number of compounds and direction-
dependent MMPs is given. In addition, the ChEMBL identifier
(ID), the target name, and abbreviation are provided. Data sets are
labeled A−Q.
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inspired by MMP-based kernel functions successfully used for
the prediction of activity cliffs.18
Transformation kernels only utilized value fragment-based
fingerprints and represented a chemical transformation in three
different ways, based upon
(i) only the difference fingerprint (DiffFP, Figure 1B)this
kernel was termed 1VD
(ii) both CommV1V2FP and DiffFP (2VCD)
(iii) the two value fragments fingerprints (2V12)
In addition, MMP kernels were constructed by adding the key
fingerprint representation to i−iii producing kernels 2VKD,
3VKCD, and 3VK12, respectively.
These six kernels were implemented using the Tanimoto
coefficient (Tc) formula and are defined by the following
equations:
=K i j( , ) Tc(DiffFP, DiffFP)i j1VD
= ·K i j( , ) Tc(V1FP, V1FP) Tc(V2FP, V2FP)i j i j2V12
= ·K i j( , ) Tc(DiffFP, DiffFP) Tc(CommV1
V2FP, CommV1V2FP)
i j
i j
2VCD
= ·K i j K i j( , ) Tc(KeyFP, KeyFP) ( , )i j2VKD 1VD
= ·K i j K i j( , ) Tc(KeyFP, KeyFP) ( , )i j3VK12 2V12
= ·K i j K i j( , ) Tc(KeyFP, KeyFP) ( , )i j3VKCD 2VCD
where i and j are two direction-dependent MMPs and Tc(FPi,
FPj) represents the Tc for comparison of the two fingerprints.
MMP kernels were expected to project potency-annotated
MMPs into features spaces in which linear modeling algorithms
could be successfully applied. SVMlight26 was used to perform
all SVR calculations. Except for the kernel functions, default
parameter settings were used.
Control Calculations. For comparison with SVR, two
conceptually different approaches were used including MMP-
based averaging analysis (MMPAV)13,14 and RF predictions.2,15
To predict the potency change of an MMP in the test set for
Figure 1.Molecular representation. (A) At the top, an exemplary MMP is shown. The shared core structure (key fragment) is colored black, and the
distinguishing value fragments (value 1 and value 2) are colored red. For potency prediction, the potency difference between MMP compounds is
monitored in a direction-dependent manner. Accordingly, two direction-dependent MMPs are obtained encoding a potency-decreasing (value 1 →
2) and a reverse potency-increasing (value 2→ 1) transformation. For each MMP, a fingerprint of the key fragment (KeyFP) and a fingerprint of its
value fragments (V1FP and V2FP, respectively) are calculated. From V1FP and V2FP, a common fingerprint (CommV1V2FP) is generated
consisting of shared bit positions. In addition, two difference fingerprints (DiffFP) are calculated from V1FP and V2FP to yield a direction-
dependent transformation representation. For direction-dependent MMPs, KeyFP and CommV1V2FP are conserved. (B) Schematic representation
of feature set fingerprints of two value fragments and of CommV1V2FP and DiffFP derived from these feature sets. The derivation of
CommV1V2FP and DiffFP is described in detail in the text.
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MMPAV, the training set was searched for MMPs containing
the same chemical transformation. If no such MMP was found,
prediction was not possible. If qualifying training set MMPs
were detected, the average potency difference of these MMPs
was calculated to predict the potency change for the test MMP.
RF modeling utilizes ensembles of decision trees for consensus
predictions. RF calculations were performed using the R27
package randomForest.28 An MMP was represented as the
difference of 51 2D numerical descriptors calculated with the
Molecular Operating Environment (MOE)29 and the potency
value of the first compound of the MMP. The numerical
descriptor set, which was not used for MMP-based SVM
modeling, was previously designed for machine learning
applications.15 For RF calculations, the number of trees was
set to 400; for all other parameters, default settings were used.
Table 2. SVR Predictionsa
A B C D E F G H I
1VD MACCS 0.21 0.26 0.32 0.34 0.38 0.34 0.30 0.42 0.45
ECFP2 0.32 0.35 0.43 0.43 0.43 0.41 0.36 0.51 0.53
ECFP4 0.34 0.39 0.46 0.47 0.46 0.42 0.38 0.53 0.55
ECFP6 0.34 0.40 0.46 0.47 0.46 0.42 0.39 0.53 0.55
2V12 MACCS 0.20 0.28 0.33 0.38 0.40 0.33 0.32 0.44 0.47
ECFP2 0.27 0.35 0.43 0.41 0.43 0.38 0.36 0.50 0.51
ECFP4 0.26 0.36 0.41 0.41 0.43 0.36 0.35 0.49 0.51
ECFP6 0.25 0.35 0.40 0.40 0.41 0.36 0.34 0.48 0.50
2VCD MACCS 0.19 0.28 0.33 0.36 0.39 0.33 0.31 0.43 0.46
ECFP2 0.29 0.36 0.43 0.42 0.43 0.39 0.35 0.50 0.51
ECFP4 0.30 0.38 0.44 0.44 0.45 0.40 0.36 0.51 0.53
ECFP6 0.29 0.38 0.43 0.45 0.45 0.39 0.36 0.51 0.53
2VKD MACCS 0.36 0.43 0.57 0.58 0.62 0.53 0.60 0.60 0.71
ECFP2 0.49 0.58 0.73 0.67 0.74 0.64 0.71 0.73 0.79
ECFP4 0.50 0.63 0.77 0.72 0.78 0.67 0.75 0.75 0.83
ECFP6 0.49 0.64 0.78 0.73 0.78 0.68 0.75 0.76 0.83
3VK12 MACCS 0.28 0.38 0.52 0.52 0.58 0.47 0.54 0.56 0.66
ECFP2 0.35 0.51 0.66 0.58 0.66 0.54 0.63 0.66 0.71
ECFP4 0.33 0.53 0.66 0.58 0.66 0.53 0.64 0.65 0.72
ECFP6 0.31 0.52 0.64 0.58 0.65 0.53 0.63 0.63 0.71
3VKCD MACCS 0.28 0.39 0.52 0.51 0.58 0.47 0.54 0.55 0.65
ECFP2 0.41 0.53 0.69 0.61 0.69 0.59 0.65 0.68 0.74
ECFP4 0.41 0.57 0.71 0.65 0.71 0.60 0.69 0.69 0.77
ECFP6 0.40 0.57 0.71 0.66 0.72 0.61 0.69 0.69 0.78
J K L M N O P Q
1VD MACCS 0.38 0.37 0.48 0.60 0.24 0.40 0.43 0.18
ECFP2 0.45 0.46 0.52 0.72 0.28 0.49 0.50 0.21
ECFP4 0.47 0.49 0.55 0.74 0.29 0.52 0.53 0.22
ECFP6 0.47 0.50 0.55 0.74 0.29 0.52 0.54 0.22
2V12 MACCS 0.40 0.40 0.50 0.64 0.24 0.42 0.44 0.15
ECFP2 0.45 0.44 0.52 0.73 0.25 0.47 0.47 0.17
ECFP4 0.44 0.44 0.53 0.72 0.24 0.46 0.48 0.17
ECFP6 0.43 0.44 0.52 0.71 0.24 0.45 0.47 0.16
2VCD MACCS 0.38 0.38 0.48 0.62 0.23 0.41 0.42 0.15
ECFP2 0.44 0.44 0.52 0.72 0.26 0.47 0.48 0.19
ECFP4 0.46 0.46 0.54 0.73 0.26 0.48 0.51 0.20
ECFP6 0.46 0.47 0.54 0.73 0.26 0.49 0.51 0.19
2VKD MACCS 0.63 0.63 0.70 0.79 0.44 0.67 0.61 0.37
ECFP2 0.77 0.73 0.79 0.89 0.51 0.76 0.73 0.48
ECFP4 0.80 0.77 0.83 0.91 0.55 0.81 0.77 0.53
ECFP6 0.81 0.79 0.83 0.91 0.57 0.81 0.77 0.54
3VK12 MACCS 0.58 0.57 0.66 0.76 0.35 0.61 0.57 0.29
ECFP2 0.69 0.64 0.72 0.85 0.38 0.67 0.64 0.36
ECFP4 0.69 0.64 0.72 0.85 0.38 0.67 0.64 0.38
ECFP6 0.67 0.63 0.71 0.84 0.39 0.65 0.63 0.38
3VKCD MACCS 0.57 0.56 0.65 0.75 0.37 0.60 0.55 0.32
ECFP2 0.72 0.67 0.75 0.86 0.44 0.70 0.67 0.42
ECFP4 0.75 0.70 0.78 0.87 0.47 0.73 0.70 0.46
ECFP6 0.75 0.71 0.78 0.87 0.48 0.73 0.71 0.47
aFor each data set, average R2 values after 10-fold cross-validation are reported for all fingerprint-kernel combinations. Overall best results are shown
in bold.
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The RF protocol followed a previous report of predictions of
MMP-encoded property changes.15
In order to evaluate if prediction accuracy resulted from
contributions of newly designed kernels or was essentially
determined by SVR, the performance of SVR calculations using
the overall preferred kernel/fingerprint combination was
compared to kernel ridge regression (KRR),30 which represents
an alternative kernel-based regression method. Therefore, the
MMP kernels were implemented in R using the package
kernlab,31 and KRR calculations were carried out using the R
package CVST.32 Except for the kernel function, default
parameter settings were used.
Learning and Scoring. Training calculations for SVR, RF,
and MMPAV were based on 10-fold cross-validation.
Compound pairs forming direction-dependent MMPs were
randomly divided into 10 nonoverlapping groups. For each
compound pair, the two direction-dependent MMPs were
assigned to the same group. Regression was performed 10
times. Each time a different group was chosen as the test set,
and the remaining nine groups were combined as the training
set.
As further control calculations, SVR was also performed
using 4-fold cross-validation on the basis of four data set subsets
(instead of 10) and, in addition, without cross-validation on
larger test sets (i.e., randomly selecting half of each data set as
the training and the other half as the test set). These
calculations were carried out in order to evaluate the influence
of training set composition and size on prediction accuracy. For
comparing KRR and SVR, no cross-validation was applied due
to the high computational expense of KRR calculations.
For each prediction, the coefficient of determination (R2),
mean absolute error (MAE), root-mean-square error (RMSE),
and Pearson’s correlation coefficient (r) were calculated
comparing the predicted and the observed potency difference
values for the test set. Following cross-validation, the average
and standard deviation (SD) of the scores for each independent
trial were calculated and used as the final prediction result. The
different performance measures applied herein are defined by
the following equations:
= − ∑ −
∑ −
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i i
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■ RESULTS AND DISCUSSION
Kernel Characteristics. Newly designed kernel functions
accounted for transformation and MMP information in
Table 3. SVR Results for the ECFP6-2VKD Combination (10-Fold Cross-Validation)a
R2 SD(R2) MAE SD(MAE) RMSE SD(RMSE) r SD(r)
A 0.49 0.06 0.48 0.04 0.84 0.10 0.73 0.04
B 0.64 0.06 0.30 0.02 0.48 0.06 0.81 0.04
C 0.78 0.01 0.23 0.01 0.37 0.01 0.89 0.01
D 0.73 0.02 0.34 0.01 0.50 0.02 0.86 0.01
E 0.78 0.02 0.24 0.01 0.37 0.03 0.89 0.01
F 0.68 0.03 0.31 0.01 0.47 0.03 0.84 0.02
G 0.75 0.03 0.29 0.02 0.46 0.03 0.87 0.02
H 0.76 0.02 0.30 0.02 0.47 0.03 0.88 0.01
I 0.83 0.02 0.27 0.01 0.41 0.02 0.91 0.01
J 0.81 0.02 0.24 0.01 0.38 0.02 0.91 0.01
K 0.79 0.03 0.33 0.02 0.50 0.04 0.89 0.02
L 0.83 0.02 0.29 0.01 0.46 0.02 0.92 0.01
M 0.91 0.01 0.18 0.00 0.28 0.01 0.96 0.00
N 0.57 0.04 0.47 0.03 0.73 0.05 0.77 0.03
O 0.81 0.02 0.22 0.01 0.35 0.02 0.91 0.01
P 0.77 0.04 0.27 0.02 0.40 0.02 0.89 0.02
Q 0.54 0.06 0.35 0.03 0.56 0.06 0.75 0.04
aFor each data set, results of SVR predictions for the preferred ECFP6−2VKD combination are reported using different performance measures
including the average and standard deviation (SD) of the coefficient of determination (R2), mean absolute error (MAE), root-mean-square error
(RMSE), and correlation coefficient (r) over 10 independent trials.
Figure 2. Best SVR predictions. For each data set, the R2 value for the
ECFP6−2VKD fingerprint−kernel combination is reported. R2
standard deviations for 10 independent trials are given at the top of
each bar.
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different ways. For example, CommV1V2FP and DiffFPs
generated for value fragments and the kernels built using
these representations took combined transformation informa-
tion and/or structural differences between exchanged sub-
structures into account. By contrast, the incorporation of
KeyFPs added core structure information to transformation
kernels and hence represented the structural context in which
transformations occurred. The design of MMP pair product
kernels is based upon pre-existing pairwise Tanimoto kernel
products.
Systematic SVR Predictions. For each data set, 24 SVR
predictions were carried out resulting from combinations of
four fingerprint descriptors (ECFP2, ECFP4, ECFP6, and
MACCS) and six kernel functions (1VD, 2V12, 2VCD, 2VKD,
3VK12, and 3VKCD), as described in detail in the Methods
section. The R2 results of 10-fold cross-validated calculations
are reported in Table 2. R2 values significantly varied for
different combinations and data sets and ranged from 0.15 to
0.91, hence reflecting significant differences in prediction
accuracy. However, regardless of the magnitude of R2 values,
most trials produced stable results with low R2 standard
deviations of, on average, only 0.037.
Kernel and Descriptor Performance. For all data sets,
MMP kernels (taking core structure and transformation
information into account) were found to perform better than
transformation kernels. The average R2 value for all calculations
with MMP kernels was 0.63 compared to 0.42 for trans-
formation kernels. Thus, structural context information was of
critical importance for accurate potency difference value
predictions associated with specific chemical transformations.
Furthermore, the best representation of a transformation was
the value difference fingerprint (1VD and the combined 2VKD
Table 4. SVR Results for the ECFP6-2VKD Combination (4-Fold Cross-Validation)a
R2 SD(R2) MAE SD(MAE) RMSE SD(RMSE) r SD(r)
A 0.45 0.03 0.50 0.03 0.88 0.09 0.71 0.02
B 0.61 0.02 0.32 0.01 0.51 0.02 0.79 0.01
C 0.75 0.01 0.24 0.00 0.39 0.01 0.88 0.01
D 0.72 0.01 0.35 0.01 0.52 0.01 0.86 0.01
E 0.76 0.01 0.25 0.01 0.38 0.01 0.88 0.01
F 0.66 0.02 0.32 0.01 0.48 0.01 0.83 0.01
G 0.74 0.02 0.30 0.00 0.47 0.01 0.87 0.01
H 0.74 0.01 0.31 0.01 0.49 0.01 0.87 0.01
I 0.82 0.00 0.28 0.01 0.43 0.01 0.91 0.00
J 0.79 0.01 0.26 0.01 0.40 0.01 0.90 0.00
K 0.78 0.02 0.34 0.00 0.51 0.02 0.89 0.01
L 0.81 0.01 0.31 0.00 0.48 0.01 0.91 0.01
M 0.90 0.01 0.19 0.00 0.29 0.01 0.95 0.00
N 0.54 0.02 0.49 0.01 0.75 0.03 0.75 0.01
O 0.78 0.01 0.23 0.00 0.37 0.01 0.90 0.00
P 0.75 0.01 0.29 0.01 0.43 0.01 0.88 0.01
Q 0.50 0.02 0.36 0.02 0.58 0.02 0.72 0.02
aFor each data set, results of SVR predictions for the preferred ECFP6−2VKD combination are reported using different performance measures
including the average and standard deviation (SD) of the coefficient of determination (R2), mean absolute error (MAE), root-mean-square error
(RMSE), and correlation coefficient (r) over four independent trials.
Figure 3. Comparison of predicted and observed potency difference values. For two exemplary data sets, 5HTT and MC4R, predicted and observed
potency value differences are compared in a scatterplot. R2 values and the number of MMPs (N) plotted are given. Each data point represents a
direction-dependent MMP.
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version), rather than the common plus difference fingerprints
(2VCD and 3VKCD) or the two individual value fingerprints
(2V12 and 3VK12). The average R2 for 1VD (0.43) was slightly
larger than for 2VCD (0.41) and 2V12 (0.40). Similarly, the
average R2 for 2VKD (0.68) was larger than for 3VKCD (0.62)
and 3VK12 (0.58). Hence, kernel 2VKD, which combined the
value difference fingerprint and the key fingerprint, performed
overall best.
ECFP fingerprints consistently yielded higher performance
than MACCS structural keys. Furthermore, increasing the
diameter of the ECFPs (and hence their topological resolution)
improved SVR prediction performance in most cases, albeit
with generally low differences between ECFP4 and ECFP6.
Preferred Combination. The combination of the 2VKD
kernel and the high-resolution ECFP6 gave the maximum R2
value among all 24 kernel-fingerprint combinations for 16 of 17
compound data sets (Table 2). In Table 3, prediction results
are reported for 10-fold cross-validation for the preferred
2VKD−ECFP6 combination. R2 values varied between 0.49
(CA2) and 0.91 (MC4R), as also shown in Figure 2. For 11 of
17 compound data sets, R2 values of at least 0.75 were obtained
(Tables 2 and 3), reflecting generally high prediction accuracy.
Again, R2 standard deviations for these calculations were very
low (Table 3), ranging from 0.01 (MC4R) to 0.06 (5-HT1A).
Alternative performance measures were applied. MAE and
RMSE results showed trends similar to those observed for R2.
MAE values varied between 0.18 (MC4R) and 0.48 (CA2) and
RMSE values between 0.28 (MC4R) and 0.84 (CA2). The
correlation between observed and predicted values was
generally high, even for predictions yielding intermediate R2
values. Only two compound data sets had correlation
coefficient (r) values below 0.8 and five data sets had values
above 0.9. In Table 4, prediction results are reported for 4-fold
cross-validation for 2VKD−ECFP6 combination. R2 values
were very similar to those obtained with 10-fold cross-
validation (Table 3) showing that test set size and composition
had no major influence on prediction accuracy.
Figure 3 shows scatterplots comparing observed and
predicted potency difference values for two exemplary data
sets with moderate (5HTT) and high (MC4R) prediction
accuracy. The observed potency differences reported in these
plots are also representative for the compound data sets under
study. Across all data sets, only ∼4.5% of the direction-
dependent MMPs encoded potency differences of 2 orders of
magnitude or more. The comparison in Figure 3 revealed that
predicted potency differences covered the entire range of
observed differences. Moreover, the pronounced diagonal
patterns resulted from the presence of many highly accurate
predictions.
Control Calculations. To put SVR performance into
perspective, control calculations were carried out using
MMPAV and RF. Especially RF calculations were relevant for
comparison with SVR, given a previous report that utilized RF
analysis to predict MMP-associated changes in property
values.15 Figure 4 reports the results of control calculations
compared to SVR using the preferred 2VKD−ECFP6
combination. MMPAV performed poorly and even produced
negative R2 for eight compound sets. Details are provided in
Table 5. Between 35% (CA9) and 70% (MC4R) of the test
Figure 4. Control calculations. For each data set, the performance of
SVR using the ECFP6−2VKD combination (blue) is compared to RF
(red) and MMPAV (green) calculations. R2 values and standard
deviations over 10 independent trials are reported.
Table 5. MMP-Based Averaging Analysisa
R2 SD(R2) MAE SD(MAE) RMSE SD(RMSE) R SD(R)
A 0.16 0.17 0.69 0.03 0.98 0.04 0.47 0.14
B −0.07 0.09 0.60 0.03 0.81 0.06 0.26 0.09
C −0.08 0.04 0.60 0.03 0.81 0.03 0.29 0.04
D −0.10 0.09 0.67 0.02 0.90 0.02 0.29 0.04
E 0.02 0.04 0.53 0.02 0.73 0.03 0.38 0.03
F 0.01 0.10 0.57 0.04 0.76 0.05 0.35 0.06
G −0.17 0.06 0.69 0.02 0.93 0.04 0.24 0.04
H 0.09 0.09 0.64 0.03 0.86 0.04 0.44 0.05
I −0.17 0.11 0.67 0.02 0.90 0.03 0.26 0.06
J 0.01 0.06 0.61 0.02 0.83 0.04 0.38 0.04
K 0.07 0.06 0.70 0.03 0.93 0.05 0.42 0.04
L 0.09 0.07 0.69 0.03 0.95 0.04 0.45 0.04
M 0.15 0.07 0.51 0.02 0.70 0.03 0.52 0.04
N −0.02 0.16 0.75 0.08 1.06 0.10 0.33 0.11
O −0.01 0.10 0.51 0.03 0.71 0.04 0.38 0.07
P 0.15 0.11 0.48 0.03 0.65 0.04 0.46 0.07
Q −0.09 0.08 0.60 0.06 0.85 0.09 0.28 0.04
aFor each data set, results of MMPAV calculations are reported using different performance measures according to Table 3.
Journal of Chemical Information and Modeling Article
dx.doi.org/10.1021/ci5003944 | J. Chem. Inf. Model. 2014, 54, 2654−26632660
MMPs could not be predicted using MMPAV because a
qualifying transformation was not available in the learning set.
It should be noted that negative R2 indicated that better
predictions would be obtained by using the mean of the entire
potency change distribution of a data set (essentially
corresponding to random predictions). This very low perform-
ance was not unexpected for a simple averaging method.
However, the results clearly indicated nonlinearity of many
MMP-encoded SARs.
RF calculations yielded much better prediction performance
than MMPAV. For most data sets, R2 values between 0.5 and
0.6 were observed for RF predictions, with a maximum value of
0.68 (MC4R and ADORA3). Details are provided in Table 6.
However, as reported in Figure 4, RF predictions did not reach
the prediction accuracy of SVR for 16 of 17 compound data
sets. Figure 5 compares R2 values for the different calculations
in boxplots and shows that the interquartile range of RF was
lower than SVR and that the median R2 value of SVR was ∼0.2
units higher.
Kernel ridge regression was compared to SVR using the
preferred 2VKD−ECFP6 combination without cross-validation
(i.e., on larger test sets). KRR is computationally much more
demanding than SVR both in terms of memory requirements
and in CPU time (KRR calculations could not be completed for
three large data sets). Results are reported in Table 7.
Compared to SVR, KRR calculations yielded a small increase
in R2 values for most data sets. These findings indicated that the
newly designed kernels were largely responsible for the
observed prediction accuracy, rather than SVR optimization
details.
Table 6. Random Forest Control Calculationsa
R2 SD(R2) MAE SD(MAE) RMSE SD(RMSE) r SD(r)
A 0.50 0.05 0.57 0.03 0.83 0.08 0.71 0.04
B 0.45 0.02 0.43 0.02 0.60 0.04 0.68 0.02
C 0.52 0.02 0.39 0.01 0.53 0.01 0.73 0.01
D 0.52 0.03 0.52 0.02 0.67 0.02 0.72 0.02
E 0.59 0.02 0.37 0.01 0.51 0.02 0.77 0.01
F 0.51 0.03 0.44 0.02 0.58 0.02 0.72 0.02
G 0.56 0.03 0.45 0.01 0.61 0.02 0.75 0.02
H 0.54 0.01 0.49 0.02 0.65 0.02 0.74 0.01
I 0.64 0.03 0.44 0.02 0.60 0.02 0.81 0.02
J 0.60 0.02 0.40 0.01 0.55 0.02 0.78 0.01
K 0.56 0.03 0.54 0.02 0.71 0.03 0.76 0.02
L 0.68 0.02 0.47 0.01 0.63 0.01 0.83 0.01
M 0.68 0.01 0.39 0.01 0.52 0.01 0.83 0.01
N 0.50 0.03 0.57 0.02 0.78 0.03 0.71 0.02
O 0.55 0.02 0.39 0.01 0.53 0.02 0.75 0.02
P 0.56 0.04 0.42 0.01 0.56 0.02 0.75 0.03
Q 0.41 0.03 0.44 0.03 0.63 0.05 0.64 0.03
aFor each data set, results of RF calculations are reported using different performance measures according to Table 3.
Figure 5. R2 comparison. The R2 value distributions resulting from the
preferred SVR combination (blue), RF (red), and MMPAV (green)
calculations are compared in a boxplot representation.
Table 7. Comparison of SVR and KRR for the ECFP6-2VKD
Combinationa
R2 MAE RMSE r
SVR KRR SVR KRR SVR KRR SVR KRR
A 0.35 0.52 0.56 0.51 0.96 0.82 0.62 0.73
B 0.53 0.59 0.36 0.33 0.56 0.52 0.74 0.77
C 0.68 0.72 0.27 0.24 0.43 0.40 0.84 0.86
D 0.64 0.69 0.41 0.38 0.59 0.55 0.82 0.84
E 0.70 0.74 0.29 0.26 0.44 0.41 0.85 0.87
F 0.60 0.63 0.36 0.34 0.52 0.50 0.79 0.80
G 0.68 0.72 0.35 0.32 0.53 0.49 0.83 0.86
H 0.67 0.72 0.37 0.33 0.56 0.52 0.83 0.86
I 0.77 0.80 0.32 0.29 0.48 0.44 0.88 0.90
J 0.73 0.30 0.45 0.87
K 0.70 0.75 0.41 0.36 0.58 0.54 0.85 0.87
L 0.75 0.36 0.55 0.87
M 0.86 0.22 0.33 0.93
N 0.48 0.57 0.54 0.49 0.80 0.73 0.71 0.76
O 0.71 0.76 0.27 0.24 0.43 0.39 0.86 0.88
P 0.69 0.74 0.34 0.31 0.47 0.43 0.84 0.87
Q 0.44 0.49 0.40 0.38 0.61 0.59 0.67 0.70
aFor each data set, results of SVR and KRR predictions for the
preferred ECFP6−2VKD combination are reported using different
performance measures including the coefficient of determination (R2),
mean absolute error (MAE), root-mean-square error (RMSE), and
correlation coefficient (r). For data sets J, L, and M, KRR calculations
could not be completed.
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■ CONCLUSIONS
In this work, we have explored support vector regression using
newly designed kernel functions for the prediction of numerical
potency differences between compounds forming MMPs.
Application of the MMP formalism for potency prediction
further expands the applicability domain of QSAR-type
approaches. This is the case because (i) many different
structural relationships are captured at the level of compound
pairs and (ii) MMPs encode well-defined chemical trans-
formations in different structural environments. For potency
difference prediction, the MMP approach was further refined by
introducing direction-dependent MMPs. By combining MMP-
based transformation analysis and machine learning approaches
such as SVR, nonlinear SARs can be captured in structurally
heterogeneous data sets. In our calculations, overall high SVR
prediction accuracy was achieved for a preferred combination of
a kernel taking transformation and core structure information
into account and a high-resolution topological fingerprint
descriptor. Transformation information was best captured by a
fingerprint representation accounting for structural differences
between the exchanged substructures. Given that potency
difference values were predicted using SVR with reasonable to
high accuracy for structurally analogous compounds from many
different data sets, the methodology introduced herein should
merit further consideration for compound potency predictions
to complement and potentially extend existing QSAR
approaches.
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Conclusions
An SVR application to predict the potency difference between MMP partners
has been presented. Six different kernel functions (three transformation kernels and
three MMP kernels) were compared. MMP kernels performed generally better than
transformation kernels across 17 data sets. SVR was compared to random forest
(RF) and kernel ridge regression (KRR). SVR outperformed RF in all but one data
set. KRR (an alternative kernel-based regression method) yielded high prediction
accuracy, slightly higher than SVR. However, its implementation was much slower
and for three data sets KRR calculations could not be completed. Because good
performance was obtained for KRR, SVR optimizations were probably not the
origin of the prediction accuracy. Rather, the kernel functions seemed responsible
for the good overall concordance between observed and predicted values.
SVR has proven to be a powerful methodology for property change prediction.
However, it is a complex methodology with a marked “black box” character. For
the next study, we used a more intuitive prediction method based on MMPA
and coupled it to a high-dimensional visualization to rationalize the results of a
multi-objective compound optimization campaign.
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7 Compound optimization
through data set-dependent chemical
transformations
Introduction
During multi-objective compound optimization, the structure of a molecule
is modified to alter its properties. These modifications are expected to improve
the ranking of the compounds for different objective functions. This process can
be rationalized as searching for specific regions of chemical space where com-
pounds with favorable property values preferentially congregate. In this study,
we combine visualization of high-dimensional property space, multi-objective
optimization, and MMPA of data set-dependent chemical modifications. Principal
component plots allow the identification of favorable regions of property space.
Chemical transformations that encode consistent property changes are used to
modify compounds in stages, moving them in the scatter plot from unfavorable
to favorable regions of property space. This study provides a proof-of-concept of
MMP-based compound optimization rationalized on the basis of visualizations of
high-dimensional property space.
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ABSTRACT: We have searched for chemical transformations
that improve drug development-relevant properties within a
given class of active compounds, regardless of the compounds
they are applied to. For different compound data sets, varying
numbers of frequently occurring data set-dependent trans-
formations were identified that consistently induced favorable
changes of selected molecular properties. Sequences of com-
pound pairs representing such transformations were deter-
mined that formed pathways leading from unfavorable to
favorable regions of property space. Data set-dependent trans-
formations were then applied to predict a series of compounds
with increasingly favorable property values. By database
searching the desired biological activity was detected for several designed molecules or compounds that were very similar to
these molecules. Taken together our findings indicate that data set-dependent transformations can be applied to predict
compounds that map to favorable regions of molecular property space and retain their biological activity.
■ INTRODUCTION
Chemical modifications occurring in pharmaceutically relevant
compounds can be systematically studied by molecule pair ana-
lysis.1,2 For example, a matched molecular pair (MMP) is
defined as a pair of compounds that are only distinguished by a
structural change at a single site,2 i.e., the exchange of a sub-
structure between these compounds, which is often referred to
as a chemical transformation.3 The MMP concept is useful for
many applications in medicinal chemistry.4,5 For example, on
the basis of MMP analysis, bioisosteric replacements have been
identified across different compound classes6 and also chemical
changes leading to the formation of activity cliffs.7,8 The
identification of bioisosteres or activity cliff-forming transforma-
tions requires the study of potency changes that are associated
with chemical transformations. In addition, the effect of trans-
formations on other compound properties can be also assessed,
which has become a popular topic in ADMET analysis.9−12 In
this context, the consequences of defined structural changes on
physicochemical properties such as solubility or more complex
compound characteristics such as metabolic stability or oral
availability are investigated.
We have searched for transformations and transformation
sequences to optimize compounds in drug development-relevant
property space. A key question of our study has been whether
structural modifications can be derived from data sets of known
active compounds that induce favorable changes in property
space and can be utilized to optimize compounds sharing the
same activity. Therefore, we set out to apply the MMP concept
and identify transformations that consistently improve mole-
cular properties of known active compounds. We then attempted
to use such transformations to delineate compound pathways from
undesired to desired regions of property space and design new
compounds.
Data set-dependent transformations (in the following re-
ferred to as set-dependent transformations) were identified in
different compound sets that led to favorable changes of selec-
ted molecules properties in varying structural contexts and
enable compound design. We then searched for newly designed
compounds in a public domain data and identified a number of
identical or very similar compounds sharing the same activity.
■ MATERIALS AND METHODS
Data Sets. Four sets of G protein coupled receptor (GPCR)
antagonists active against the adenosine A2a (A2AR), can-
nabinoid CB2 (CB2), dopamine D2 (D2R), or μ-opioid
receptor (MOR) were collected from ChEMBL (release 14).13
Only compounds with high-confidence activity annotations and
available Ki values were selected. If multiple Ki values were
available, their geometric mean was calculated as the final com-
pound potency. If Ki values for a compound differed by more
than 1 order of magnitude, it was omitted from further con-
sideration. The data sets contained between ∼1400 and ∼2100
compounds, as summarized in Table 1.
Descriptors and Value Ranges. For all test compounds,
four descriptors were calculated using the CDK Toolkit14 in
KNIME.15 These descriptors included molecular weight (MW),
topological polar surface area (TPSA), the number of rotatable
bonds (rotN), and the water/octanol partition coefficient (logP).
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The ADME-related property descriptor classification scheme
introduced by Lobell et al.16 was applied to distinguish between
favorable (green), intermediate (yellow), and unfavorable (red)
compound property descriptor value ranges. For property
space analysis, the following value range combinations were
defined:16 favorable: LogP ≤ 3, MW ≤ 400, TPSA ≤ 120,
rotN ≤ 7; intermediate: LogP 3−5, MW 400−500, TPSA 120−
140, rotN 8−10; unfavorable: LogP > 5, MW > 500, TPSA >
140, rotN > 10.
Chemical Transformations. Transformation size-restricted
MMPs were calculated as described previously8 using a variant of
the algorithm by Hussain and Rea.3 The size and size difference
between fragments exchanged between compounds forming an
MMP were limited to maximally 13 and 8 non-hydrogen atoms,
respectively, to focus transformations on chemically meaningful
replacements.8 All size-restricted MMPs representing the same
chemical transformation were identified. Transformations were
classified as f requent transformations if they occurred in at least
10 different MMPs. If several possible transformations existed
for a given MMP, the smallest transformation was selected. In
contrast to previous MMP applications, in our current analysis
each MMP [A,B] defined two direction-dependent transformations,
i.e., A→B and B→A. This was done because transformations were
Figure 1. Transformation evaluation. To assess property changes as a consequence of a frequently occurring transformation, MMPs representing the
transformation are analyzed. The descriptor value differences between compounds 2 and 1 forming each MMP are calculated and averaged over the
MMPs.
Table 1. Compounds, MMPs, and Transformationsa
data set A2AR CB2 D2R MOR
compounds 2154 1393 1442 1415
MMPs 13791 8123 7757 7952
transformations 15640 10344 11102 9988
frequent 240 114 76 116
preferred 47 31 18 30
aFor each data set, the total number of compounds, MMPs, corresponding
transformations, and the number of frequent and preferred transformations
are reported.
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associated with specific changes in descriptor values for each
compound, which might be favorable in one direction and un-
favorable in the other. Due to the consideration of direction-
dependent transformations, the total number of unique tran-
sformations exceeded the number of MMPs, as reported in
Table 1. Depending on the compound data set, between
∼7,500 and ∼14,000 MMPs were obtained that yielded
∼10,000 to ∼15,500 unique transformations.
Set-Dependent and Preferred Transformations. All
frequent transformations identified for a compound set were
classified as data set-dependent transformations. For each accepted
transformation, the difference in descriptor values between
compounds forming each MMP representing this transfor-
mation in the compound set was determined, and the values
were averaged over all MMPs, as schematically illustrated in
Figure 1. Transformations were classified as preferred (with
respect to a given data set) if they consistently moved the
values of all descriptors in a favorable direction (i.e., from red to
green) or if values of one or more descriptors changed in a
favorable way, while values of the others remained constant.
Preferred transformations were not permitted to change any
descriptor value in an unfavorable manner.
Transformation-Dependent Descriptor Value
Changes. Descriptor value changes induced by preferred
transformations were systematically assessed and predicted. For
each qualifying transformation, the corresponding MMP set
was 10 times randomly divided into half. For 50% of the MMPs
(training set), the transformation-dependent descriptor value
changes were calculated and used to predict descriptor values
for the test set (i.e., the remaining 50% of the MMPs). For the
latter, the actual values were then determined, and the co-
efficient of determination R2 for the predicted and observed
values was calculated for each of the four descriptors for the 10
independent predictions.
Visualization. For the display of compound sets and pathways,
descriptor values of compounds were subjected to scaled principal
component analysis (PCA) using R.17 For each compound, the
values for the first and second principal component were cal-
culated as the x- and the y-coordinates, respectively, to obtain a
2D projection. The two first principal components accounted
for 81% (CB2) to 94% (D2R) of the overall variance of the
descriptor values. Compounds were represented as dots and color-
coded using a continuous spectrum from green (all descriptor
values were favorable) over yellow (partly unfavorable values)
to red (all descriptor values were unfavorable). Pathways were
delineated by connecting compounds forming MMPs with directed
edges.
Compound Pathways. Within each data set, MMP
sequence pathways between compounds in unfavorable and
favorable regions of descriptor space were identified. Therefore,
as a pathway start and end point, a compound in the unfavorable
and favorable region was selected, respectively, and the shortest
path between these compounds was determined. A pathway
consisted of compound pairs forming overlapping MMPs, e.g.,
path A−B−C was formed by MMPs [A,B] and [B,C]. Hence,
these pathways were defined by a series of chemical tran-
sformations that generated compounds with increasingly favorable
descriptor values.
Compound Optimization. Starting from compounds
located in unfavorable property space, a series of set-dependent
transformations were applied to predict new compounds. During
each step, a transformation was randomly selected among those
that modified descriptor values toward favorable regions.
Transformation-based optimization was terminated if no favorable
descriptor value changes were observed during subsequent itera-
tions or when designed compounds entered favorable regions of
descriptor space. For each compound, 20 independent optimiza-
tion trials were carried out. Each trial was permitted to include a
maximum of 20 steps. From all trials for a given compound, the
one yielding the highest proportion of predicted compounds with
database matches relative to the total number of designed
compounds per trial was prioritized, as further discussed below.
Table 2. Conserved Transformationsa
aPreferred transformations are listed that consistently occurred in all four
compound data sets together with their average descriptor value changes.
Figure 2. Compound pathway visualization. A compound pathway is
delineated using arrows in the PCA projection of a hypothetical data
set. Molecules are represented as nodes that are color-coded using a
spectrum ranging from unfavorable to favorable descriptor values.
Compounds connected by an arrow form an MMP and are related to
each other by the corresponding transformation. Hence, the pathway
follows a sequence of overlapping MMPs from an unfavorable to a
favorable region of descriptor space.
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Searching for Predicted Compounds. Each predicted
compound was searched in ChEMBL. If the designed com-
pound was not detected, a near neighbor search was carried
out for database molecules having MACCS key18 Tanimoto
similarity19 >0.9. Activity annotations of matched compounds
or near neighbors were analyzed. If candidate molecules were
found to have the same receptor antagonist annotation as the
start compound, they were selected and their potency values
were recorded to monitor potency progression among matches
during optimization.
■ RESULTS AND DISCUSSION
Study Concept. We have been interested in investigating
how to systematically optimize chemical properties of active
compounds and “move” them through structural modifications
into favorable regions of property space. We have selected four
widely considered features (descriptors) that are known to account
for drug development-relevant properties and for which un-
favorable, intermediate, and favorable value ranges have been
determined.16 The selected properties included molecular size (MW),
Figure 3. continued
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Figure 3. Compounds pathways. In (A) and (B), representative pathways from the A2AR and MOR data sets are shown, respectively. At the top of
each representation, the compounds forming the pathway are shown and labeled with their ChEMBL ID. Substructures exchanged along the path are
colored red. Below the structures color-coded property descriptor values are listed for each molecule. In addition, compound potencies (pKi values)
are reported using an analogous color code from green (lowest potency within the data set) over yellow to red (highest potency). At the bottom, the
compound pathway is delineated in the corresponding section of the PCA projection of the data set.
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polar surface area (TPSA), flexibility (rotN), and lipophilicity
(logP). In contrast to the original classification scheme of
Lobell et al., we did not include aqueous solubility in our
analysis because solubility models available to us did not
produce consistently accurate values. For evaluating sequences
of structural changes, the chosen property space was suitable,
especially because unfavorable and favorable regions in this
space could be clearly distinguished for the compound sets
under study (and separated in PCA projections).
A key question of our analysis has been whether it might be
possible to derive structural modifications from data sets of
known active compounds that display a general tendency to
induce favorable changes in property space and that could then
be applied to optimize compounds sharing the same activity.
To these ends, we have applied the MMP concept to syste-
matically identify chemical transformations and search for set-
dependent transformations that occurred in different structural
environments (i.e., different MMPs) and the subset of preferred
transformation that consistently changed property values in a
favorable manner.
Transformation Analysis. We first determined all MMPs
and direction-dependent transformations in each of the four
compound sets under study. Then, we identified transforma-
tions that were represented by at least 10 different MMPs,
which dramatically reduced the number of candidate transfor-
mations, as reported in Table 1. The number of these frequent
transformations ranged from 76 (D2R) to 240 (A2AR). For
each qualifying transformation, average descriptor value changes
were calculated for all corresponding MMPs per class, as illu-
strated in Figure 1. Next, we searched for frequent transformations
that consistently moved compounds toward preferred regions of
property space. The possibility to identify such transformations
was a priori not unlikely. For example, considering the simplest
case, a given transformation always changes molecular weight in
a defined manner, regardless of the compound it is applied to,
and if a transformation reduces molecular weight, it would
generally be considered favorable.
In order to address transformation generality within a given
set of active compounds, we searched for preferred transfor-
mations. As reported in Table 1, the majority of set-dependent
transformations did not yield consistently favorable property
changes. However, preferred transformations were identified in
each set. For A2AR, CB2, MOR, and D2R, the number of
preferred transformations was 47, 31, 30, and 18, respectively.
Only six preferred transformations were conserved in all four
data sets, as reported in Table 2. Because the set-dependent
transformations were derived from compounds sharing the
same activity, they are likely to retain activity if applied to an
active compound. This is an important aspect bridging between
data mining and compound design.
After identifying preferred transformations for each com-
pound set, we next assessed their predictive capacity. Therefore,
the set of MMPs representing each transformation was 10 times
divided in half. For each training set, transformation-dependent
descriptor value changes were determined and used to predict
descriptor values of test set compounds, which were then com-
pared with calculated test set values via 10-fold cross validation.
These predictions were found to be highly accurate for all four
data sets (more so than we might have expected), yielding R2
values of 0.96 for D2R and 0.99 for A2AR, CB2, and MOR.
Thus, preferred transformations yielded nearly identical changes in
descriptor values toward favorable property space, regardless of the
structural environment they occurred in, which reflected desired
set-dependent generality. Previously, the potential structural
context dependence of MMP-associated effects has been
pointed out.12 The high R2 values obtained in our analysis
indicated that there was relatively little context-dependence of
MMP-based property effects for the compound sets we studied.
Detection of Compound Pathways. PCA projections
revealed that compounds in all four data sets were widely
distributed over unfavorable and favorable regions in property
space. Hence, in the next step, we systematically searched the
data sets for all MMP sequence pathways leading from a com-
pound located in unfavorable property space to a compound in
favorable space that involved preferred and other transfor-
mations. A model of such a pathway is shown in Figure 2. For
A2AR, D2R, CB2, and MOR, 46,029, 4569, 1200, and 672
qualifying compound pathways were detected, respectively. On
average, these pathways included 11.2 (A2AR), 9.3 (D2R), 15.2
(CB2), and 9.2 (MOR) compounds. Exemplary pathways with
compounds and associated property values are shown in Figure
3. Hence, in this retrospective data set analysis, many MMP
sequence pathways bridging between unfavorable and favorable
regions of property space were found that involved preferred
transformations.
Compound Optimization. Finally, we attempted to design
compounds forming optimization paths using set-dependent
transformations. At each step, only transformations were accepted
that generated analogs with predicted favorable value changes for
one or more descriptors while keeping other descriptor values
within their current ranges. As starting points for compound
design, all data set compounds were selected that mapped to
unfavorable regions in the PCA projections and had a pKi value
greater than 7 (i.e., property optimization was modeled for
relatively potent compounds). Depending on the data set,
between 27 and 56 candidate compounds were identified as
starting points (Table 3). These compounds were subjected to
sequences of randomly chosen set-dependent transformations
(see Methods) to design a series of new analogs. For each
candidate compound, it was determined whether optimization
trial(s) generated new analogs that reached favorable regions
of property space. If so, we searched for these analogs in
ChEMBL. If an analog was not found, a near neighbor search
was carried out (see Methods). The results of our optimization
trial are reported in Table 3. In this table, database search
results are only reported for terminal analogs of optimization
paths. The optimization trials revealed that compound optimization
Table 3. Optimization Trialsa
data set A2AR CB2 D2R MOR
optimization candidate compounds 36 35 27 56
did not reach favorable space 17 0 27 34
reached favorable space no NN 8 11 0 17
NN 8 24 0 4
active NN 3 0 0 1
aFor each data set, the number of compounds subjected to optimi-
zation trials (”optimization candidate compounds”) is given, and the
subsets of these compounds for which predicted analogs did not reach
or reached favorable regions of property space are reported. For the
final analog of an optimization trial reaching favorable space, the
results of near neighbor analysis are also provided. “No NN” and
“NN” means that no near neighbor and one or more near neighbors of
the final analog were found in ChEMBL, respectively. In addition,
“active NN” means that a near neighbor sharing the same receptor
antagonist activity annotation was identified.
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at least partly succeeded for three of four compound classes,
with the exception of D2R. In the latter case, no analogs of any
of the 27 start compounds reached favorable property space,
although compounds were found to move in the right direction,
albeit in too small steps. D2R also produced the overall smallest
number of set-dependent and preferred transformations. By
contrast, all analogs derived from all 35 CB2 starting points
reached favorable space. For 24 compounds, near neighbors of
Figure 4. continued
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the terminal analog of a path were identified in ChEMBL, but
none of these closely related compounds was known to share
CB2 activity. For MOR, trials for 22 of 56 candidates suc-
ceeded, and in five of these cases, near neighbors were identi-
fied, one of which was known to have MOR antagonist activity.
Furthermore, for A2AR, 19 of 36 candidate compounds yielded
derivatives that reached favorable property space. For 11
terminal compounds, near neighbors were identified, and three
of these were annotated with A2AR antagonist activity.
Figure 4 shows the results of two successful optimization
trials for CB2 and A2AR, respectively. In a number of successful
optimization trials, intermediate pathway compounds also had
exact matches or near neighbors with shared activity, which was
also the case for the two exemplary trials in Figure 4. It can be
seen how designed compounds approached and reached favorable
property space while essentially retaining comparable potency
levels. Thus, set-dependent transformations were activity-conservative,
consistent with principles of the approach.
Figure 4. Compound optimization. In (A) and (B), exemplary compound optimization paths are shown originating from compound 596135 of data set CB2
and from compound 473440 (A2AR), respectively. Representation elements are according to Figure 3. Structures of designed compounds (left) and database
matches (right) are shown in the middle of the figure and are numbered according to the table insert at the top. For each designed molecule, predicted descriptor
values are reported in the table insert. For matches and near neighbors, potency values are given. In the table insert, database compounds that exactly matched
designed compounds are designated “EM” and near neighbors of designed compounds “NN”. At the bottom, designed compounds (black nodes) were mapped
into the PCA projection of the data set on the basis of their descriptor values. The optimization path formed by these predicted compounds is traced.
Journal of Chemical Information and Modeling Article
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Taken together, the results in Table 3 and Figure 4 indicate
that compound property optimization on the basis of set-
dependent transformation is a feasible task. In light of the data-
base search results and detected near neighbor relationships, a
number of designed compounds might also be attractive can-
didates for experimental evaluation. Hence, the compound set-
centric and transformation-based compound design strategy
introduced herein should merit further investigation using
different compound classes and molecular properties.
Concluding Remarks. In this study, we have addressed the
question whether structural modifications can be identified for
sets of compounds sharing the same activity that display a
general tendency to further improve molecular properties. If so,
such modifications might be applied for compound design. For
the purpose of our analysis, we have adapted the MMP and
transformation concepts that are suitable for the systematic identi-
fication of chemical changes within variable structural contexts, i.e.,
modifications that are shared by pairs of structurally distinct
compounds. The MMP concept is not the only possible route
to prospective compound design and optimization. For exa-
mple, knowledge-based sets of structural transformation have
also been utilized.20 In our study, varying numbers of set-
dependent and preferred transformations were identified for
four different data sets that induced favorable molecular pro-
perty changes in different compounds. In these data sets, we
identified large numbers of MMP sequence pathways that led
from active compounds located in unfavorable regions of
property space to others in favorable regions. We then devised
a compound design protocol applying randomly selected trans-
formations to iteratively generate derivatives of compounds
located in unfavorable property space and produce compound
paths leading into favorable space. For three of four compound
sets, many optimization trials were successful and often yielded
attractive derivatives. Lead optimization is a multiparametric
process that requires the improvement of druglike molecular
properties alongside compound potency, consistent with the
basic ideas underlying our approach. In summary, the approach
introduced herein closely combines compound data mining and
prospective compound design and can provide design suggestions
for experimental studies. Our findings indicate that set-dependent
transformations can be applied, even in a random fashion, to
generate compounds with favorable molecular properties.
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Conclusions
Here, we have presented a novel methodology that combines multi-objective
optimization based on MMPA and visualizations of high-dimensional space. Four
sets of compounds active against different G protein coupled receptors were ob-
tained. Four previously described descriptors and eight threshold values112 were
used to guide the multi-objective optimization procedure. Principal components
were used to display the four-dimensional space and follow the modification
of compounds from unfavorable to favorable property values. Chemical trans-
formations were obtained from MMPs for each data set and their effect on the
four properties was analyzed. Those transformations that had a consistent effect
were used to modify compounds with unfavorable property values. Half of the
selected compounds could be optimized in this manner. In some cases, compounds
similar to the final, optimized molecule could be found in public databases with
defined activity against the data set target. Therefore, data set-dependent chemical
transformations were in many cases activity conservative.
In this study, visualization of high-dimensional space was used to rationalize a
computational compound optimization procedure. Principal component plots of
property space provided an overview of compound distribution. In the next study,
we introduced star coordinate and parallel coordinate plots to study chemical
space. These displays are used to explore different drug-like subspaces obtained
as equivalent solutions of a multi-objective optimization procedure.
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8 Visualization of multi-property
landscapes for compound selection
and optimization
Introduction
Chemical space is frequently studied using a set of molecular descriptors to
generate high-dimensional property spaces where each descriptor represents a di-
mension. These spaces are vast and finding drug-like subspaces, where active and
bioavailable compounds are located, is of prime importance to find promising can-
didate molecules for optimization. In this study, we present two high-dimensional
visualizations, the star coordinate and the parallel coordinate plot, to the medicinal
chemistry community. Star coordinates are used to represent distinct drug-like
subspaces obtained from an optimization task allowing to differentiate between
numerically equivalent solutions. Parallel coordinates are used to study the dis-
tribution of descriptor values and compare drugs and bioactive compounds. My
main contribution to this study was the generation and analysis of star coordinate
and parallel coordinate plots.
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Visualization of multi-property landscapes for compound selection
and optimization
Antonio de la Vega de Leo´n1 • Shilva Kayastha1 • Dilyana Dimova1 •
Thomas Schultz2 • Ju¨rgen Bajorath1
Received: 16 June 2015 / Accepted: 27 July 2015
 Springer International Publishing Switzerland 2015
Abstract Compound optimization generally requires
considering multiple properties in concert and reaching a
balance between them. Computationally, this process can
be supported by multi-objective optimization methods that
produce numerical solutions to an optimization task. Since
a variety of comparable multi-property solutions are usu-
ally obtained further prioritization is required. However,
the underlying multi-dimensional property spaces are typ-
ically complex and difficult to rationalize. Herein, an
approach is introduced to visualize multi-property land-
scapes by adapting the concepts of star and parallel coor-
dinates from computer graphics. The visualization method
is designed to complement multi-objective compound
optimization. We show that visualization makes it possible
to further distinguish between numerically equivalent
optimization solutions and helps to select drug-like com-
pounds from multi-dimensional property spaces. The
methodology is intuitive, applicable to a wide range of
chemical optimization problems, and made freely available
to the scientific community.
Keywords Compound optimization  Activity
landscapes  Structure–property relationships  Multi-
objective optimization  Multi-property landscapes 
Visualization
Introduction
The exploration of structure–activity relationships (SARs) in
large and structurally heterogeneous compound data sets is
strongly supported by SAR visualization methods [1]. The
concept of activity landscapes (ALs) [2] provides integrated
views of compound similarity and activity relationships and
has been applied for SAR visualization [1, 2]. Several
approaches to the design of two- (2D) and three-dimensional
(3D) ALs have been introduced that typically consider
activity as the sole compound property. Exemplary 2D AL
designs include simple ‘‘structure–activity similarity (SAS)
maps’’ [3] that plot structural similarity against activity
similarity on the basis of pairwise comparisons of data set
compounds and, in addition, various network representa-
tions. For example, the ‘‘network-like similarity graph’’
(NSG) [4] has been an original network-based AL design in
which nodes represent compounds and edges pairwise (fin-
gerprint) similarity relationships. Nodes in NSGs are anno-
tated with potency and numerical SAR score information.
Another more recent design has been ‘‘intuitive networks for
structure–activity relationship analysis’’ (inSARa) [5] in
which reduced graphs of active compounds are used to
determine their maximum common substructures (MCSs).
TheseMCSs are then represented as nodes that are connected
by edges indicating hierarchicalMCS relationships. Original
compounds are then assigned to corresponding MCSs and
represented as a second node category, i.e., compound nodes
colored by potency. MCS-based visualization methods have
Antonio de la Vega de Leo´n and Shilva Kayastha have contributed
equally to this work.
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also been introduced to organize individual compound series
and elucidate SAR patterns [6–8]. In addition to network
representations, tree-like structures have been designed to
graphically organize compound series and study SAR trends
in chemical neighborhoods [8, 9]. Several network- [7] or
tree-like [8, 9] visualizations can be rationalized as local 2D
ALs because they predominantly or exclusively focus on
individual compound series (rather than structurally
heterogeneous data sets).
Going beyond global or local 2D representations, the
design of 3D ALs can be approached in different ways.
Given a 2D representation of structural similarity rela-
tionships, an intuitive way of generating a 3D AL is adding
a biological response surface as a third dimension. This
typically requires extrapolation of a hypersurface from
sparsely distributed compound activity values, which has
been accomplished by adapting the kriging method from
geostatistics [10]. An alternative approach to 3D AL design
is subjecting a high-dimensional chemical descriptor space
to dimension reduction to obtain a 3D view, as exemplified
by the ligand induced structure–activity relationship dis-
play (LiSARD) [11]. Compound positions in this space can
then be annotated with activity information.
Chemical space visualization is not confined to AL
views. Rather, different visualization techniques have also
been introduced to generalize chemical space display
including, for example, similarity-based compound net-
works [12] and molecular layout algorithms [13] for
smaller data sets, projections from high-dimensional
descriptors spaces based on principal component analysis
for large (or very large) data sets [14, 15], and generative
topographic mapping (GTM) [16]. GTM was designed to
project from high-dimensional feature spaces onto latent
2D space representations in which points (nodes) corre-
spond to normal probability distributions derived from the
original data space that determine the mapping of com-
pounds to the latent space. As such, GTM does not rep-
resent an AL view as conventionally defined.
Returning to the AL concept, we emphasize two of its
cardinal features: firstly, it is activity-centric (i.e., activity is
considered as a single structure-related property); secondly,
it is descriptive in nature (i.e., ALs are used to analyze SARs
but not predict active compounds). Both of these features
limit the applicability of AL representations for compound
optimization, which typically is a multi-objective task.
During iterative optimization, multiple biologically relevant
compound properties are considered in combination with
activity, focusing on the key question,which compound(s) to
make next [17]. In the practice of medicinal chemistry, this
process is predominantly driven by chemical experience and
intuition, although it can also be supported by computational
means. In computational chemistry, multi-property opti-
mization is typically attempted using evolutionary
algorithms [18–20] or property-weighted objective func-
tions [20], often in combination with Pareto ranking [19, 20]
of numerical solutions. These multi-objective methods
usually produce reasonable numerical solutions of opti-
mization tasks but are not expected to find the globally best
solution. Multi-objective optimization typically produces a
variety of comparable solutions and it is often difficult to
further differentiate between them and rationalize charac-
teristic features in multi-dimensional property space.
Herein, we introduce an approach to visualize multi-
property landscapes, further extending the AL concept, and
graphically analyze solutions of property-weighted objec-
tive functions. The methodology makes it possible to fur-
ther differentiate between numerically equivalent
optimization solutions and prioritize them for specific tasks
by viewing them in a multi-dimensional data set context.
Materials and methods
Compound data selection
In order to model compound optimization processes, data
sets were assembled that consisted of two types of com-
pounds active against the same target: bioactive compounds
from medicinal chemistry sources and approved drugs.
Bioactive compounds were extracted from ChEMBL [21]
(version 20). Only compounds with reported direct interac-
tions (i.e., target relationship type ‘‘D’’) against human tar-
gets at the highest assay confidence level (i.e., confidence
score 9) and precisely defined equilibrium constants (Ki
values) were considered. Compounds with multiple Ki
measurements for the same target were retained if all
reported values fell within the same order of magnitude. In
this case, the arithmetic mean was calculated as the final
potency annotation. Approved small molecule drugs with
specific target annotations were assembled from DrugBank
[22] (version 4.1). To ensure that potency information was
available for all drugs and bioactive compounds considered
in the analysis, only drugs were retained for which high-
confidence activity measurements were available in
ChEMBL.All qualifying compounds and drugswith activity
against the same target were organized into target-based
compound sets. Each target set was required to contain at
least 100 bioactive compounds and at least 10 approved
drugs. Table 1 summarizes the composition of six target sets
satisfying the above criteria assembled for our analysis.
Multi-dimensional property space
A multi-dimensional property space was generated using
14 descriptors accounting for different molecular proper-
ties relevant for chemical optimization, as summarized in
J Comput Aided Mol Des
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Table 2. Properties represented by 13 calculated descrip-
tors included, among others, hydrophobic and aromatic
character, molecular complexity, hydrogen bonding
potential, charge, and surface properties. In addition,
compound potency (pKi; negative decadic logarithm of the
equilibrium constant) was used as a descriptor. Experi-
mental pKi values for data set compounds were taken from
ChEMBL (version 20). The descriptor a_ringR (fraction of
ring atoms in a molecule) was calculated with the aid of the
OpenEye toolkit [23] and the remaining 12 descriptors
were calculated using the Molecular Operating Environ-
ment (MOE) [24]. This 14-dimensional feature space was
designed as a reference space for exemplary multi-property
optimization. The feature set selected for our proof-of-
concept investigation can of course be replaced by any
other number of calculated descriptors and/or experimen-
tally determined properties, depending on the specific
optimization tasks.
Property space projection and optimization
Compound subsets with preferred feature value combina-
tions were selected from multi-dimensional feature space.
Therefore, compound distributions in 14-dimensional fea-
ture space were projected onto a one-dimensional space. A
projection of the data was obtained by multiplying an
n 9 p data matrix, X, with n sample points in p dimen-
sions, with a p 9 d projection matrix, A (here with p = 14
and d = 1). Accordingly, the projection of compound i was
given by the formula: vali ¼
Pp
j¼1 wjvj, where vj (from X)
was the value for descriptor j and wj (from A) the weight
given to descriptor j [25]. The value of this projection was
used as the multi-objective function (MOF) value for
numerical optimization of a compound subset selection.
Values of the 13 numerical descriptors were scaled rela-
tive to the observed pKi range to ensure that no descriptors
numerically dominated the value distributions.
Table 1 Data sets combining
bioactive compounds and
approved drugs
Target ID Target name Bioactive CPDs Drugs
231 Histamine H1 receptor 572 25
1867 Alpha-2a adrenergic receptor 453 23
210 Beta-2 adrenergic receptor 355 19
2035 Muscarinic acetylcholine receptor M5 282 14
4302 P-glycoprotein 1 242 49
4605 Small intestine oligopeptide transporter 181 14
For the six target-based data sets, the ChEMBL target ID, number of bioactive compounds (CPDs), and
approved drugs are reported
Table 2 Descriptors
No. Name Definition Property Unit
1 a_acc Number of hydrogen bond acceptors Hydrogen bonding Integer
2 a_aroR Fraction of aromatic ring atoms Aromaticity Percentage
3 a_don Number of hydrogen bond donor atoms Hydrogen bonding Integer
4 a_ringR Fraction of ring atoms Molecular complexity Percentage
5 b_rotR Fraction of rotatable bonds Flexibility Percentage
6 chiral_u Number of chiral centers Stereochemistry Integer
7 Fcharge Sum of formal charges Charge Integer
8 logP(o/w) Log of octanol/water partition coefficient Hydrophobicity Log unit
9 logS Log of aqueous solubility Solubility Log (mol/L)
10 PEOE_VSA_FHYD Fractional hydrophobic van der Waals surface area Surface property Percentage
11 PEOE_VSA_FPNEG Fractional negative polar van der Waals surface area Surface property Percentage
12 PEOE_VSA_ FPPOS Fractional positive polar van der Waals surface area Surface property Percentage
13 Pot Potency (pKi) Activity Log (M)
14 Weight Molecular weight Molecular size Da
The set of 14 descriptors used for feature space generation is listed and defined
J Comput Aided Mol Des
123
Optimization was guided by maximizing the MOF value.
Therefore, a systematic search was performed using four
different weight values for each descriptor {-1.0, -0.33,
0.33, 1.0}.All 414 (*270millions) possible projectionswere
systematically explored. The weighting scheme chosen for
our analysis can be easily exchanged for different properties
and optimization tasks. The search procedure is not depen-
dent on a specific methodology or strategy. Descriptor
weights can be obtained using alternative approaches
including, among others, regression techniques. If the
number of features becomes too large for an exhaustive
search, stochastic search strategies can also be applied.
Compounds were ranked based on their MOF value and
the top 20 compounds were analyzed. Projections were pri-
oritized based on the number of approved drugs within the
top 20 ranking. In prioritized set of projections, MOF value
corresponded to our drug-likeness model of compounds
meaning that compounds with higher MOF values had
properties similar to approved drugs. Thus, projections with
a significant enrichment of drugs among top-ranked com-
pounds were considered to originate from drug-like sub-
spaces representing favorable multi-feature combinations.
Our current analysis scheme is focused on the exploration of
drug-like subspaces for the generation of which reference
sets of known drugs are essential. However, compound ref-
erence sets with other characteristic properties of interest can
be used for mapping and derivation of descriptor weights.
Visualization of projections
For the visualization of individual projections, the Star
Coordinate (STC) [26] representation was adopted from
computer science. STC is a multi-dimensional visualization
technique that arranges coordinates in predefined positions
sharing the same origin at the center. The position of a
compound in the STC visualization was dependent on the
position of each coordinate (descriptor) and the values of
the compound for each coordinate.
More formally, the position of compound i in the STC
visualization was given by the formula: i~¼Ppj¼1 vjd~j,
where d~j represented the position of descriptor j and vj the
value for descriptor j. The position of descriptor j was
calculated as follows: its weight obtained from MOF
optimization provided the y-axis value. Along the x-axis,
all descriptors were ordered lexicographically and given
incremental values between -1 and 1 to distribute them
evenly. Figure 1a shows a schematic STC visualization for
an individual compound. For a given projection, the STC
visualization provides a 2D representation of the data set
distribution in multi-dimensional property space. STC for
multi-property space display was implemented in-house in
Java based upon the JUNG library [27].
STC visualization was complemented by the Parallel
Coordinate (PAC) [28] representation, another multi-di-
mensional visualization technique from computer science
that organizes features (descriptors) on parallel axes. Each
axis represents all possible values for a descriptor, ranging
from the minimum (top of the axis) to the maximum value
(bottom). Compounds are then represented as lines that
traverse all descriptor axes at positions corresponding to
the value for each descriptor. Figure 1b shows an exem-
plary PAC representation. The molecular PAC represen-
tation was also implemented in-house in Java. STC
visualizations of projections were generated to further
differentiate numerically comparable optimization solu-
tions and view subsets of top-ranked compounds in the
context of global data distributions from multi-dimensional
feature space.
For comparison, principal component analysis (PCA) of
unweighted and weighted descriptor spaces was carried out
using R [29] and the first and second principal components
(PCs) were used to generate conventional PC plots.
Because these plots generate a two-dimensional view of
multi-dimensional data that maximize the original vari-
ance, they are often used to represent high-dimensional
spaces. However, their primary goal is the generation of an
uncorrelated view with maximum variance and hence the
visualization might not be chemically informative.
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Fig. 1 Star and parallel coordinates. a A schematic STC represen-
tation for a single compound (gray dot) and five descriptors (A–E).
Gray arrows represent descriptor vectors forming the star coordinate.
Red arrows (dA to dE) represent weighted vectors obtained by
multiplying the descriptor value of the compound with the corre-
sponding vector. The position of the compound is determined by the
sum of all weighted vectors (indicated by blue arrows for dB to dE).
b An exemplary PAC plot for the same compound. Descriptors (A–
E) are assigned to parallel horizontal lines. The red line traces the
descriptor values of the compound
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Results and discussion
Methodological principles
The simultaneous consideration of multiple properties
beyond potency is a requirement of compound optimiza-
tion in medicinal chemistry. Therefore, the activity-centric
AL concept, which is useful for SAR exploration, might
be further extended to rationalize multi-property land-
scapes. Analyzing multi-dimensional property spaces
generally is a complicated task, which is typically
addressed using dimensionality reduction. The basic idea
underlying the methodology introduced herein was to
visualize compound distributions in multi-property space
in which numerical optimization is carried out. Multi-
property optimization carried out in the context of our
analysis was guided by the use of approved drugs as
internal standards. Compound rankings based upon pro-
jections with a significant enrichment of drugs at top
ranked positions were thought to originate from drug-like
subspaces in multi-dimensional property space. Thus,
highly ranked data set compounds had property combi-
nations comparable to drugs and were thus considered
preferred candidates for selection and further optimization
efforts. A known conundrum of numerical multi-objective
optimization is that typically a variety of high-scoring
solutions are obtained that are difficult to distinguish.
Therefore, it was attempted to visualize compound dis-
tributions underlying best projections to analyze rankings
within the data set context and further differentiate them.
These visualizations were designed to provide a detailed
view of multi-property landscapes, as discussed in the
following.
Multi-property landscape display
The STC representation provides the core visualization of
multi-property space. Figure 2 illustrates how an STC
view is obtained for a model compound set from
descriptor weights and multi-dimensional coordinates. For
a given projection, the STC visualization provides a 2D
view of the underlying compound distributions in multi-
dimensional property space. Figure 3a shows an exem-
plary STC visualization for an actual compound data set
and a given projection. In addition, Fig. 3b shows the
corresponding PAC view and Fig. 3c the top five com-
pounds from the ranking. The five compounds have
similar chemical structure. Hence, MOF value ranking
likely includes a similarity-property principle component.
At the top of the STC view, the drug-like subspace is
delineated by the subset of highly-ranked compounds
including 13 drugs, with the majority of compounds being
clearly separated from the prioritized subspace (Fig. 3a).
Similarity relationships between compounds in STC views
were substantially different from those in high-dimen-
sional space (on average 21.5 % nearest neighbors over-
lap). Comparable average overlap values (12.8–25.2 %)
were obtained for other STC views shown in Fig. 5b, d.
The corresponding PAC representation reveals which
descriptor contributions dominate the projection (Fig. 3b).
For some descriptors, values of highly ranked compounds
significantly differed (e.g., a_acc, logP(o/w)), whereas
their values were narrowly confined in other cases (e.g.,
a_don, a_ringR, b_rotR). Moreover, largely distinct value
ranges of a few descriptors were observed for highly
ranked molecules compared to many other bioactive
compounds (e.g., a_ringR, b_rotR), which strongly con-
tributed to the separation. Thus, the PAC representation
complements the STC visualization by identifying prop-
erty settings that distinguish compounds in drug-like
subspaces from others and evaluating relationships
between descriptor settings. Thus, PAC representations
can be used to study feature correlation patterns. For
example, the line traces in Fig. 3b reveal a negative
correlation between the a_ringR and b_rotR descriptors.
Finally, PAC also provides a visual representation of the
original high-dimensional space, as it displays all
descriptor values for each compound. Therefore, the PAC
representation is independent of specific projections and
helpful to analyze the STC view.
Multi-property optimization
We next carried out a systematic multi-property opti-
mization as a basis for practical applications of the newly
introduced visualization approach. The set of chemically
intuitive features selected for our conceptual investigation
can be replaced by any other calculated or experimentally
determined compound characteristics relevant for opti-
mization tasks. For the multi-objective function contain-
ing our 14-descriptor set with four possible weights per
descriptor, a systematic search of all possible projections
from multi-dimensional space was carried out. Each
projection yielded a MOF value for any bioactive com-
pound and drug based on which a ranking was generated.
More than 270 million weight combinations were ana-
lyzed and prioritized based on the number of drugs in the
top 20 compound ranking. For all data sets, drug
enrichment was only detected in a small subset of pos-
sible weight combinations, as shown in Fig. 4. Hence,
delineation of subspaces populated with drugs required
very specific multi-parameter settings, as one should
expect. Nonetheless, for the different data sets, there were
between 20 and *500 projections that yielded maximum
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drug enrichment (between nine and 18 drugs for the
different sets), as also shown in Fig. 4. Thus, these pro-
jections represented equivalent numerical optimization
solutions. The corresponding compound rankings covered
most drugs in the data sets (43–95 %; on average 70 %)
but only a small fraction of bioactive compounds
(3–16 %; on average 8 %) mapping to drug-like sub-
spaces. Furthermore, many projections producing maxi-
mum drug enrichment had very similar weight
combinations. However, projections with very different
combinations (descriptor contributions) were also found.
Therefore, solutions with maximal drug enrichment hav-
ing similar or distinct weight combinations were further
analyzed through visualization. The successful delineation
of specific drug-like subspaces for all data sets indicated
that the search procedure took compound similarity rela-
tionship implicitly into account.
Visualization of projections and comparison
of compound distributions
A large number of STC representations were generated for
different data set projections. Figure 5 shows exemplary
comparisons. In Fig. 5a, two projections with distinct
descriptor weight combinations are shown for beta-2
adrenergic receptor ligands that produced large drug
enrichment (and shared 11 of 13 drugs in their top 20
rankings). Figure 5b compares the STC representations of
these projections. The compound distributions differed
significantly for these two projections representing
numerically equivalent optimization solutions. This might
be expected because distinct weight combinations charac-
terized these projections. Although both projections dis-
played significant drug enrichment, projection 1 clearly
separated top ranked compounds from others and also
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Fig. 2 Star coordinate
representation of multi-
dimensional compound data.
For a model data set comprising
six compounds with five
different properties, the
generation of an STC view is
illustrated. Descriptor positions
and compound 1 correspond to
Fig. 1a. Descriptor positions
resulted from lexicographical
ordering along the horizontal
axis combined with weight
settings for a given projection
(with a descriptor weight
combination shown in the inset).
Compound positions resulted
from matrix calculations shown
at the bottom and summation of
descriptor contributions
(pathway calculations). For two
exemplary compounds, 1 and 3,
pathways are traced. Compound
rank positions increase along
the vertical axis
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Other drug compounds Other bioacve compounds
Star Coordinates Parallel Coordinates
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logP(o/w)
FCharge
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Rank CPD ID Structure
1 1146
2 2303613
3 74632
4 1415
5 00567
Ranked list of compounds
Fig. 3 Views of a multi-property landscape. Compound distributions
of small intestine oligopeptide transporter ligands (ChEMBL target
ID 4605) for a given projection were displayed using a STC and
b PAC representations. In the STC representation, points represent
individual compounds and color-coding distinguishes drugs (cyan)
and bioactive compounds (orange). Top ranked molecules are
depicted with a black border. In addition, shading of compounds
indicates their rank, from dark colors (high rank, beginning at rank
21) to light colors (low rank). In the PAC representation, descriptors
are assigned to vertical evenly spaced lines (spanning their value
ranges) and compounds are depicted as lines (horizontal traces)
color-coded as in (a). c The top five compounds from the ranking of
the projection including two drugs (4 and 5). Orange and cyan
compound (CPD) IDs correspond to ChEMBL and DrugBank IDs,
respectively
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spread the compound data set across the property space,
providing a clear view of compounds in increasingly large
distances from the prioritized subspace. By contrast, in
projection 2, the bulk of the data set was concentrated in a
small region of property space and the separation of highly
ranked and other compounds was only marginal. Hence,
the property settings of projection 2 rendered data set
compounds much more similar in multi-dimensional
property space than the settings of projection 1, as clearly
revealed by STC visualization. Therefore, for the selection
of candidate compounds for chemical optimization efforts
focusing on drug-like subspace, preference would be given
to projection 1.
In Fig. 5c, two projections with similar descriptor
weights are shown for alpha-2a adrenergic receptor ligands
that yielded large drug enrichment (and shared seven of
eight drugs among the top 20 compounds). Figure 5d
shows the STC visualizations of these projections.
Although the weight combinations were very similar, the
compound distributions were distinct, contrary to expec-
tations, as further discussed below.
For comparison with STC, Fig. 5e shows PC plots (us-
ing the first and second PC) of the unweighted descriptor
space and weighted descriptor combinations of projections
1 and 2. In unweighted descriptor space, PCA did not yield
a separation of drugs and bioactive compounds. Moreover,
the PC plots of projection 1 and 2 were very difficult to
interpret and remained essentially inconclusive. By con-
trast, the STC representations of projection 1 and 2 in
Fig. 5d reveal a clear separation of top ranked and other
data set compounds, but with different characteristics. The
STC view of projection 1 shows that many data set com-
pounds including remaining drugs were located proximal
to the prioritized subspace, while only a small number of
lowly ranked compounds were far removed from it.
However, the STC view of projection 2 in Fig. 5d reveals a
significant spread of the compounds across multi-dimen-
sional property space (similar to projection 1 in Fig. 5b)
including the majority of drugs, although the weight set-
tings of projection 1 and 2 were comparable. In the case of
projection 2, the STC view also shows that the drug-like
subspace was less well-defined than in other cases, with
many drugs (including two highly ranked ones) located
distantly from many top ranked compounds. From these
STC views, individual compounds can be easily selected
for further analysis. Taken together, the STC visualizations
provided a well-resolved picture of compound distributions
in multi-dimensional property space for otherwise very
similar projections.
Concluding remarks
High-dimensional property spaces for compound opti-
mization or data set analysis are generally difficult to
represent and navigate. While the potency-centric AL
concept has substantially contributed to graphical SAR
exploration, especially for larger and structurally hetero-
geneous data sets, little efforts have thus far been made to
visualize multi-dimensional property landscapes that
combine activity with other optimization-relevant proper-
ties. Typically, dimension reduction techniques such as
PCA are applied to evaluate feature contributions in multi-
dimensional space. Different types of graphical analysis are
expected to aid in the rationalization of multi-dimensional
property spaces. Therefore, a visualization methodology
for multi-dimensional property spaces has been developed,
as reported herein. Our analysis was based upon the gen-
eration of drug-like subspaces in chemical space, which
takes molecular similarity relationships implicitly into
account. However, it would also be feasible to focus an
analysis explicitly on selected distance relationships in
chemical space (or generate subspaces for compound ref-
erence sets with other characteristic properties).
Our study introduces the STC and PAC concepts,
adapted from computer graphics, to the medicinal chem-
istry community. STC/PAC visualization of compound
data is designed to complement multi-objective optimiza-
tion, provide access to multi-dimensional data distribu-
tions, and aid in compound selection. For a given
Fig. 4 Numerical comparison of projections. A projection was
created for each weight value setting of the multi-objective function
containing 14 descriptors and the number of drugs within the 20 top
ranked compounds was determined. The graph reveals the number of
weight combinations yielding largest numbers of highly-ranked drugs
across the different target sets (colored by target IDs given in
Table 1)
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Fig. 5 Visualization of projections. Exemplary projections are visu-
alized and compared. In (a) and (b), two projections generated for
beta-2 adrenergsic receptors (ChEMBL target ID 210) are shown. The
corresponding top 20 rankings contained 13 drugs each (11 of which
were the same). a Compares the weight combinations (settings) for
these projections and b their STC visualizations. Points represent
individual compounds and are color-coded according to Fig. 3a. In
(c) and (d), two projections generated for alpha-2a adrenergic
receptor ligands (ID 1867) are shown. The corresponding top 20
rankings contained eight drugs each (seven of which were the same).
c Compares the weight combinations (settings) for these projections
and d their STC visualizations. In (b) and (d), STC visualizations
were scaled to the same value ranges. e PCA-based data set
projections (using the first two PCs) with unweighted descriptors
(top, drugs colored cyan and bioactive compounds gray) and
weighted descriptors from projection 1 (middle) and 2 (bottom) taken
from (c). PCA plots of projections are color-coded as in (d)
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projection and compound ranking, the STC visualization
provides a 2D representation of a compound distribution in
multi-dimensional property space and views highly ranked
compound subsets in the data set context. In addition, the
PAC representation compares individual property contri-
butions and identifies property settings that distinguish
highly ranked compounds from others. We have demon-
strated that STC visualizations help to differentiate
numerically equivalent optimization solutions with similar
or distinct property settings. The data sets used herein are
made freely available [30].
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Conclusions
We have performed a systematic search of projections of the high-dimensional
space on the basis of a multi-objective function. This function was a weighted
linear combination of descriptor values and was used to prioritize compounds.
The selection of weights was modeled as an optimization task, where the number
of drug compounds with largest function values was maximized. Different weight
combinations gave identical results and were considered numerically equivalent
by the optimization. However, when they were used to create star coordinate
plots to explore these drug-like subspaces, compound distributions were very
different even among similar weight combinations. Relationships between differ-
ent descriptors were analyzed with parallel coordinate plots. These plots could
also differentiate descriptor value distributions between drugs and bioactive com-
pounds.
The previous two studies have revealed applications of coordinate-based vi-
sualizations in different multi-objective optimization settings. The use of these
plots can offer an overview of the data, like principal component plots, or can
focus on drug-like subspaces, like star coordinate. Nonetheless, distances in these
plots may not reflect true similarity relationships in high-dimensional space. In the
next study, we develop a novel coordinate-free representation of high-dimensional
space that better emphasizes important similarity relationships.
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9 Chemical space visualization:
transforming multi-dimensional
chemical spaces into similarity-based
molecular networks
Introduction
Chemical space can be portrayed in different ways. Coordinate-free (such
as graphs) and coordinate-based displays (such as scatter plots) are both used
in chemoinformatics. Molecular representations frequently dictate which visu-
alization type is applied. Networks are traditionally built for fingerprint-based
similarity and substructure relationships. Molecular descriptors are displayed
through coordinate-based plots, such as those described in the last two chapters.
The analysis of descriptor distance relations in network representations has not
received much attention. Here, we introduce a novel coordinate-free visualization
based on chemical space networks (CSNs). Distance relations in high-dimensional
property space are transformed to similarity relations and used to build networks.
This visualization is called transformation-CSN (TRANS-CSN) because of its abil-
ity to transform coordinate-based property spaces to coordinate-free network
representations.
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1Chemical space visualization: transforming multi-dimensional chemical
spaces into similarity-based molecular networks
Antonio de la Vega de León and Jürgen Bajorath
Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität Bonn,
Dahlmannstr. 2, D-53113 Bonn, Germany.
Background: The concept of chemical space is of fundamental relevance for medicinal chemistry and chemical informatics.
Multi-dimensional chemical space representations are coordinate-based. Chemical space networks (CSNs) have been
introduced as a coordinate-free representation. Results: A computational approach is presented for the transformation
of multi-dimensional chemical space into CSNs. The design of transformation CSNs (TRANS-CSNs) is based upon
a similarity function that directly reflects distance relationships in original multi-dimensional space. Conclusions:
TRANS-CSNs provide an immediate visualization of coordinate-based chemical space and do not require the use of
dimensionality reduction techniques. At low network density, TRANS-CSNs are readily interpretable and make it
possible to evaluate structure-activity relationship (SAR) information originating from multi-dimensional chemical
space.
Introduction
The concept of chemical space is popular in medicinal
and computational chemistry [1, 2]. Chemical space is
generally rationalized as the union of all chemically fea-
sible compounds [1]. With on the order of 1060 possible
small molecules [2], chemical space is ultimately finite
but so vast that it cannot be studied or represented in
its entirety. Rather, only small sections of theoretically
possible chemical space are typically explored, in par-
ticular, biologically relevant chemical space [1], which
is populated with biologically active small molecules or
compounds having the potential to be active, given their
chemical properties. Chemical space is often also intu-
itively envisioned as a multi-dimensional space across
which compounds are distributed in a star-like manner [1].
In computational chemistry and chemical informatics,
coordinate-based chemical space representations essen-
tially mimic such an imaginary multi-dimensional space
[3, 4]. Since there is no generally accepted or applicable
computational representation of chemical space, coordi-
nate-based representations make use of varying numbers
of molecular descriptors, i.e., more or less complex math-
ematical models of chemical structure and/or properties,
to generate a coordinate system into which compounds
are placed based on their descriptor values. Depending
on the specific requirements of different applications,
such as compound classification, diversity analysis, or
activity prediction, the composition of descriptor spaces
varies, but they have in common that they are mul-
ti- or high-dimensional. Accordingly, visualization of
coordinate-based chemical space representations is not
straightforward and requires the application of statistical
dimensionality reduction techniques [3, 5] such as princi-
pal component analysis (PCA) [1, 3] or multi-dimensional
scaling (MDS) [5] to generate two- or three-dimensional
projections of chemical space.
As an alternative to coordinate-based chemical space,
coordinate-free representations can also be considered,
which are generated by determining all pair-wise rela-
tionships between compounds [6]. For example, a rudi-
mentary coordinate-free space representation is provided
by a similarity value matrix of a compound collection.
As more advanced representations, similarity-based mol-
ecular networks have been introduced as a paradigm
for coordinate-free chemical space representation [6]. In
such networks, nodes represent compounds and edges
connecting pairs of nodes represent similarity relation-
ships. However, distances between nodes in network
representations do not correlate with chemically rele-
vant distances and this is why they are regarded as
coordinate-free representations. From an algorithmic
viewpoint, they are indeed coordinate-free because they
are generated from pair-wise similarity matrices. These
similarity-based compound networks were originally gen-
erated on the basis of fingerprint-based Tanimoto simi-
larity values using pre-defined threshold values for SAR
analysis [7]. They have also been applied to explore
chemical libraries [8] and the applicability domain of
QSAR models [9]. Chemical space networks (CSNs) [6]
represent a generalization of similarity-based compound
networks. The major determinant of the topology of
CSNs, their characteristic features, and SAR informa-
tion content is the way in which molecular similarity is
accounted for, i.e., the choice of similarity measures [6],
which has been systematically investigated in CSNs of dif-
ferent design. Therefore, although CSNs have originally
been introduced on the basis of Tanimoto similarity [10],
other types of CSNs have been constructed on the basis
of substructure-based similarity [11], hybrid measures
combining numerical similarity measures and substruc-
ture similarity [12], or asymmetric similarity functions,
leading to the presence of directed edges in CSNs [13].
As coordinate-free chemical space representations, CSNs
have the advantage that they provide an immediate vi-
sualization of chemical space and enable its interactive
navigation [6].
2Table 1: Compound setsa
Target ID Target Name Compounds
210 Beta-2 adrenergic receptor 374
231 Histamine H1 receptor 597
1867 Alpha-2a adrenergic receptor 476
2035 Muscarinic acetylcholine receptor M5 296
4302 P-glycoprotein 1 291
4605 Small intestine oligopeptide transporter 195
aFor each data set, the ChEMBL target ID, target name, and the number of active compounds is reported.
Herein, we introduce a new computational approach
for chemical space display, which establishes a method-
ological link between coordinate-based and coordinate-free
space representations. Therefore, multi-dimensional chem-
ical spaces based on continuous descriptor values (rather
than fingerprints) are transformed into a new type of
CSN using a specifically defined similarity function that
converts inter-compound distances in multi-dimensional
space into scaled similarity relationships. This makes it
possible to directly visualize multi-dimensional chemical
space representations in a new format, without the need
for dimension reduction techniques. Given the unique-
ness of the descriptor coordinate-to-similarity transfor-
mation, these CSNs conceptually differ from previous
network representations and provide a view of trans-
formed chemical space. The central aspect of this study
is the transformation of coordinate-based into coordi-
nate-free chemical space views. The resulting CSNs are
shown to be informative for structure-property analysis.
Methods
Compound sets
For chemical space transformation, six previously re-
ported compound sets taken from ChEMBL (version 20)
[14] and DrugBank (version 4.1) [15] were used. These
data sets were originally used to delineate drug-like sub-
spaces in multi-dimensional chemical space [16]. Bioac-
tive molecules were extracted from ChEMBL for which
direct interactions with a human target at the highest
level of assay confidence were reported. Only inhibition
constant (Ki) values were considered as activity mea-
surements. Compounds with multiple potency records
that differed by more than one order of magnitude were
not considered. If all values fell within the same order of
magnitude, the arithmetic mean of all reported Ki values
was used as the final activity value. Potency values were
recorded as pKi values, i.e., the negative decadic loga-
rithm of Ki values. Compound sets from ChEMBL were
complemented with drugs from DrugBank for which ac-
tivity against the same target was reported and potency
values were available in ChEMBL. Table 1 reports the
composition of the six compounds sets.
Descriptors
Molecules were represented using a set of 13 numeri-
cal molecular descriptors reported in Table 2. These
descriptors were previously selected to account for chem-
ically intuitive features with relevance for SARs and
shown to yield resolved compound distributions in mul-
ti-dimensional space [16]. Hence, we had prior evidence
that this descriptor set, albeit limited in size, was suit-
able for chemical space transformation. Among others,
chemical features accounted for by these descriptors that
were relevant for biological activity included hydrogen
bond potential, flexibility/rigidity, solubility, and various
molecular surface characteristics. All structural descrip-
tors except a_ringR (ring content of a molecule) were
calculated using the Molecular Operating Environment
[17]. The a_ringR descriptor was calculated using an
in-house script based upon the OpenEye toolkit [18].
Coordinate-based chemical space represen-
tation
The numerical descriptors were used to generate a 13-di-
mensional chemical space. For each compound, the de-
scriptors were calculated and scaled to unit variance to
ensure equivalent contributions to distance relationships
in chemical space. Scaled descriptor values were then
used as a coordinate vector to define the position of each
compound in multi-dimensional space.
Two-dimensional chemical space projec-
tions
PCA and MDS were used to project multi-dimensional
space onto a two-dimensional representation. They rep-
resent standard approaches for dimension reduction of
multi-dimensional chemical space representations and
are conceptually distinct. PCA creates a set of uncor-
related principal components from linear combinations
of original descriptors that capture the variance within
the original data set. The first two principal components
were used as axes to generate a scatterplot representa-
tion. MDS accounts for pair-wise distances between data
points in original space (rather than global data variance)
and attempts to preserve these distance relationships in
lower-dimensional space representations. MDS was used
here to generate two-dimensional projections of multi-
-dimensional space. PCA and MDS calculations were
carried out using in-house Python scripts based upon
the scikit-learn package [19] using default parameter
settings.
3Table 2: Descriptorsa
Name Description
a_acc Number of hydrogen bond acceptors
a_aroR Fraction of aromatic ring atoms
a_don Number of hydrogen bond donors
a_ringR Fraction of ring atoms
b_rotR Fraction of rotatable bonds
chiral_u Number of unconstrained chiral centers
Fcharge Sum of formal charges
logP(o/w) Log of partition coefficient (octanol/water)
logS Log of aqueous solubility
PEOE_VSA_FHYD Fraction of hydrophobic surface area
PEOE_VSA_FPNEG Fraction of negative polar surface area
PEOE_VSA_FPPOS Fraction of positive polar surface area
Weight Molecular weight
aThe 13 descriptors used to generate the multi-dimensional chemical space are defined.
Chemical space networks
CSNs are generated on the basis of pair-wise compound
similarity relationships. Therefore, pair-wise Euclidian
distances between compound descriptor vectors in mul-
ti-dimensional space were determined and transformed
into similarity values within the range [0,1] using the
following formula:
Similarity = 1− distance
Max(distance)
So-defined similarity values correlated with fractions of
the maximal distance in multi-dimensional descriptor
space. From the complete similarity matrix, CSN ad-
jacency matrices were calculated for varying similarity
threshold values. CSNs were then generated using the
Fruchterman-Reingold algorithm [20] and visualized us-
ing in-house Java programs based on the JUNG library
[21]. The force-directed Fruchterman-Reingold layout
algorithm places densely connected objects closely to-
gether and separates clusters from each other. As a
consequence, edge lengths and distances between com-
pounds and compound clusters in CSNs have no chemical
meaning.
Network properties
CSNs were characterized using two major network prop-
erties including edge density and modularity [22, 23].
Density represents the fraction of all possible edges that
are present in a network and is calculated as follows:
Edge density = 2m
n(n− 1)
where m is the number of edges and n the number of
compounds.
CSNs are best compared and interpreted at low edge
densities at which modularity is typically high [10]. Mod-
ularity is a measure for the cluster structure of a network.
In CSNs, high modularity corresponds to the presence
of well-defined compound communities [10]. Modularity
values depend on the function δ(i, j), such that δ(i, j) = 1
if molecules i and j belong to the same cluster and zero
otherwise [23]. For modularity calculations, the cluster
distribution within a CSN must be algorithmically deter-
mined, for which the Newman algorithm was used [24].
Modularity was then calculated as:
Modularity = 12m
∑
1≤i,j≤n
(
aij − kikj2m
)
δ(i, j)
where m is the number of edges, aij is the value in the
adjacency matrix for compounds i and j and ki is the
degree of compound i.
Results and discussion
Projections of coordinate-based chemical
space
Initially, compound data sets were distributed in a 13-di-
mensional chemical space based on descriptor coordi-
nates. In such coordinate-based representations, each
chosen descriptor or feature adds a dimension to multi-di-
mensional space. These chemical space representations
are widely used for applications in chemical informatics
such as diversity analysis, compound classification, or
activity prediction. In these multi-dimensional spaces,
most computational operations are carried out numeri-
cally. However, multi-dimensionality, albeit suitable for
numerical analysis, complicates graphical exploration of
chemical space. In order to visualize coordinate-based
chemical space representations, dimension reduction tech-
niques such as PCA or MDS must be employed, which
is another standard procedure in chemical informatics.
Figure 1 shows PCA and MDS projections of our
13-dimensional reference space for two exemplary com-
pound sets. Dimension reduction is typically accompa-
nied by a loss of information. For example, the first two
principal components shown in Figure 1 account for only
49.9% (set 210) and 48.4% (1867) of the original data
variance in multi-dimensional space. PCA and MDS pro-
jections yielded different compound distributions. For
compound set 210, the PCA projection indicated that
4Figure 1: Exemplary chemical space projections. For two
different compound sets, ligands of beta-2 adrenergic receptor
(210, Table 1) and alpha-2a adrenergic receptor (1867), orig-
inal multi-dimensional descriptor space was projected onto
two dimensions using the first two components from principal
component analysis (PCA) or via multi-dimensional scaling
(MDS).
most compounds were more similar to each other than
it appeared to be in the MDS view. In both projections
of set 1867, the bulk of the compounds formed a densely
populated central region. On the basis of these pro-
jections, it would essentially be impossible to interpret
compound relationships in chemical space. Hence, PCA
or MDS plots can only provide a rather approximate
two-dimensional view of chemical space.
Transformation CSNs
The major aim of our study was to transform multi-
-dimensional chemical space into an alternative coordi-
nate-free representation that can be directly visualized.
A possible approach was the use of CSNs that can be
constructed using different similarity measures. This
required that pair-wise similarity relationships in CSNs
accurately accounted for all possible compound relation-
ships in multi-dimensional space. Importantly, relative
compound positions in multi-dimensional space were
determined by vectors of numerical property descrip-
tors not taking compound structure directly –or any
form of structural relationships– into account. There-
fore, inter-compound distances in descriptor space were
converted into scaled similarity relationships, which were
then used to construct CSNs. The use of property dis-
tance-derived similarity (dd-sim) based upon numerical
descriptor values in multi-dimensional space is a unique
feature of these CSNs compared to earlier designs. Be-
cause these CSNs were used for the transformation of
coordinate-based chemical space they were designated
transformation CSNs (TRANS-CSNs). TRANS-CSNs
are by design closely linked to the original multi-dimen-
Figure 2: Network properties. Edge density (top) and
modularity (bottom) are monitored for representative CSNs
with increasing similarity threshold values.
sional representations and aim to convey the chemical
information contained in the spaces in a conceptually dif-
ferent manner, making it accessible through immediate
visualization.
TRANS-CSN properties
TRANS-CSNs are threshold networks, which have a
different edge density for each chosen dd-sim threshold
value. In the extreme case, a completely connected
network with density of 1 is obtained for a similarity
threshold value of 0 (i.e., all compounds are considered
similar to each other). On the other hand, a minimally
connected network would be obtained for a threshold
of 1. In this case, edges would only be drawn between
compounds having identical descriptor coordinates.
TRANS-CSNs were generated for our six compound
sets from multi-dimensional chemical space under sys-
tematic variation of similarity thresholds. Density as a
function of similarity thresholds is reported in Figure 2
(top graph). All density curves followed the same path
and five of six curves were very similar. Density remained
very high for threshold values up to 0.6 before notable
reductions were detected. A characteristic feature of the
density curves was that they reached a low level of edge
density (≤ 10%) at large threshold values (≥ 0.80), also
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Figure 3: Comparison of TRANS-CSNs to PCA and MDS projections. For the beta-2 adrenergic receptor ligand set (210), (A)
shows TRANS-CSNs at six different similarity thresholds. The threshold values and the edge density (in percent) of CSN are
reported at the upper left of each graph. (B) shows the PCA projection of the compound set and (C) the MDS projection onto
which TRANS-CSN similarity relationships obtained at the six different threshold values are mapped.
indicating that many compounds had similar descriptor
coordinates.
The bottom graph in Figure 2 reports modularity as
a function of dd-sim thresholds and complements the
observations made for edge density. Modularity and
density curves were essentially inverted mirroring the
direct dependence of CSN modularity on edge density.
Until a threshold of 0.6, modularity was very low and
then began to increase. A sharp increase occurred for
threshold values greater than 0.80. In this region, minute
changes in density lead to small-magnitude fluctuations
in modularity, leading to a more rugged appearance of
the modularity than the density curves. At large dd-sim
threshold values, when network density was less than
10%, modularity reached high values greater than 0.9.
Figure 3A shows corresponding TRANS-CSNs for an
exemplary compound set, beta-2 adrenergic receptor lig-
ands (set 210). These network views very well illustrate
the relationships between dd-sim thresholds, density,
and modularity and also reveal that TRANS-CSNs were
capable of resolving relationships between compounds
in chemical space much better than projections using
dimension reduction techniques. At density levels of
10.1% and 6.8%, the CSNs still contained a large and
densely connected central network component. However,
at density levels of 4.5% and 2.6% –corresponding to
dd-sim thresholds of 0.84 and 0.86, respectively– sepa-
rate compound communities emerged and the networks
became readily interpretable at a global level. At fur-
ther decreasing density of 1.8% and 1.1%, communities
were gradually dissolved, due to low connectivity. Hence,
there was a delicate balance between threshold values,
modularity, and global appearance for TRANS-CSNs.
The relation between similarity threshold and density
values for sets 4605 and 231 was very similar to set 210.
A similarity threshold value of 0.84 was suitable to create
interpretable TRANS-CSN views of 3.6% and 4.3% den-
sity, respectively. For data sets 1867 and 4302, a slightly
increased threshold value of 0.86 was required to yield
equivalent resolution and interpretability of CSNs. At
this marginally higher threshold value, TRANS-CSNs
of data sets 1867 and 4302 had density values of 4.6%
and 4.1%, respectively. For set 2305, the same threshold
value of 0.86 was used and produced an edge density
that was slightly larger (5.3%). Overall, there was only
little variation in threshold values and ensuing edge den-
sities of TRANS-CSNs for these compound sets, which
displayed comparable resolution.
In Figure 3B, similarity relationships resulting from
different dd-sim thresholds were mapped onto the PCA
projection of the compound set, i.e., compound pairs
with similarity meeting the threshold were connected.
Mapping of similarity relationships showed that they
could hardly be interpreted on the PCA background
and, in addition, that relative compound positions of-
ten significantly differed in TRANS-CSNs and the PCA
projection. Equivalent observations were made when
mapping similarity relationships onto the MDS projec-
tion of the set, as shown in Figure 3C. By contrast, for
TRANS-CSNs, it was possible to inspect network views
at threshold values between 0.8 and 0.9 and select CSN
views that best resolved compound relationships and
were interpretable in a meaningful way.
Structure-activity relationships
One of the prime applications of chemical space represen-
tation, however they might be generated, is the analysis
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Figure 4: Compound mapping. Shown is a side-by-side comparison of a TRANS-CSN (dd-sim threshold of 0.88) and a PCA
projection for the set of beta-2 adrenergic receptor ligands. Nodes are colored by compound potency using a continuous spectrum
from red (lowest potency) over yellow to green (highest). Two corresponding regions in these graphs are delineated and enlarged.
Five compounds are labeled (1-5) and their structures are shown.
of compound-property relationships including –first and
foremost– structure-activity relationships (SARs). For
SAR exploration, compounds are annotated with activity
information and subsets of similar compounds are ana-
lyzed. For this purpose, the focus changes from a global
view, required for studying compound distributions in
chemical space, to a local view to identify compounds
having different SAR characteristics. An example of
a TRANS-CSN with potency information is shown in
Figure 4. The TRANS-CSNs for the beta-2 adrenergic re-
ceptor ligand set at the threshold of 0.88 was color-coded
according to compound potency. The annotated TRAN-
S-CSN revealed a variety of compound communities with
different potency distributions, which encoded different
local SARs. A representative community is highlighted
in the TRANS-CSN that consisted of compounds having
comparably high potency. The corresponding region was
mapped in the PCA projection of the compound set
where it had largely different composition, also including
compounds with very low potency. Here, compound rela-
tionships were not resolved, as most compound positions
overlapped, and local SARs were difficult, if not impossi-
ble to interpret. By contrast, compound communities in
the TRANS-CSN generally displayed well-defined SAR
characteristics, as shown in Figure 4. In many cases,
compounds with similar (high or low) potency formed
communities; in others, communities contained pairs
of compounds with large potency differences (activity
cliffs). Taken together, these observations indicated that
the original chemical space representation using numer-
7ical descriptors with emphasis on chemically intuitive
properties was sensitive to SARs and, in addition, that
TRANS-CSNs –as a coordinate-free representation– pro-
vided a high-resolution view of this space. A primary
reason for this observation likely was the way in which
molecular similarity or dissimilarity was accounted for.
TRANS-CSNs are based upon compound similarity rela-
tionships that directly reflect distance relationships in
original coordinate-based chemical space, whereas dimen-
sion reduction methods account for relative compound
positions and distances in different, often more indirect
ways. Thus, TRANS-CSNs are thought to be a mean-
ingful alternative representation of multi-dimensional
chemical space.
Conclusions
Chemical space can be rationalized in different ways
and there is no generally applicable representation of
chemical space. Visualization and navigation of chemical
space continue to be challenging tasks in computational
medicinal chemistry and chemical informatics. Multi-di-
mensional coordinate-based reference spaces have been
used for many applications. As an alternative, coordi-
nate-free space representations can also be considered.
CSNs have recently been introduced as a paradigm for
coordinate-free chemical space display. So far, coordi-
nate-based and coordinate-free representations have been
used in a mutually exclusive manner. Herein, we have
introduced a computational approach to transform mul-
ti-dimensional chemical spaces into a new type of CSN
using a similarity function that converts inter-compound
distances in original space into scaled similarity values.
Therefore, TRANS-CSNs directly capture relationships
between compounds in multi-dimensional space and en-
able immediate visualization. Hence, these molecular
networks provide a link between methodologically dis-
tinct ways of representing chemical space and further
advance our ability to navigate and interpret biologically
relevant sections of chemical space.
Future perspective
The development of methods for coordinate-free repre-
sentation of chemical space is still in its early stages.
CSNs are currently the most advanced representations
and of particular interest for the analysis of bioactive
compounds and their relationships. However, SAR ap-
plications are just beginning to be explored. In our
view, the introduction of TRANS-CSNs is another im-
portant step forward because they are intimately linked
to conceptually distinct coordinate-based chemical space
representations and thus enable previously unconsidered
applications. Of course, the ability to visualize multi-di-
mensional coordinate-based spaces without dimensional-
ity reduction is an advance in itself, and it is anticipated
that many graphical analyses of such spaces will be car-
ried out. However, there may be more. For example,
since most multi-dimensional chemical space constructs
are based upon numerical property descriptor values,
they are only indirectly related to compound structure
and activity. A key question in the generation of such
references spaces often is whether or not they might be
activity-sensitive and suitable to explore SARs in a mean-
ingful way. TRANS-CSNs make it possible to directly
evaluate this question, as also discussed herein, because
they can be used to analyze subsets of compounds that
are closely related to each other in original property
spaces –and emerge as compound communities in CSNs–
and evaluate whether or not SAR information associated
with such compounds is interpretable and makes sense.
Do compounds that are close to each other in feature
space often have similar activity? Are there well-defined
activity cliffs? Or are activity values more or less ran-
domly distributed over compounds that are similar to
each other or dissimilar? Obtaining insights along these
lines will likely provide important clues as to whether a
given chemical reference space is suitable for a specific
application at hand. Moreover, since TRANS-CSNs can
be easily annotated with compound property informa-
tion, such considerations are not limited to SAR analysis
but can be extended to structure-property analysis in
general. Hence, we expect that chemical space display
using TRANS-CSN will find a variety of applications.
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Conclusions
A novel CSN was described that bridges coordinate-based property spaces
and coordinate-free network representations. TRANS-CSNs were built using a
similarity measure based on the Euclidean distance in high-dimensional property
space. Compared to PCA and MDS, TRANS-CSN quickly identified communities
of molecules with similar properties. TRANS-CSN visualizations were sensitive
to the similarity threshold values used to create the networks. The analysis of
networks with edge density lower than 0.05 and high modularity was straight-
forward. TRANS-CSNs provided novel insights into high-dimensional property
spaces compared to dimensionality reduction techniques.
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10 Conclusion
Structural relations between bioactive compounds can be analyzed in different
ways. MMPs have become a very important tool in chemoinformatics. They are
the preferred way to represent activity cliffs and several visualizations use them
as a similarity criterion. They also provide comprehensive sets of chemical trans-
formations, where the effect of these transformations on various properties can be
studied.
This thesis has added to the chemoinformatics field by first measuring the
effect of MMPs on two properties relevant for drug discovery: ionization state
and ligand efficiency. For many targets, active molecules shared an IS-class. The
chemical transformations found in MMPs did not often change the IS-class; more
than 85% of the MMPs were ionization state conservative. Nevertheless, one out
of three molecules had MMP partners with different IS-class. Additionally, MMP-
cliffs generally encoded chemical changes that increased ligand efficiency between
the weakly and the highly potent cliff partner. The ligand efficiency change was
on average larger than that found for fingerprint-based activity cliffs.
Additionally, MMP extensions have been developed in this thesis. First, ret-
rosynthetic rules have been used to create second generation MMPs. These new
MMPs encode chemical transformations that originate from bonds created by
common reactions. This makes it easier for medicinal chemists to apply these
transformations for the synthesis of new compounds. Then, a novel methodology
to map compounds to existing MMS has been presented. This method has been
applied to obtain preliminary SAR information of confirmed hit compounds by
mapping them to MMS obtained from bioactive compounds. The SAR information
can be used to guide the optimization of hit compounds. Further, predictive SVR
models of activity difference between MMP partners were developed. MMP-based
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kernel functions enabled the accurate prediction of activity change using SVR
models. KRR models that used these kernel functions were also able to achieve
high prediction accuracy. This thesis has developed a number of extensions of
MMPs that are useful for different tasks such as activity prediction, SAR analysis,
or computer-aided compound design. They add to previous research and further
emphasize the importance of MMPs in modern chemoinformatics applications.
Representations of chemical space have also been a focus of this thesis. First,
principal component plots were combined with MMPA of property changes to
guide and visualize compound optimization efforts. These plots allowed the
identification of regions of space with favorable property values. Molecules with
unfavorable property values were modified with MMP-derived chemical transfor-
mations, moving them along the space towards the favorable regions previously
identified. Next, star coordinate and parallel coordinate plots have been adapted
for medicinal chemistry applications. Star coordinate plots were used to visualize
drug-like subspaces generated from a multi-objective optimization search. These
subspaces were considered equivalent by the optimization procedure but gen-
erated distinct compound distributions. Parallel coordinates were used to study
property value distributions in high-dimensional space. Finally, a novel visualiza-
tion of high-dimensional space, TRANS-CSN, represented a first approximation
of network representations to property spaces in chemoinformatics. Compared to
dimensionality reduction techniques such as PCA and MDS, it was able to high-
light important similarity relationships in high dimensional space. The techniques
described in this thesis aid in the analysis of specific subspaces and of compound
communities in property space.
Concluding, this thesis has expanded the applicability domain of MMPs with
a focus on properties relevant for drug discovery. It has also introduced new
visualizations to explore chemical space and aid in compound optimization.
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